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ABSTRACT
Current ideas of human gut immunity are derived heavily
from animal studies; the few human studies have mainly
addressed cellular aspects, and those on immunoglobulins
and antibodies have used serum (or rarely jejunal aspi¬
rate) to investigate immune events at the gut level,
assuming that these fluids are representative of the gut.
The aims of this thesis were to develop, evaluate, and
apply protocols for the study of gut secretions in man.
Saliva was examined as a secretion in its own right, to
investigate the relationship between systemic (serum) and
mucosal antibodies, and as a potential mirror of immune
events occurring more distally in the gut. Methods for
the collection and processing of jejunal fluid, and
intestinal fluid obtained via whole gut irrigation were
then developed.
Enzyme linked immunosorbent assay techniques were used to
measure total immunoglobulin concentrations and antibody
levels to three representative dietary protein antigens,
in saliva, intestinal fluid, jejunal aspirate, and serum.
Healthy subjects and groups of patients with a variety of
gut diseases likely to have increased immunity were
examined.
There was great physiological variation in immunoglobulin
concentrations and antibody levels in saliva, which were
universally decreased by eating. In patients on a gluten-
free or elemental diet, salivary antibody levels were
maintained despite a lack of antigen stimulation. Neither
saliva nor serum reflected immunity in gut lavage fluid,
(ii)
the only regularly observed relationship being a positive
correlation between serum and saliva, especially after
gut mucosal damage had occured. Differences between
control subjects and patients with coeliac disease were
insufficient to allow the use of saliva as a diagnostic
or clinical tool. Smoking strikingly influenced immuno¬
globulin concentrations, with a dose-dependent and re¬
versible decrease in salivary IgA, and an increase in
IgM. These alterations were not due to changes in the
numbers of immunoglobulin-producing cells in the parotid
gland. Smoking may also decrease IgA in lavage fluid.
Immunoglobulins and antibodies were regularly detected in
lavage fluid. There were increased immunoglobulin concen¬
trations and antibody levels in lavage fluid of both
treated and untreated patients with coeliac disease and
dermatitis herpetiformis, most markedly of IgM. There was
no evidence of secretory immunodeficiency in patients
with inflammatory bowel disease.
In conclusion, novel avenues of investigating gut immuni¬
ty have been explored. There were marked variations in
secretory immunity in healthy subjects and in patients
with gut diseases known to have an immunological compo¬
nent. Neither saliva nor serum reflected gut immunity;
therefore the gut should be studied directly.
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CHAPTER ONE: INTRODUCTION, AIMS, AND APPROACH
INTRODUCTION
The study of the gut mucosal immune system in humans is
relevant to a number of common and severe gastrointesti¬
nal diseases both in the developed countries and in the
developing world. Aspects of gut immunity have wide-
ranging implications in the aetiology, pathology, and
treatment of various infective, inflammatory, and, per¬
haps, neoplastic diseases of the gut . The study of human
gut mucosal immune responses has been hindered by practi¬
cal difficulties, and ethical considerations, with re¬
spect to access to gut cells and secretions. Thus, cur¬
rent ideas of human gut immunity are derived heavily from
animal studies, and it is widely acknowledged that animal
models are frequently not representative of man. Human
studies have mainly looked at histological aspects, and
those on immunoglobulins and antibodies have mostly used
serum to investigate immune events at the gut level,
assuming that serum is representative of gut secretions.
Only a few studies have used mucosal secretions, some¬
times from outwith the gut or from small sections of gut,
and have again assumed that these secretions are repre¬
sentative of the gut without any supportive evidence.
As the early stage of a programme of work in Edinburgh on
the mucosal immune system in man, the broad aim of this
thesis was to develop, evaluate, and apply protocols for
the study of gut secretions. To begin with, saliva was
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examined firstly as a secretion in its own right, second¬
ly to investigate the relationship between systemic
(serum) and mucosal antibodies, and thirdly as a poten¬
tial mirror of immune events occurring more distally in
the gut. As the studies progressed, two new topics
emerged as meriting further work with respect to gut
secretory immunity, smoking and inflammatory bowel dis¬
ease.
APPROACH
Firstly, technical questions with regards to the type of
saliva to be studied, the methodology and timing of
salivary collection, and to the treatment and preserva¬
tion of saliva, were answered. Three common food proteins
were chosen as representative dietary antigens, and
standard enzyme linked immunosorbent assay (ELISA) tech¬
niques employed to measure total immunoglobulin concen¬
trations and antibody levels to the food protein antigens
in saliva, intestinal fluid and serum. Groups of healthy
clinical and laboratory staff were examined to establish
reference ranges. Later on, groups of patients with a
variety of gut diseases likely to have increased immunity
were studied, namely those with inflammatory bowel dis¬
ease, coeliac disease, or dermatitis herpetiformis. It
became apparent that there was great physiological varia¬
tion in immunoglobulin concentrations and antibody levels
in saliva. In particular the influence of smoking on




Methods for the collection and processing of intestinal
fluid obtained via whole gut irrigation were then de¬
veloped using both healthy subjects and patients with a
variety of gastrointestinal diseases. Initially I intend¬
ed to use the ELISPOT technique to count numbers of gut
mucosal immunoglobulin- and specific antibody-producing
cells, obtained by biopsy from the small bowel at endos¬
copy or via Crosby capsule, as a "gold standard". Howev¬
er excellent results for immunoglobulin concentrations
and antibody levels derived from assay of intestinal
fluid diverted efforts away from the cellular aspects.
Serum, saliva, and intestinal fluid were then obtained
from healthy subjects, and a cross-sectional study on
patients with inflammatory bowel disease was conducted.
Serial salivary samples on patients beginning an elemen¬
tal diet devoid of food protein antigens were also ob¬
tained.
Confirmation of the influence of smoking on salivary
immunoglobulin concentrations prompted investigation
into the mechanism of these effects. Study of numbers of
immunoglobulin-producing cells in parotid gland specimens
from normal parotid tissue obtained at surgery was under¬




The thesis begins in section I with a general review of
salivary and intestinal secretory immune physiology and
pathophysiology; the literature on healthy smokers, as
related to this thesis, is emphasised in the relevant
chapter later on. The basic methodologies and the techni¬
cal developments and experiments, in particular the
protocols for collection, processing, and assay of saliva
and intestinal fluid are described in this section.
In section II the physiology of salivary and intestinal
fluid immunoglobulins and antibodies in healthy subjects
and in patients with coeliac disease and dermatitis
herpetiformis is discussed, as is the relationship be¬
tween serum, salivary, and intestinal immunoglobulins and
antibodies. In section III the effects of smoking on
salivary immune parameters in two very different popula¬
tions from Edinburgh and Cairo are described. The altera¬
tions in immunoglobulins and antibodies in the cross-
sectional study of patients with inflammatory bowel
disease are reported. Finally the thesis is concluded
with a general discussion of the findings, and future
studies prompted by the work.
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CHAPTER TWO: REVIEW OF SALIVARY AND GOT IMMUNE
PHYSIOLOGY
Introduction
The gut immune system is comprised of all mucosal and
exocrine tissues from the mouth to the rectum, of which
the salivary glands are thought to be a part. There have
been many recent and excellent reviews of the components,
anatomy, and physiology of the gut associated lymphoid
tissues and these will not be repeated here (Brandtzaeg
et al, 1985; Doe, 1989; Elson, 1985; Elson et al, 1986;
Marsh, 1987). In this chapter I will confine my review to
aspects of the anatomy, development, and physiology of
salivary and gut secretory immunity in man directly
relevant to the subject matter of my thesis.
SALIVARY GLANDS
Innnunohistology
Secreting either directly or via a duct into the mouth
are three major pairs of, and many minor, salivary
glands. The parotid, sublingual and submandibular glands
comprise the three major pairs of glands. All have simi¬
lar ratios of immunoglobulin isotype-producing cells,
although the density of those cells may vary between
glands (Korsrud and Brandtzaeg, 1980). In man IgA-produc-
ing cells predominate, with 80-90% of all immunoglobulin-
producing cells dedicated to this isotype. The remainder
of the cells are IgM, IgG, and IgD producers with between
one and six percent each, IgE-producing cells are virtu-
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ally absent (Korsrud and Brandtzaeg, 1980; Beckenkamp,
1985) . The many scattered minor salivary glands have
similar isotype ratios to the major glands and may have
greater density of IgA- containing cells (Matthews et al,
1985), although IgA cell numbers may be equalled by those
of IgM (Deslauriers et al, 1985) and these glands may
have a substantial role in oral immunity. A comprehensive
review by Nair and Schroeder clearly presents firm evi¬
dence for this role, and supports Mesteckys' theory that
minor salivary glands may react directly to topical
antigens (Mestecky et al, 1978), which have gained local
access through the salivary ducts as well as participat¬
ing in the immune response of the common mucosal immune
system (Nair and Schroeder, 198 6) . Animal studies have
demonstrated that the complete range of cells necessary
for an immune response is present within salivary glands.
In IgA deficiency, IgM producing cells may predominate
(Brandtzaeg, 1971a), although in one patients' parotid
glands IgD-positive plasma cells increased, with the
proportions of cells being 20%, 27%, and 53% for IgM,
IgG, and IgD respectively (Korsrud and Brandtzaeg, 1980).
At least one group consider that immunocyte numbers in
parotid salivary glands may not reflect the secretory
immunoglobulin content of parotid or of mixed saliva, as
the parotid glands have a comparatively low density of
immunocytes, and immunoglobulin isotype percentages may
not be a reflection of the global oro-pharyngeal immuno-
6
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cyte population (Beckenkamp, 1985). Others have shown
good correlation for immunoglobulin isotype concentration
between parotid saliva and labial saliva when sampling
healthy subjects. Their study may have been flawed by the
use of semi-quantitive, comparative, methodology, and
their use of autopsy specimens raises the possibility of
autolytic artefacts. They also suggested that the isotype
distribution of the B cells in the secretory tissue may
not be a reflection of the salivary immunoglobulins
secreted (Deslauriers et al, 1985).
Immunoglobulin valency and production
Most IgA-positive plasma cells in salivary glands produce
dimers or larger polymers, as evidenced by an 84% cyto¬
plasmic affinity rate for secretory component, and a 92%
J-chain positivity. Both of these percentages are reduced
in inflammation; Brandtzaeg and Korsrud considered that
the former reduction suggested a switch to proportionally
greater monomeric IgA production and that the latter
suggested clonal maturation (Brandtzaeg and Korsrud,
1984). They advance little evidence to support this
hypothesis, comparisons with dissimilar tissues forming
the basis of their arguments. Secretory IgA in saliva is
largely dimeric, usually 90% or more (Delacroix et al,
1982; Smith et al, 1987b), although Delacroix does not
state if whole or parotid saliva is studied, and the
number of subjects studied is small (n=7). After produc¬
tion within the immunocyte, transcellular uptake, trans¬
port, and secretion through and from the acinar cells is
7
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likely to be a physiological parallel of that seen across
the gut epithelium (Nakamura et al, 1985; Ahnen et al,
1985).
IgA subclasses
All secretions contain proportionally more IgA of sub¬
class 2 when compared with serum, (e.g. salivary mean
percentage IgA2 37±13%, intestinal perfusate 30±5%,
serum [range + maximum standard deviation] 18-21±8%)
(Delacroix et al, 1982); this may alter during the course
of a secretory immune response to certain bacterial
antigens (Streptococcus pyogenes, Bacteroides fragilis
and E. coli lipopolysaccharide [LPS]) when there may be a
further increase in the proportion of IgA2, in contrast
to other bacterial infection (Strep mutans glucuronyl-
transferase [GTF]) or candidal infection where IgAl may
similarly increase, both proportionally and in absolute
amount (Brown and Mestecky, 1985; Jeganathan et al,
1987). In this latter study the IgA2 subclass dominance
of anti-Candida albicans antibodies in health was re¬
versed by oral infection (Jeganathan et al, 1987). In
another study, specific anti- pneumococcal antibodies of
both IgA subclasses increased equally after pneumococcal
vaccination (IgAl x2.4, IgA2 x2.0), with no increase in
total IgA. A much greater increase was seen for IgG
(x4.5) and IgM (x4.0) specific antibodies in saliva (Lue
et al, 1988). Thus the nature of the antigen may deter¬
mine which of the two subclasses the corresponding IgA
antibody will be composed of, and it seems that in parot-
8
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id saliva a specific antibody response may be largely
associated with either IgAl or IgA2 (Brown and Mestecky,
1985) .
DEVELOPMENT OF SALIVARY IMMUNITY
Immunoglobulins are detectable in saliva shortly after
birth, with IgA being found in 50% of full-term neonates,
but only 8% of pre-term infants by 8-14 days. These rates
of detection increase to 83% and 63% respectively by 15-
21 days, with serum IgA becoming detectable a few days
later (Haworth and Dilling, 1966). The investigators used
cotton- wool to collect parotid saliva however, and
acknowledged potential contamination by mixed saliva
and loss of IgA by absorption onto cotton-wool by this
method. They also used the insensitive radial immunodif¬
fusion technique for immunoglobulin determination. A more
recent study using ELISA detected specific IgA and IgM
antibodies to E. coli 0 antigen and to poliovirus type I
on day one of life in neonates. These antibodies were
found in saliva of a child whose mother had hypogamma-
globulinaemia (Mellander et al, 1986). A comprehensive
longitudinal study, using mixed saliva, of 165 infants
followed for 5 years demonstrated low (<1 ELISA unit)
levels of antibodies to E. coli for the first 4 years of
life (Gleeson et al, 1987a). Low levels of salivary IgM
were detected at four weeks, and IgD was present in an
inverse concentration to IgA. It was thus rarely detected
after six months of age (Gleeson et al, 1987b). A further
well-conducted study by this group suggested a maturation
9
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sequence for IgA in saliva. Sucrose density gradient
centrifugation was used to study the molecular form of
IgA; they demonstrated that whilst in the first year of
life both monomeric and dimeric IgA could be detected in
saliva, that by the second year only the dimeric form was
found. Secretory component was always present, but was
not biochemically linked to the monomeric IgA present
(Cripps et al, 1989).
Further maturation of salivary immunity occurs through
childhood, with children at 12 to 17 months having higher
whole salivary IgA concentrations than those aged 12
months or less. This may be linked to the eruption of
teeth; the use of whole saliva unfortunately prevents
clear interpretation due to the possibility of crevicular
leakage (Gahnberg et al, 1985). A study of 1,539 children
suggested that IgA was generally lower than in adults,
but reached adult levels at age 6 years; unfortunately
IgG and IgM were not assayed (D'Amelio et al, 1986). Most
studies concur that adult salivary immunoglobulin concen¬
trations are reached by four to six years of age, and
specific antibody titres somewhat later at five to nine
years (D'Amelio et al, 1986; Tenovuo et al, 1987; Gleeson
et al, 1987a).
Influence of breast feeding
Breast feeding increased total salivary IgA and IgM
levels, and specific IgA antibody levels to E. coli, at 6
days in 15 breast-fed infants, but not salivary IgG or
10
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IgM antibodies to E. coli, nor any isotype of antibody to
tetanus toxoid when compared with 15 bottle-fed infants.
By 6 weeks however the antibody levels in the two groups
of infants were similar (Stephens, 1986). Others have
failed to find any influence of breast feeding on the
ontogeny of the salivary immune response (Gleeson et al,
1982), or found that bottle-fed infants had higher sali¬
vary IgA levels (Ostergaard, 1985). Unfortunately these
studies were also carried out on whole saliva.
Ageing and salivary immunity
There is a large literature on the influence of ageing on
systemic immune parameters but few studies of its effects
on secretory immunity. The published work is almost
exclusively concerned with salivary immunity. In a small
study, reported in abstract only, using insensitive
radial immunodiffusion techniques on unstimulated saliva
obtained after breakfast, total salivary IgA and IgG
levels were not different between 10 young and 10 old
subjects; IgM was not detected (Ganguly et al, 1987).
Others have demonstrated a fall in total IgA concentra¬
tion in human nasal secretions with age (Alford, 1968).
Whilst IgA subclasses in parotid saliva did not change
with ageing in a comprehensive study by Smith et al, they
did find low levels of specific antibody to S. mutans GTF
and poliovirus in elderly humans (70-91 years) when
compared with young adults. This may reflect changes in
the number or function of T and/or B cells, or simply
decreased antigen exposure (Smith et al, 1987a). Dimin-
11
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ished salivary and nasal secretory responses to influenza
immunisation have been noted in a well-designed study
comparing young adults with adults aged >60 years. Whilst
this may be interpreted as decreased capacity for immune
response, (Waldman and Bergmann, 1987) it may reflect the
higher pre- existing specific antibody levels found in
the saliva and nasal secretions of elderly subjects which
might exclude the pathogens. Furthermore, the "elderly"
subjects were not particularly elderly.
In summary, there is general agreement that secretory
immunoglobulins and antibodies in saliva become detect¬
able in the neonatal period, and slowly mature to adult
levels by age 4-9 years. There is no conclusive evidence




PHYSIOLOGY OF SALIVARY IMMUNOGLOBULINS
Relationship to salivary flow and proteins
There are many studies demonstrating the marked variation
in salivary protein concentrations and composition, and
these have been briefly reviewed (Dawes, 1981). Although
IgA secretion rate and concentration has been meticulous¬
ly studied by Brandtzaeg, and reported in a classic
series of papers, (Brandtzaeg et al, 1970; Brandtzaeg,
1971a and 1971b) neither total IgG nor IgM, nor anti¬
bodies of any specificity have been subject to such
scrutiny. Brandtzaeg was also limited by the relatively
crude methodology available at that time, and found it
necessary to concentrate saliva forty times using acryla-
mide rods after addition of merthiolate preservative, and
sometimes to further concentrate, by lyophilization,
prior to assay by single radial immunodiffusion. Use of
sensitive, modern ELISA techniques removes the need for
any of these processing steps with their concomitant
estimated loss of IgA of at least 20% (Brandtzaeg et al,
1970), indeed for this thesis samples of saliva needed
dilution rather than concentration to achieve optimum
assay conditions (chapter 4).
Despite these caveats it seems clear from these and other
studies that salivary IgA concentrations are inversely
correlated with salivary flow rate (Mandel and Khurana,
1969; Brandtzaeg, 1971b). This inverse relationship seems
to hold true when prolonged stimulation or collection of
13
Review
saliva is undertaken, but no data exists on sampling
limited to a few minutes. Brandtzaeg took continuous
whole and parotid salivary samples for up to 105 minutes
from seven subjects and showed that when flow rate in¬
creased salivary IgA concentration decreased, but that
the rate of IgA secretion increased. Salivary flow was
simulated by lemon juice, and serial samples over an hour
using this technique gave consistent results for IgA
concentration (Brandtzaeg, 1971b).
The relationship of IgA with total salivary protein or
components such as lactoferrin, peroxidase, and lysozyme
is weak or absent (Brandtzaeg, 1971b; Rudney and Smith,
1985), and the authors conclude that IgA should not be
expressed as a function of total protein present.
Effects of food and eating
Only a single small study using insensitive methodology
has addressed the effect of eating itself on salivary IgA
concentration; IgA concentration fell after a meal (South
et al, 1966). A further small study which is nevertheless
unique studied the influence of regular ingestion of a
food (yogurt) on the levels of antibodies to two compo¬
nents of that food (Streptococcus thermophilis and Lacto¬
bacillus bulgaricus). Antibodies were present in both
groups but no differences in IgA, IgG, or IgM antibody
levels in saliva (or urine) were found when comparing
yogurt eaters with non-eaters, although serum IgG anti¬
bodies to S. thermophilis were higher in the yogurt
14
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eaters. Antibody levels to Streptococcus lactis were
studied before and after eating a fermented milk product
containing the bacterium. Antibodies were present prior
to ingestion, and did not change in titre (Carlsson and
Bratthall, 1985). One interpretation of these data is
that the bacterium was excluded from the gut by these
antibodies and was thus unable to stimulate the mucosal
immune apparatus; this explanation is also suggested by
several studies discussed later (Clancy et al, 1983;
Waldman et al, 1986; Waldman et al, 1987).
Differences between whole and parotid saliva
When studying saliva the choice of which type of saliva
to collect is limited to either whole (mixed) saliva, or
to parotid saliva for practical reasons . Several au¬
thors have demonstrated that whole saliva is partly
comprised of small but significant amounts of serum-
derived crevicular fluid (which includes, of course,
serum immunoglobulins) which seeps out at the gingival
margins (Brandtzaeg et al, 1970; Izutsu at al, 1985;
Lindstrom and Folke, 1973) . This contamination, especial¬
ly when there is inflammation in the oral cavity, may
lead to high IgA and IgG concentrations in whole saliva.
A comparison of whole salivary immunoglobulin concentra¬
tions in healthy elderly people with and without teeth
found that those subjects without teeth had 80% less
total IgG than their dentate peers. Unfortunately parotid
saliva was not analysed (Gronblad and Lindholm, 1987).
Parotid saliva is not susceptible to contamination by
15
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crevicular fluid and, although the authors debate about
the real contribution of crevicular leakage to whole
salivary immunoglobulin and antibody concentrations, the
consensus view is that parotid saliva is the purer secre¬
tory fluid.
Physiological variation in salivary immunoglobulins and
antibodies
There are conflicting studies on the day-to-day variation
in secretory immunoglobulin concentrations and specific
salivary antibody levels between individuals. Unstimulat¬
ed and, even moreso, stimulated salivary IgA levels in
children showed good correlation over both a short (10
minutes) and long (two years) period in one study (Brat-
thall and Widerstrom, 1985). Unfortunately whole saliva
was collected, and, where appropriate, secretion was
stimulated by the subjects chewing paraffin gum, a sub¬
stance which absorbs immunoglobulins (Brandtzaeg, 1973).
In another study IgA in whole saliva and parotid saliva
was subject to marked variability in seguential samples
taken from individuals at weekly intervals (Rudney et al,
1985). In both studies there was good correlation between
immunoglobulin concentrations in stimulated and unstimu¬
lated saliva. The only paper which assessed specific
antibody variation over a prolonged period (4 months)
demonstrated marked fluctuations in antibody levels to
oral streptococci in 12 serial samples of parotid saliva.
Antibody levels correlated with each other, and with
total IgA concentration in the five subjects studied in
16
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this small but important paper. Interestingly parotid
saliva had greater antibody activity than whole saliva
(Gahnberg and Krasse, 1981).
Circadian and hormonal influences
A large prospective analysis of whole salivary IgA con¬
centrations in 289 children over three years showed no
seasonal fluctuations, although IgA did vary considerably
within an individual. It would have been valuable to
sample saliva more than twice a year in order to exclude
significant alterations (Wagner et al 1982). A much
smaller study of the influence of the time of year on
salivary IgA in nine subjects did find fluctuations but
was flawed methodologically in several areas. Paraffin
gum chewing was used to stimulate whole salivary flow.
This may increase crevicular leak and may absorb immuno¬
globulins from the saliva (see above). Different dura¬
tions of salivary collection were employed, and parotid
salivary samples were collected for unspecified periods
until a certain volume of saliva had been obtained,
immediately after collection of whole salivary samples.
The study showed that both for whole and parotid saliva,
IgA concentration is lower in springtime than in autumn,
and non-specifically increased in pregnancy, especially
in the third trimester and early post-partum period
(Widerstrom and Bratthall, 1984) . A further study on
hormonal variations throughout the menstrual cycle did
not show any effect on salivary immunoglobulin concentra¬
tions (Bratthall and Widerstrom, 1984). Others have shown
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a decrease in salivary IgA in the premenstrual phase of
the cycle in man (Kubitz et al, 1986). No other gender-
related differences have been reported, and a study of
1,539 subjects demonstrated no difference in IgA concen¬
trations between male and female children (Aguirre et al,
1987) .
Stress
Stress has repeatedly been shown to be associated with a
decreased salivary IgA, as is "negative" mood, whilst a
"positive" mood, relaxation, and happiness are associated
with an increase in salivary IgA concentrations (Jemmott
et al, 1983; Dillon et al, 1985; Green and Green, 1987;
Kubitz et al, 1986; Stone et al, 1987). In a number of
the studies correlation of decrease in IgA with stress
(within subjects) was poor, and definitions of stress
were loose. No account was taken of tobacco or alcohol
use (Jemmott et al, 1983; Stone et al, 1987). However the
uniformity of results in the papers, studying either
whole or parotid saliva and using different types of
stress, supports the relationship. The decrease in sali¬
vary IgA concentration may occur shortly after the end of
the stressful period, may be preceded by a transient
increase, and may be related to high catecholamine levels
generated by the stress (McClelland et al, 1985).
Exercise
Severe exercise transiently reduces salivary IgA and IgM,
the effects lasting less than 24 hours. Along with other
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described immune alterations this supports anecdotal
statements by athletes of an increased susceptibility to
illness during intense training (Tomasi et al, 1982;
Mackinnon et al, 1987).
Nutrition
In studies on the effect of nutritional status on sali¬
vary immunity, diminished IgA concentrations were only
found in those children who were severely malnourished
and in whom gut and other infections and infestations
were present (Watson et al, 1985). Another study of
malnourished adults found an increased concentration of
salivary IgA and IgG. Cotton-wool was used for salivary
collection, which took much longer in the malnourished
group than the controls. Most of the patients had neo¬
plastic disease or chronic inflammatory disease whereas
the controls largely had ischaemic heart disease. Like
the first study, radial immunodiffusion was used to
quantify immunoglobulins (Cheatham et al, 1984). Thus the




SALIVARY IMMUNITY AND ORAL INFECTION
Introduction
The interpretation of studies on the effects of secretory
immunity on oral infection must be tempered with the
knowledge that just as in the more distal gastrointesti¬
nal tract, defence mechanisms are multiple and include
other proteins such as lactoferrin, peroxidase, lysozyme,
an intact mucosa, and salivary flow. Support for this
multifactorial scheme comes from several studies, con¬
firmed and reviewed by Tenuvuo (Tenuvuo et al, 1987).
Dental caries
Conflicting reports of salivary total immunoglobulin
concentrations and of specific antibody levels in dental
caries exist. Salivary antibodies may protect the oral
cavity; IgA anti-S. mutans antibodies in parotid saliva
decreased numbers of S. mutans bacteria found in both
dental plaque and in whole saliva following 10 days of
oral immunisation with killed S. mutans bacilli (Gregory
and Filler, 1987). A detailed survey of antibodies to
seven S. mutans serotypes in 12 volunteers suggested that
dental colonisation by S. mutans species was inversely
proportional to specific salivary IgA antibody levels
(Gregory et al, 1985). Other work described above sup¬
ports this finding (Smith and Taubman, 1987a). A high
natural level of parotid salivary IgA anti-S. mutans
ribosomal antibody correlated in healthy individuals with




However others have found that caries-susceptible chil¬
dren had a more rapid increase in whole salivary total
IgA concentrations in the second year of life compared
with controls, although levels fell towards those of the
caries- free controls by 4 years of age (Alaluusua,
1983). In a study which measured parotid salivary total
IgA by single radial immunodiffusion, high IgA concentra¬
tions were inversely correlated with the incidence of
caries, and positively related to gingival inflammation
(Orstavik and Brandtzaeg, 1975). Unfortunately the use
of total immunoglobulin levels rather than antibodies,
and of whole saliva, render interpretation of many of
these reports difficult (Bruno et al, 1985).
Upper aero-alimentary infection
In oral candidiasis specific salivary anti-Candida albi¬
cans IgA antibody was increased, falling with treatment
of the infection towards normal. No details of the meth¬
odology or timing of collection, nor the type of saliva
are given (Jeganathan et al, 1987). Total salivary IgA
was decreased in the acute phase of infectious mononu¬
cleosis (Marklund et al, 1984), although to confirm the
theory that mucosal immunoincompetence leads to suscepti¬
bility to infectious mononucleosis, sampling should
really have been prospective and have included data from
subjects not acutely ill.
A remarkably low mixed salivary total IgA concentration
was found in children prone to upper respiratory tract
infections (Lehtonen et al, 1987). Salivary IgA levels
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when the children were healthy were inversely correlated
with the number of upper respiratory tract infections
contracted in one year in another study of children, with
salivary IgA levels rising considerably during an acute
respiratory infection (Isaacs et al, 1984). A decreased
salivary IgA level in patients with active graft-versus
host disease may explain why these subjects are predis¬
posed to sino-bronchial infection (Izutsu et al, 1983;
Izutsu et al, 1985).
Experimental induction of salivary antibodies
There have been a number of recent studies on the effects
of natural exposure to or vaccination with various bacte¬
rial and viral antigens on salivary antibody response. An
oral killed polyvalent bacterial vaccine containing
Haemophilus influenzae and Staphylococcus aureus, given
on three occasions over two months resulted in an in¬
crease in antibodies to H. influenzae in the parotid
saliva of 55% of subjects compared with 6.7% of controls
taking placebo. The antibodies were mainly IgA, and there
was no change in total salivary immunoglobulin concentra¬
tions, in specific salivary antibodies to a control
antigen (E. coli), or in serum antibodies. The presence
of high pre-immunisation antibody levels was inversely
correlated with the antibody response to vaccination
(Clancy et al, 1983) .
Natural exposure of infants to poliovirus resulted in
salivary antibodies detectable at one month of age,
reaching adult levels by six months. Vaccination with
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either live attenuated or inactivated virus by mouth
required three doses before antibodies were detected,
with a further increase in levels after a fourth vaccina¬
tion. Not surprisingly, natural exposure seemed more
efficient at inducing a response than vaccination (Carls-
son et al, 1985). In a study flawed by the use of whole
saliva stimulated by chewing paraffin gum (see above),
the above results were reinforced in an investigation of
natural cholera infection and oral vaccination with B
subunit-whole cell vaccine. Following natural infection
>80% of patients had a rise in salivary specific anti¬
bodies compared with 44% after two vaccinations (Jertborn
et al, 1986), [see below for more details].
Other studies have demonstrated the independence (from
systemic immunity) and kinetics of the salivary immune
response. A well-conducted study of 14 subjects and 11
controls showed a rise in parotid salivary specific
antibodies after an intensive schedule (13 doses in the
first regime, followed by 5 doses in the second regime)
of oral vaccination with a Streptococcal GTF combined
with aluminium phosphate as an adjuvant. No changes
occurred in serum antibodies. No rationale is given for
the large number of immunisations however, and only one
control group, immunised with aluminium phosphate, was
used. A second group of controls given streptococcal GTF
would have allowed assessment of the usefulness or other¬
wise of the adjuvant effect of the aluminium phosphate
(Smith and Taubman, 1987a).
In a well-designed but small study (n=8) both IgAl and
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IgA2 antibodies were induced in parotid saliva and other
secretions by oral vaccination with killed S. mutans
given daily for ten days. The antibodies persisted for
>50 days. Seven further days vaccination resulted in a
more rapid and greater response which persisted longer
than previously (Gregory and Filler, 1987). Furthermore
in these last two studies there was an effect on both S.
mutans reaccumulation (Smith and Taubman, 1987a) and
viability in dental plague (Gregory and Filler, 1987).
Three papers report on the comparative efficacy of sali¬
vary antibody induction via parenteral and oral routes. A
killed pertussis vaccine was given either orally or
parenterally on days 2, 3, 4, and 5 after birth, followed
by a booster dose at 42 days in over 20,000 neonates.
Oral vaccination led to IgA specific antibodies in whole
saliva in the majority of children, whereas parenteral
vaccination did not result in any salivary antibodies
(Baumann et al, 1985). Salivary antibodies in whole
saliva in a group of children who received oral poliovi-
rus vaccination at two months were compared with a group
who had two parenteral vaccinations at 9 and 10 months.
At age one year, 26% of the orally vaccinated group had
antibodies, compared with 9% of the parenterally vacci¬
nated group. Unfortunately the groups were from differ¬
ent countries (North America and Scandinavia), and the
parenteral group was small, 13 subjects, (Smith et al,
1986). A double-blind, placebo-controlled, trial of oral
enteric-coated versus intra-muscular killed influenza A
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vaccine demonstrated a rise in salivary (and nasal) IgA
specific antibodies after four weeks only in the orally
vaccinated group. Once more, pre-immunisation antibody
levels were inversely correlated with the post-vaccina¬
tion antibody rise (Waldman et al, 1986) .
Two reports suggest memory for both cellular and humoral
components of the local IgA immune response at the mucos¬
al level to both bacterial and viral antigens (Ebersole
et al, 1983; Wright et al, 1983).
Correlations between antibodies in saliva, other secre¬
tions, and serum
A paper describing antibody responses to acute rotavirus
infection in the serum and duodenal secretions of ten
children reports that one week after their diarrhoeal
illness, there was a significant rise in IgM specific
antibodies in both serum and secretions. In the convales¬
cent phase four weeks later IgA and IgG antibodies were
present in serum, and only IgA antibodies in duodenal
secretions. Ten children with bacterial enteritis acted
as control subjects (Davidson et al, 1983).
Gut lavage was used to obtain samples of intestinal fluid
for assay of four antigens of enterotoxigenic Escherichia
coli in 15 patients with acute watery diarrhoea due to
the bacterium. Serum, saliva, and breast milk were also
assayed. The majority of patients had a greater than two¬
fold increase in their intestinal fluid antibody levels,
and associated rises in saliva and breast milk antibody
levels. However, the relationships between these incre-
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merits were not clear (Stoll et al, 1986).
A key paper, briefly alluded to above, assessed antibody
responses in whole saliva, breast milk, and serum, and
made comparisons with intestinal secretions obtained by
saline lavage of the gut following oral cholera vaccina¬
tion or natural disease (Jertborn et al, 1986) . There
were a few relatively minor methodological problems;
heat-treated whole saliva was used, and intestinal lavage
was heat-inactivated and concentrated, which may account
for the poor reproducibility in duplicate testing of
samples. The numbers of patients who responded with a
rise in antibody levels restricts interpretation of the
data, some of which (correlations) would have been more
appropriately analysed by non-parametric methods. Despite
these criticisms the findings remain important. After
three immunisations, 13 of 15 subjects had a rise (> 2.3-
fold) in antibodies to cholera toxin in gut lavage fluid,
and 7 of 15 subjects had a rise (>1.5-fold) in salivary
antibodies. The rise in salivary antibodies had a sensi¬
tivity of 53% and 50% in predicting a rise in intestinal
antibody levels after one and two immunisations respec¬
tively, with positive predictive values of 77% and 88%.
IgA specific antibodies to cholera in saliva correlated
with IgA antibodies in intestinal lavage after both the
first (r=0.48, n=25) and second vaccinations (r=0.51,
n=18; p<0.05 for both). Furthermore, lavage IgA anti¬
bodies correlated with both serum IgA (r=0.4, n=25,




In a study reported in brief, antibodies to S. mutans (a
common oral commensal bacterium) were measured in tears
and parotid saliva and found to be of similar levels, the
conclusions being that a common mucosal immune system
regulated levels from a distance (Allansmith et al,
1983) . A further paper from the same group reverses the
original conclusions. Antibody levels were higher to S.
mutans in parotid saliva than in tears, whilst antibody
levels to Staphylococcus epidermidis (a skin commensal)
were the reverse of this pattern. The final conclusion
was that local antigen concentrations regulate the final
level of antibodies in secretions (Gregory and Allan-
smith, 1986). However this thesis founders on the assump¬
tion that the parotid gland is local; unless antigen
travels up the parotid duct from the oral cavity, induc¬
tion of antibodies by oral antigens must be indirect. The
high serum titres found also suggest that systemic immu¬
nisation has occurred and this may bias analysis from the
mucosal standpoint.
Thus salivary antibody function may parallel that in more
distal intestinal secretions, reducing viral, bacterial,
and fungal colonisation and infection as referred to
above (Baumann et al, 1985; Czerkinsky et al, 1987; Holt
et al, 1987; Kurz et al, 1986; Jertborn et al, 1986;




IgA is the serum immunoglobulin most commonly deficient,
with approximately one in 700 adults with low or unde¬
tectable levels (Haeney, 1990). The equivalent data for
salivary IgA is derived from three studies. In two stud¬
ies from the same group, published two years apart, the
incidence of salivary IgA deficiency was 3 of 1000 adult
males by radial immunodiffusion using a 7S standard
(D'Amelio et al, 1982), and none of 315 adult males using
a more sensitive nephelometric assay (D'Amelio et al,
1984). No details of the method of salivary collection
are given. In infants the incidence of salivary IgA
deficiency fell from 6% at 4 months of age to 1% at 20
months, where the lower limit of detection was 5mg/L (van
Asperen et al, 1985).
Salivary IgA deficiency may predispose to an increase in
the frequency and severity of atopy (Taylor et al, 1973).
Salivary IgA deficiency was more frequent amongst the
infants of atopic parents when compared with children of
non-atopic parents, but within the former group absence of
whole salivary IgA did not result in a greater incidence
of clinical atopy (Van Asperen et al, 1985). Atopy in the
infants, who were aged four to 20 months, was based on
reported symptoms and skin prick testing, both of which
may not be more than 50% specific or sensitive (Lehmann,
1980). However, others have also found that salivary IgA
concentration is low in atopic children with a diagnosis




In assessing any possible effects of salivary IgA defi¬
ciency it seems important to measure specific antibody
levels as well as total immunoglobulin concentrations. In
salivary IgA deficiency peak serum immune complex levels
after a milk challenge were inversely related to the
titre of antibodies to milk proteins in saliva, but not
to total serum or salivary immunoglobulins (Cunningham-




The effects of smoking on the systemic immune system have
been extensively studied, and recently were comprehen¬
sively reviewed (Holt, 1987) . In particular, it seems
that smoking is associated with a decrease in serum
levels of immunoglobulins A, G, and M, and, generally,
increased IgE and IgD concentrations (Burrows et al,
1981; Burrows et al, 1982; Gerrard et al, 1980; McSharry
et al, 1985; Robertson et al, 1984; Warren et al, 1982),
some reports dissenting (Friedhoff et al, 1986). Where
studied, these alterations were found to be reversible.
Natural killer cell activity is reduced (Ginns et al,
1985; Sopori et al, 1985), certainly in heavy smokers
(Phillips et al, 1985). Total T cells and both T^ and (to
a lesser extent) Tg cells are increased in moderate
smokers, with heavy smokers in contrast showing a de¬
crease in the Th^s ratio, although Ts function was im¬
paired when assayed with PWM stimulated cells (Burton et
al, 1983; Hughes et al, 1985). Again these effects were
thought to be reversible. In uterine cervical epithelium
there were reduced numbers of macrophages in smokers
(Barton et al, 1988).
Surprisingly studies directed at exploring the effects of
smoking on the mucosal immune system are scarce. There
have been a few studies on total immunoglobulin concen¬
trations in saliva. A small (n=8), highly selected, group
of elderly edentulous males had decreased whole salivary
IgA, comparisons between other groups of smokers and non-
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smokers failing to demonstrate any difference in IgA
concentrations. No standards were used in the assays, of
which some were radial immunodiffusion and some immuno-
turbidimetric because of instrument unavailability
(Bennett and Reade, 1982) . A further study limited by
size and inappropriate statistics showed a trend towards
an increase in whole salivary IgA on stopping smoking
which failed to reach significance, (Hersey et al, 1983).
Others used paraffin-chewing to stimulate whole salivary
flow, but failed to find any differences in IgA concen¬
trations between smokers and non-smokers, nor any effect
of nicotine chewing gum alone on salivary IgA in a large
investigation (Olson et al, 1985). A paper on secretory
IgA concentrations in oropharyngeal carcinoma also as¬
sessed smoking and non-smoking controls using two methods
of collection for whole saliva, 1) simple expectoration
for 15 minutes, followed by 2) saline oral washing. In
the expectorated samples from smokers low IgA levels were
observed, whereas in the washings high concentrations
were present when compared with the non-smoking controls.
The groups were small (9 smokers, 8 controls), four of
the smokers had severe periodontal disease, and the
controls were subjects with miscellaneous oto-rhino-
laryngological conditions including allergic and infec¬
tive diseases. The patients with carcinoma had high
concentrations of IgA in their saliva, which was mainly
secretory (Watanabe et al, 1983).
Few papers have addressed the effects of smoking on
either serum or secretory antibody responses to mucosal-
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ly- encountered antigens. The studies which have done so
have generally recorded a diminished serum antibody
response to antigens encountered at mucosal surfaces.
Antigens associated with pigeon breeders lung were as¬
sessed in the serum of pigeon breeders in central Scot¬
land. Serum antibodies were detectable in one of 23
smokers, compared to 39 of 65 non-smokers, with an in¬
crease in antibody levels in ex-smokers in this well-
conducted study (McSharry et al, 1985). Similarly 14 of
15 non-smokers but only 13 of 41 smokers, all working in
the same room in a cigar factory, had serum antibodies to
bacterial antigens found in the humidifier water from
that room and, importantly, this was independent of acute
respiratory symptoms. Nevertheless it is still impossible
to exclude bias due to pre-existing respiratory problems
(Andersen et al, 1982). Titres of serum antibodies to
enterically-encountered antigens (C. albicans and E.
coli) were not different between the groups. Minor criti¬
cisms were that total and not isotype-specific antibodies
were estimated, and the statistical analysis was qualita¬
tive, not quantitative. It is suggested that the lack of
an effect of smoking on these latter two antibodies is
because the two antigens do not enter the body through
the respiratory mucosa where smoking is likely to have
its most profound effect.
The only report on mucosal antibodies in smokers suggests
a decreased production of antibodies to cotton dust
bacterial antigens (Pseudomonas and Enterobacter) in
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nasal secretions of wood and cotton workers at two mills.
Although IgG and IgA antibodies were lower in smokers at
both mills, this difference was only significant for IgG
antibody levels in the workers from the wood mill. Once
more numbers were small, and importantly it is not stated
how many cigarettes were smoked (Rylander et al, 1982).
Two papers assessed the effects of smoking on oro- phar¬
yngeal colonisation with commensal organisms. Increased
concentrations of Lactobacilli and S. mutans were found
in the whole saliva of smokers, numbers of lactobacilli
correlating with cigarettes smoked per day (Heintze,
1984). A large study found that although smokers had the
same carrier rate for Candida albicans in the mouth and
saliva, that those who were colonised had double the
number of colony-forming units compared with the non¬
smoking carriers. However the overlap of results between
the smoking and the non-smoking groups was wide, and the
differences failed to reach statistical significance,
(Oliver and Shillitoe, 1984).
Of relevance are studies of immunoglobulins in respirato¬
ry tract secretions. Although studies of saliva have
found a decrease in secretory immunoglobulins, IgA and
IgG were elevated three- or four-fold in the broncho-
alveolar lavage fluid of 6 smokers (manual/farming work¬
ers, mean age 39.5 years, all males) when compared to 6
non-smoking students (mean age 23 years, three males).
Other proteins in the lavage fluid were unchanged, sug-
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gesting a true local increase in production. No IgM was
detected. This may be a reflection of the insensitivity
of radial immunodiffusion assay (Velluti et al, 1983). In
contrast, mucosal immunodeficiency induced by smoking has
been demonstrated by decreased IgA levels in broncho-
alveolar lavage (Gotoh et al, 1983). Others have failed
to demonstrate any difference in IgA concentrations, but
found an increase in IgG (Warr et al, 1977).
A study of cells in broncho-alveolar lavage fluid ob¬
tained from volunteer non-smokers and smokers show that
the latter have diminished numbers of 0KT4+ and increased
numbers of 0KT8+ cells, the changes correlating with
total smoke dose. In peripheral blood there were higher
leucocyte, total lymphocyte, and OKT8+ cells in the
smokers, but no significant change in the OKT4/OKT8
ratio. In contrast in lavage the alteration in the ratio
of OKT4/OKT8 cells was highly significant (Costabel et
al, 1986).
Two recent studies provide further evidence of the ef¬
fects of smoking on local aero-alimentary immunity. In a
case-controlled study of naso-pharyngeal meningococcal
carriage during an outbreak of meningococcal disease,
smoking significantly increased the carriage rate. The
more cigarettes smoked, the greater the odds ratio, espe¬
cially above 20 cigarettes daily. Unfortunately secretory
antibodies to meningococcus were not measured (Stuart et
al, 1989); diminished local antibody production may have
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accounted for the increased carriage rate. A study of
smoking habits in platinum refinery workers demonstrated
convincingly that smoking increases, in a dose-dependent
manner, the risk of developing occupational sensitisation
to platinum salts. Platinum is known to induce occupa¬
tional asthma, although the study addressed skin tests
and respiratory symptoms, and not reversible airways
obstruction. However smokers, especially of more than 10
cigarettes daily, were much more likely to develop a
positive skin test, respiratory symptoms, and to leave
employment because of these symptoms than were non-
smokers (Venables et al, 1989).
Summary
There is a reversible decrease in serum IgA, IgG and IgM,
and an increase in IgD and IgE in smokers. There are
diminished serum (and possibly secretory ) antibody
responses to antigens encountered via mucosal surfaces.
There is an increase in the carriage rate or colonisation
of aero-alimentary pathogens in smokers. There are no
real data on the influence of smoking on salivary immuno¬
globulin concentrations, and conflicting data on immuno¬
globulin concentrations in respiratory tract secretions.
INTESTINAL, FLUID PHYSIOLOGY
Introduction
There has been little or no systematic study of immuno¬
globulins or antibodies in intestinal fluid in vivo in
man. The few reports which exist have mainly used jejunal
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aspirate as the gut secretion. One group has used saline
to lavage the gut, and another assayed solid faeces. Most
studies are descriptive, and provide no information on
basic gut secretory physiology. All reports can be fault¬
ed in one or more of several areas: small numbers of
subjects, heterogeneous groups of both controls and
patients, failure to use protease inhibitors (immediate¬
ly) , the use of insensitive assays, and inappropriate
statistical analysis. Nevertheless, they are the only
reports available, and as such are summarised below.
Cells and secretions
Early studies on duodenal aspirate universally demon¬
strated the prescence of IgA but failed to detect IgM or
IgG in 80% of the samples. This may have been because of
insensitive methodology, or a failure to use protease
inhibitors, (eg. Plaut and Keonil, 1969). There is common
consensus that intestinal fluid IgA and IgM are locally
produced (Jonard et al, 1984), but debate as to whether
or not IgG and IgD are locally or plasma derived (Hjelt
et al, 1988) . Virtually all studies have found that IgA
is present in the highest concentration, followed by IgM
and IgG. More recently others have detected IgD in small
amounts (Hjelt et al, 1988), and IgE-producing plasma
cells have been demonstrated in gut mucosa, although
molecular IgE itself has not been found in secretions
(Savilahti, 1972) .
Intestinal IgA was found to be present both as a dimer
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and monomer, just as is the case with saliva (Bull et al,
1971).Intestinal IgA increases in concentration with age,
at least in childhood, with children under two years
having lower concentrations than older children (Savi-
lahti, 1972). In a study, on faeces, of a miscellany of
diseases presenting with diarrhoea, the ratio of monomer-
ic to total IgA increased, as did total IgA concentra¬
tions (Meillet et al, 1987). Adults have higher ratios of
polymeric to monomeric IgA which correlates positively
with polymeric IgM concentrations (Hjelt et al, 1988) .
There seems to be little variation with time in IgA
concentration in freeze- dried stools in a sequential
study, a single sample correlated well (r=0.84) with the
mean of a daily complete stool collection and concentra¬
tions seemed to be stable over several days (Haneberg and
Aarskog, 1975). No data are available on either intesti¬
nal immunoglobulins or antibodies in elderly humans.
Effects of eating, and of infection
The effects of a meal on duodenal and upper small bowel
immunoglobulin concentrations has only been subjected to
a cursory study in four volunteers, levels increasing in
two and decreasing in the other two subjects (Samson et
al, 1973). On the effects of intestinal infection however
there is consensus. IgA concentrations increase in intes¬
tinal fluids or faecal samples after gastroenteritis due
to salmonella (LaBrooy et al, 1980; LaBrooy et al, 1982;
Hoj et al, 1984), Yersinia (Fletcher et al, 1988), ro¬
tavirus (Davidson et al, 1983), shigella (LaBrooy et al,
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1980; Keren et al, 1988), experimentally-induced and
naturally acquired cholera infection (Jertborn et al,
1986), and in fact any infectious gastroenteritis (Hane-
berg and Aarskog, 1975) or diarrhoeal disease (Meillet et
al, 1987).
With gut infection, IgM antibody levels rose quickly but
were not sustained, although as might be expected, the
specific IgA antibody concentrations were maintained
(Davidson et al, 1983). Antibody titres showed enormous
variation both in initial magnitude of response and in
rate of decline, with antibody being detectable for as
little as two weeks or as long as one year after acute
infection (LaBrooy et al, 1980). One group perfused
isolated jejunal loops in vivo to assess the antibody
response to typhoid vaccination. A specific antibody
response was induced in all 14 subjects, and was present
three weeks later (Bartholomeusz et al, 1990). There was
no correlation between serum and intestinal antibody
levels.
Correlations between antibodies in lavage and in other
fluids.
Studies addressing the correlation between immunoglobulin
concentrations and antibody titres in intestinal fluid
with values in other secretions have given variable
results. No correlation with parotid saliva was found in
one study, although groups were heterogeneous and small
in number, and may have been at different stages of gut
infection (LaBrooy et al, 1980). Whole gut saline lavage
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was used to obtain intestinal fluid in order to assess
gut secretory antibody response after natural cholera
infection or vaccination. IgA specific antibodies were
induced in gut lavage fluid in the majority of subjects,
and parallelled by a rise in IgA antibody titres in whole
saliva (r=0.51, p<0.05), in breast milk, in serum (r=0.4,
p<0.05), and by IgG antibody titres in serum (r=0.55,
p<0.01), (Jertborn et al, 1986).
Generally, although the relative numbers of IgA, IgM, and
IgG gut plasma cells are reflected by the concentrations
of immunoglobulin isotypes in gut fluid, no-one has
satisfactorily demonstrated any correlation between the
two parameters (see below).
Investigation of intestinal immunity
Only recently has a pilot study using a safe, non-inva¬
sive technique been described which allows assessment of
intestinal secretory immunity. A non-absorbable polyet-
hyleneglycol-electrolyte lavage solution, taken orally
allows measurement of immunoglobulins in gut fluid, and
is safe in patients with renal, hepatic, and cardiac
disease (Gaspari et al, 1988).
Inflammatory bowel disease
Little information exists on secretory immunoglobulin
concentrations in patients with inflammatory bowel dis¬
ease. Levels of IgA were normal, but IgG was high in the
freeze- dried faeces of patients with quiescent ulcera-
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tive colitis (Haneberg and Aarskog, 1975). There were no
differences detected between controls and 36 heterogene¬
ous patients with Crohn's disease when jejunal aspirate
was assayed, and no correlation between jejunal aspirate
immunoglobulin concentrations and in vitro jejunal biopsy
immunoglobulin production (Jones et al, 1976). In one
other study resected small and large bowel specimens from
nine patients with Crohn's disease were perfused with
saline at 4oC for 24 hours. There was a higher recovery
of IgG from involved mucosa when compared with uninvolved
bowel (Bergman et al, 1973).
In contrast many reports exist on the mucosal cell popu¬
lations and in vitro immunoglobulin production in inflam¬
matory bowel disease. Despite some controversy, generally
they demonstrate increased numbers of all isotypes of
plasma cells, with a proportionally greater increase in
the number of IgG cells in involved mucosa (Brandtzaeg
and Baklien, 1976; Rosekrans et al, 1980; Scott et al,
1984). Findings in ulcerative colitis seems to be similar
to those in Crohn's disease (Bookman and Bull, 1979;
Soltoft, 1969)
Coeliac disease
In patients with coeliac disease jejunal aspirate IgA,
IgG and IgM are reported to be increased in one report
(Lancaster-Smith et al, 1974), with another study only
able to demonstrate an increase in IgM concentrations
(Douglas et al, 1970).
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Insensitive tests which failed to discriminate between
isotypes showed that antibodies to food proteins are
detectable in the intestinal fluid of patients coeliac
disease (Ferguson and Carswell, 1972; Katz et al, 1968;
Mawhinney and Love, 1975). Recently, using sensitive
ELISA techniques, two further reports have given con¬
flicting results. One suggests that antibody levels in
intestinal fluid may be correlated with the degree of
intestinal damage (Volta et al, 1988), whereas the other
study does not find this (LaBrooy et al, 1986). Anti¬
bodies to foods can also be found in normal children
however (Ferguson and Carswell, 1972) . In patients with
coeliac disease, jejunal aspirate antibodies to a gluten
fraction and to Blactoglobulin had not significantly
fallen six months after changing to a gluten-free diet,
whilst serum antibody levels did drop (LaBrooy et al,
1986).
Again, more information exists on mucosal plasma cell
populations and immunoglobulin production, the consensus
of which suggests an increase in IgA and IgM plasma cells
(Ciclatira et al, 1986; Douglas et al, 1970; Scott et al,
1984; Wood et al, 1986; Wood et al, 1987), with the occa
sional report extending that finding to IgG cells (Wood
et al, 1987).
Summary
IgA is the predominant immunoglobulin in gut secretions,
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followed by IgM and IgG. All isotypes increase in a
number of gut diseases, such as infection, inflammatory
bowel disease, and coeliac disease, perhaps with IgG
increasing proportionally more in active IBD and IgM in
coeliac disease. A specific antibody response to oral
infection/vaccination can be detected in gut fluids. Few
correlations have been satisfactorily demonstrated be¬
tween gut fluid immunoglobulins or antibodies when assay¬
ing serum or other mucosal secretions, with one or two
exceptions. Little is known about the basic physiology of
intestinal secretory immunity in vivo, especially in
healthy subjects.
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CHAPTER THREE: SUBJECTS AND STANDARD METHODOLOGY
INTRODUCTION
In this chapter the origin and documentation of the
subjects who participated in the studies is described.
Standard methodologies in widespread use, which needed
little or no modification for the purposes of the thesis,
are also described.
SUBJECTS
Pilot studies and technical experiments.
Serum and salivary specimens for the pilot studies were
obtained, with informed consent, from healthy laboratory
and clinical medical staff without noting details of age,
sex, or social habits, and similarly from in-patients on
the Gastrointestinal unit. Permission from the Lothian
area ethical committee had been obtained for the collec¬
tion of serum and saliva.
Salivary and intestinal secretory physiology.
1. Healthy volunteers.
To describe the basic physiology of parotid saliva,
healthy volunteers were recruited from laboratory and
clinical medical staff. All volunteers were taking a
normal diet containing the food protein antigens under
study, and were not abusing alcohol or taking any medica¬
tions likely to influence the studies. Demographic de¬
tails were recorded on a standard proforma (appendix
ix), which included an alcohol and smoking history, a
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dietary history with specific questions on intake of
bread (to allow an approximate guide to the intake of
gliadin), milk (for Slactoglobulin), and eggs (for oval¬
bumin) , a history of any medical problems and a list of
any drugs taken. Demographic data on these healthy volun¬
teers are given in table 3.1.
Table 3.1 Details of healthy subjects — saliva studies
Sex
Subjecrts M F total age smoki
(n) (n) (n) median (range)
Study
18 hr variation 6 3 9 27 (21-31) 1
alcohol 5 3 8 25.5 (23-32) 2
dietary antigens £
eggs - Y 8 13 21 40 (18-92) 4
- N 7 6 13 23 (14-84) 1
bread- Y 8 10 18 34.5 (18-81) 4
- N 7 8 15 25 (14-84) 0
milk - Y 8 11 19 36 (18-92) 4
- N 6 5 11 23 (14-84) 0
Age, sex, and smoking habits of control subjects, from
whom samples were obtained in the studies of salivary
physiology concerning 1) 18 hour variation during a
single day, 2) after a single dose of alcohol, and 3) in
subjects including (Y) or not including (N) eggs, bread,
and/or milk in their diets. Key: * = p=0.04, (Mann-Whit¬
ney test) subjects taking egg significantly older than
those without egg in diet. There were no other signifi¬
cant differences in age, sex, or smoking habits between
the groups (Chi-squared and Kruskal-Wallis tests).
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2. Healthy patients.
Some of the studies on the physiology of immunoglobulins
and antibodies in saliva, serum, and intestinal fluid
were conducted using patients investigated by the gas¬
trointestinal unit for clinical problems. Patients were
deemed healthy and included in the study if at the end of
clinical and laboratory assessment they had a diagnosis
of functional disease, or of minor clinical medical
problems, unlikely to influence the immune parameters
being studied. Patients with infective, immune, inflamma¬
tory, or neoplastic disease were excluded. Full demo¬
graphic details were recorded as above, including the
patients' final diagnosis. Salivary and serum samples
were obtained on all subjects, and in addition if clini-
Table 3.2 Details of healthy subjects - lavage studies
Sex
Subject M F total age (yrs)















Demographic details of subjects participating in study of
physiology of lavage fluid. The groups of control sub¬
jects were derived from healthy volunteers, and from
healthy patients (see text for details). There were no
significant differences for age and sex distribution
between the groups, (Kruskal-Wallis test).
45
Subjects and standard methodology
cal investigation included a barium enema or colonoscopy
patients were asked if they would have lavage as a rapid
bowel preparation (as detailed in chapter 4) rather than
the standard two day laxative regime of sodium picosul-
phate, codanthromer, and oral fluids only. If clinical
investigation included a jejunal biopsy patients were
asked to consent that aspiration of jejunal contents
could also be carried out. Details of these healthy
patients are included in tables 3.1 and 3.2.
3. Patients with dermatitis herpetiformis.
In a collaborative study conducted by Dr. Carolyn McDon¬
ald from this laboratory, in conjunction with Dr David
Table 3.3 Subject details - salivary physiology
Sex
Subject N F total age smokei
(n) (n) (n) median (range)
controls 13 15 28 25.5 (14-34) 6
coeliac disease
- untreated 14 18 32 41.5 (16-78) 9
- treated 14 20 34 42 . 0 (15-72) 7
dermatitis herpetiformis
- ND, NH 8 4 12 58. 0 (27-86) 2
- ND, P/SVA 8 3 11 64.0 (15-83) 2
- GFD, NH 11 8 19 49.0 (28-82) 7
- GFD, P/SVA 15 3 18 52 . 5 (26-77) 5
Age, sex, and smoking habits of control subjects, and
patients with coeliac disease or dermatitis herpetifor¬
mis, from whom samples were obtained in the study of
salivary physiology. Key: ND = normal diet, GFD = glu¬
ten-free diet, NH = normal jejunal histology, P/SVA =
partial or sub-total villous atrophy. No differences
between groups (Kruskal-Wallis test).
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Gawkrodger from the department of Dermatology at the
Royal Infirmary of Edinburgh, a well-defined cohort of
patients with dermatitis herpetiformis was being investi¬
gated.
Table 3.4 Subject details - correlation studies
Sex
Subject M F total age (yrs)
(n) (n) (n) median (range)
Controls
ser/sal vs - lav 9 16 25 53 (21-92)
- asp 13 15 28 25.5* (14-84)
Coeliac disease
Untreated
ser vs - sal 14 18 32 41.5 (16-78)
ser/sal vs - asp 12 14 26 39.5 (16-78)
- lav 6 9 15 43 (28-62)
Treated
ser vs - sal 14 20 34 42 (15-72)
ser/sal vs - asp 9 13 22 42 (15-72)
- lav 8 11 19 46 (16-72)
Dermatitis herpetiformis
NH, GFD 10 11 21 52 (27-82)
P/SVA, ND 12 7 19 54 (15-83)
P/SVA, GFD 17 4 21 52 (26-80)
Heterogeneous subjects
10 14 24 45 (22-72)
Legend: Demographic details of subjects used in study of
relationships within the systemic and mucosal immune
systems. Key - ND = normal diet, GFD = gluten-free diet,
NH = normal jejunal histology, S/PVA = subtotal or par¬
tial villus atrophy; ser = serum, sal = saliva, asp =
aspirate, lav = lavage. Controls having jejunal aspirate
younger than other groups, * p<0.05, Mann-Whitney test.
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On request, samples of saliva were also collected from
these patients in addition to the serum already obtained
for the original study. All patients had had a dietary
history for gluten taken by a trained dietitian and a
recent jejunal biopsy, in addition to other details on
the standard questionnaire as for the healthy patients
above. Clinical details are given in tables 3.3 and 3.4.
4. Patients with Coeliac disease.
Patients presenting with a new diagnosis of, and those
with established and treated, coeliac disease who were
undergoing jejunal biopsy for clinical purposes, were
asked to participate in the study and to give salivary
and serum samples at the time of jejunal biopsy. Clinical
details were recorded on the standard proforma. These
patients were also invited to undergo gastrointestinal
lavage for the purposes of the study on intestinal secre¬
tions. Clinical details are given in tables 3.3 and 3.4.
5. Smoking and epithelial head and neck tumours.
In the first phase of this topic of study, patients with
the following disorders attending the relevant outpatient
clinics at the Royal Infirmary of Edinburgh were recruit¬
ed as non-gastrointestinal disease controls: treated
hyper- and hypothyroidism, obesity, bulimia nervosa, and
patients with epithelial head and neck tumours both
untreated and after a course of radiotherapy. These
patients were recruited with the help of Dr Magdy Riad,
an otolaryngology research fellow, in a collaborative
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study. A control group of healthy clinical, laboratory,
and technical staff including both smokers and non-smok¬
ers were also studied. These control subjects were not
age- and sex-matched for the patient groups, and only
brief demographic details were recorded.
In the second phase of this study, patients newly pre¬
senting with epithelial tumours of the oropharynx, hypo-
pharynx, and larynx to the outpatient clinics of clinical
and radiation oncology at the Western General Hospital
were studied prospectively prior to and following a
course of radiotherapy. Dr Mark Gaze, registrar in radia¬
tion oncology, identified patients and obtained the
samples. Brief details including smoking habits, denti¬
tion, clinical status, and treatment regimen were record¬
ed.
In the third phase of this study, to confirm the findings
from the previous phase, it was necessary to recruit
subjects who smoked but abstained from alcohol. In col¬
laboration with Dr. Riad, who collected the samples,
healthy non-smokers, smokers, and ex-smokers from a non-
drinking population were recruited from clinical, labora¬
tory and ancillary staff, and from patients attending for
the removal of ear wax at the Ain Shames University
Hospitals, Cairo, Egypt. In addition, all patients with
epithelial head and neck tumours who were attending the
Department of Otolaryngology in these hospitals were
invited to participate. Healthy subjects and patients did
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not take alcohol, and non-smoking groups were separately
age- and sex-matched for healthy smokers and for the







non-smokers 31 83 114 19 11 30
smokers 19 9 28 27 20 47
ex-smokers
-2yr - - - 11 10 21
ex-smokers
-5yr - - - 10 7 17
age + sex
matched for
tumour patients — — — 18 10 28
Tumour patients
untreated
-current smokers 13 4 17 14 4 18
- ex-smokers 7 7 7 7 4 11
- non-smokers 7 7 7 0 1 1
- unknown 5 5 10 0 0 0
total 18 9 27 21 9 30
irradiated
-current smokers 0 0 0 7 2 9
- ex-smokers 7 7 7 14 7 21
- non-smokers 7 7 7 0 0 0
- unknown 26 12 38 0 0 0
total 26 12 38 21 9 30
Other malignancies
smokers — — — 4 1 5
non-smokers - - - 7 7 14
total - - - 11 8 19
Sex distribution of subjects from whom parotid saliva was
obtained for the- study of the effects of smoking on sali¬
vary immunoglobulins. Key: ? = not recorded, - = not re¬
cruited. No differences were found when comparisons were
made between appropriate groups (Kruskal-Wallis test).
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Table 3.6 Subject age - smoking study









tumour pts 51.6 (34-61)
Tumour patients
prospective group 65.7 (49-83)
upper aero-alimentary
tract
untreated 56.1 (41-69) 52.7 (31-64)
irradiated 56.4 (31-81) 59.0 (48-73)
other malignancies 53.1 (43-81)
(Cairo)
Median age (range), in years, of subjects from whom parotid
saliva was obtained for the study of the effects of smoking
on salivary immunoglobulins. No significant differences
were found when comparisons were made between appropriate
groups (Kruskal-Wallis test).
tumour patients. Finally, a group of age- and sex-
matched patients with tumours outwith the head and neck
region were recruited from the same hospital. Details of
the site of the tumour in both these and the head and
neck tumour patients were recorded, and are shown in
table 3.7. A control group of patients with tumours
outwith the head and neck were also recruited for com¬
parison. Clinical details of all of the subjects are
recorded in tables 3.5, 3.6, and 3.7.
Patients who had received radiotherapy had been treated
with a standard 52.5 Gy course in 20 treatments over a
mean of 30.14 (±5.8) days, range 26-50. The field of
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irradiation did not include the parotid glands.





















Sites of primary tumours in patients from whom parotid
saliva was obtained in the study of the effects of smoking
on salivary immunoglobulin concentrations
The final phase of this aspect of mucosal immunity in¬
volved obtaining parotid gland specimens. They were taken
from cadavers undergoing routine post-mortem examination
at the Western -General Hospital with the collaboration of
Dr Margaret Mclntyre (consultant pathologist), and from
operative specimens of parotid glands of patients under¬
going parotidectomy for parotid adenoma in the City
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Hospital, the Royal Infirmary, and the Western General
Hospital, Edinburgh. The specimens were kindly collected
by Professor AGD Maran from the department of Otolaryn¬
gology.
6. Inflammatory bowel disease.
Patients were recruited from the new and review gastroin¬
testinal outpatient clinics at the Western General Hospi¬
tal, from those attending the gastrointestinal investiga¬
tion suite, and from inpatients on the gastrointestinal
and surgical wards. For all patients full demographic
details were recorded on the standard proforma as above.
Serum and parotid saliva were obtained from all patients
and, as for coeliac disease, if clinical assessment was
to include barium enema or colonoscopy, or the patients
were due to have surgery necessitating bowel preparation,
they were invited to have that preparation via gut lavage
as above (and see chapter 4). Clinical details are given
in table 3.8.
Clinical questionnaire.
A questionnaire was completed for all subjects, (except
where stated for the pilot studies), healthy volunteers
as well as patients. The format of this questionnaire was
altered at one stage, after the influence of smoking,
alcohol and diet had been appreciated. The questionnaire
is shown in appendix (ix) and records age, sex, diet and
drugs as well as details of health status, smoking,
alcohol intake, and dentition.
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Table 3.8
study
Subject details - inflammatory bowel disease
Sex
Subject N F total age (yrs)
(n) (n) (n) median (range
Controls 9 13 22 30.5 (22-56)
Crohn's disease
active - NS 5 2 7 28 (17-62)
— S 3 8 11 40 (10-66)
total 8 11 18 34 . 5 (10-66)
inactive - NS 1 1 2 41.5 (37-46)
— S 2 3 5 36 (16-65)
total 3 4 7 37 (16-65)
Ulcerative colitis
inactive - NS 12 6 18 51 (27-80)
— S 6 5 11 44 (22-55)
total 18 11 29 46 (22-80)
Demographic details of volunteer subjects, and patients
with inactive and active Crohn's disease, and patients
with inactive ulcerative colitis, subdivided by smoking
habits. Key: NS = non-smokers, S = smokers. There were no
significant differences in age and sex between the groups
(Kruskal-Wallis test).
Universal comments and exclusions.
Full informed consent was obtained in every case. Prior
to collection of saliva in every subject, the oral cavity
was examined clinically for evidence of local sepsis
(overt periodontal sepsis, pharyngitis, tonsillitis,
dental abscess), if any of these conditions were present,
the person was excluded from the study and saliva was not
collected. Similarly, unless specifically stated, any
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subject with immunological, neoplastic, inflammatory, or
an active infective disease was excluded from study.
METHODS
Introduction.
Standard methods for the measurement of total protein and
total antibody activity in body fluids are well estab¬
lished. For the purpose of this thesis, simple, safe,
reliable and reproducible techniques were required,
preferably ones which needed little in the way of extra
equipment. The Pierce modification of the Lowry method
for protein assay was already being used in this labora¬
tory for other purposes.
1. Protein assay.
The Pierce method uses Bicinchoninic acid (BCA) as a
protein assay reagent (Pierce (UK) Ltd, 36, Clifton Road,
Cambridge). It is based on the reaction of protein with
p 4. -|_i.
alkaline copper which produces copper . The stable,
soluble reagent reacts with this copper1-1" to form an
intense purple-coloured solution at 562nm, two molecules
of BCA complexing with one cuprous ion. The standard
protocol is fully described in appendix (i).
The Pierce protein assay is a recent modification of the
Lowry method, offers several advantages over the origi¬
nal, and was thus chosen to assay total protein concen¬
trations in saliva and intestinal fluid. By eliminating
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vortexing and precise, timed reagent addition the Pierce
modification is simpler than Lowry's method, is more
sensitive, has increased compatibility with non-ionic
detergents, and has a wider linear working range.
The Pierce method gave reproducible results and excellent
correlations for the standard curves. In the pilot study,
salivary protein concentrations were a mean 1.684 ± 0.468
(sd), range 0.98-2.54mg/ml (n=26). Although lavage fluid
gave similarly reliable results for protein concentra¬
tions, the addition of various protease inhibitors and
fetal calf serum to the specimens reguired to inhibit
immunoglobulin and antibody degradation (see chapter 4)
added exogenous protein to the assay and prevented inter¬
pretation of total protein concentrations.
2. Enzyme linked immunosorbent assay of serum antibodies.
An enzyme linked immunosorbent assay (ELISA) technique
had also been previously used to measure total serum
antibody activity to three common food protein antigens
in humans in this laboratory, and was currently in use
for the measurement of isotype-specific serum antibodies
to ovalbumin in a mouse model. This working assay was
adapted for use in these studies. Test ranges of assay
reagent dilutions were carried out and minor modifica¬
tions were made. The final protocol is described in
appendix (ii).
Absorption and dilution studies confirmed the specificity
of the antibody detection (appendix ii). Variation of the
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assay results is given in chapter 4. Although there are
several methods suitable for the measurement of total
immunoglobulins and antibodies, the enzyme-linked immuno¬
sorbent assay (ELISA) was chosen as the standard tech¬
nique for the analyses performed for this thesis. All
equipment necessary was available, as was previous expe¬
rience with the assay. The other advantages of ELISA
were its high sensitivity, adaptability, and reproduci¬
bility. The assay was also fairly simple to perform, and
avoided the use of radioactive reagents with their haz¬
ards and need for caution which the chief rival methodol¬
ogy, radioimmunoassay, did not.
3. Measurement of total serum immunoglobulins.
The availability of a routine assay in the hospital
clinical biochemistry department for total immunoglobulin
A, IgG and IgM levels in serum meant that these assays
could be conveniently carried out by that department with
their kind agreement, and the permission of Dr G Blun-
dell. The immunoglobulin levels are assayed by immunotur-
bidimetry, using a Monarch centrifugal fast analyser,
with two dilutions to check for antigen excess, and using
a British working standard for human serum immunoglobu¬
lins G, A, and M (67/99) as a reference standard (Nation¬
al Institute of Biological Standards, Potters Bar,
Herts). Results were expressed in iu/ml.
4. Collection of saliva and sterilisation of apparatus.
The collection and processing of parotid saliva and
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lavage was largely carried out using disposable equipment
where possible, to reduce time spent on cleaning and to
guarantee sterlility. In some instances however it was
necessary to re-use equipment. When re-usable equipment
was used to obtain patient and volunteer samples disin¬
fection became important. The only equipment which came
into this category for the purposes of this thesis were
the Carlsson- Crittenden cups. Other non-disposable items
used in the collection and assay procedures were cleaned
and disinfected in the standard manner, but were not in
contact with subjects and the cleaning procedure will not
be described.
Sterilisation of Carlsson—Crittenden cup.
After collection of saliva, the cup itself was cleaned
under the tap in running water to remove any gross con¬
tamination by secretions. The tubing was then flushed
through with tap water at high velocity using a full 60
ml. syringe for each tube. The tubes were cleared of
water with 60 mis. of air passed through at high pressure
again with a hand-held syringe. The whole apparatus was
then immersed in 100% ethanol, ethanol was aspirated
through the tubing with a syringe, and the entire assem¬
bly left to soak for 15 minutes submersed in the ethanol.
The apparatus was then removed from the ethanol, air
dried using a 60 ml syringe as previously described, and
left to dry out fully between adsorbent paper overnight.
Paired swabs were taken from the cup, and saline lavage
of the tubing obtained from 20 Carlsson-Crittenden cups
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after sterilisation. These samples were sent for bacteri¬
ological and virological culture. No significant growth
of bacteria, nor detection of viruses was found. The
method for cleaning and disinfecting the Carlsson-Crit-
tenden cups proved entirely satisfactory and the concen¬
tration of alcohol and the immersion times were both well
in excess of the minimum recommended by local infection
control standards.
5. Immunohistology.
To identify isotype-specific plasma cells in parotid
glands, a standard immunoperoxidase technique was applied
to both post-mortem and per-operative samples. This is
detailed in appendix (iii).
Reasonable preservation of architecture, with lymphocytes
with positive staining for IgA, IgG and IgM were found.
There was significant background staining on post-mortem
specimens, making identification of plasma cells more
difficult, but fresh, per-operative specimens were free
from this problem. The standard protocol for immunoper¬
oxidase staining for other tissues worked well without
any modifications being made, and resulted in slides
adequate for plasma cell counting. The numbers of plasma
cells of each isotype were enumerated by direct visual
counting of cells under a light microscope per ten high-
power fields for each specimen.
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6. Cellobiose—maimitol permeability test.
To assess intestinal permeability during an alcohol
challenge, the above test was used. It is based upon the
principle that sugars of differing molecular sizes are
absorbed at differential rates, and are dependent on
different aspects of the gut mucosa. The absorption of a
small molecular sugar is proportional to the surface area
of the epithelium of the gut, whilst the absorption of a
large molecular sugar is inversely proportional to the
integrity of the mucosa. Both sugars used are excreted
unchanged in the urine.
After an overnight fast, the two sugars (cellobiose -
large molecule, and mannitol - small molecule) are dis¬
solved in 200mls of water and drunk after the bladder has
been voided. Nothing is taken by mouth for two hours,
after which subjects can have water ad libitum. All urine
is collected, and a final voiding of the bladder is
requested at the end of the test at five hours after
ingestion of the sugar solution. The urine sample volume
is measured, and the sugar concentrations determined by
enzymatic methods, with the use of a spectrophotometer. A
ratio of the two sugars in the urine is derived and
compared to a reference ratio for our laboratory. A value
above this range suggests an increase in gut permeabili¬
ty.
7. DATA STORAGE AND PROCESSING
The computer hardware and software used in the prepara¬
tion of this thesis are given in appendix (iv), along
with comments as to their suitability and limitations.
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8- STATISTICS
Statistical analyses were carried out using a number of
different methods. The non-parametric Mann-Whitney U test
was used for all unpaired comparisons of groups of
results. Student's t-test and Wilcoxon's paired rank sum
test were used for paired data, and either the Kendall
(on the Amstrad computer, using the Amstat statistical
software programme) or the Spearman (using the Minitab
statistical software programme on the IBM-compatible
computers) rank correlation coefficients for non-paramet¬
ric regression analysis. The Chi-squared test, with Yates
correction when small numbers were being analysed, was
used for qualitative data. Where multiple comparisons
between groups were being made, oneway analysis of vari¬
ance (for parametric data) or the Kruskal-Wallis test
(for non-parametric data) were performed initially. If a
significant difference was found, then comparisons be¬
tween individual groups were made by the Mann-Whitney U
test. A probability value of p=0.05 or less was taken as
being significant, however where many statistical tests
were performed with regards to one set of analyses, only
a p value of less than 0.01 was regarded as significant
(this applies particularly to chapter 8).
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CHAPTER FOUR: TECHNICAL DEVELOPMENTS AND EXPERIMENTS
Introduction
Having decided to collect pure parotid saliva on the
grounds that it was a pure secretory fluid, it was
necessary to establish the best method of salivary
collection, and to determine whether or not the
methodologies developed for ELISA analysis of
immunoglobulins and antibodies in serum were applicable
to saliva. The specificity and reproducibility of these
ELISA assays were also determined. Parotid saliva was
treated with a mucolytic, with a detergent, and by soni-
cation in attempts to increase the recovery of immuno¬
globulins at assay; the possibility of contamination by
crevicular fluid leaking in between the collecting cup
and the buccal mucosa was also assessed. The other major
aims at this stage were to establish a method for the
collection of whole gut intestinal fluid by gut lavage,
and to establish methodologies for the assay of total
immunoglobulins and antibodies in gut lavage fluid.
SALIVA
Approach
In practical terms there were two possible methods for
collecting parotid saliva, cannulation of the parotid
duct being discounted on the grounds of invasiveness and
time required, making the method unsuitable for use as an
outpatient procedure. The two remaining methods were 1)
to use an occlusive cup placed over the parotid duct or
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2) to use absorbent material such as cotton-wool or a
dental roll, placed between the upper second molar tooth
(opposite the parotid duct), and the cheek. The use of
such absorbent material would be simpler, faster, and
possibly as good as using a cup. Therefore bilateral
samples of parotid saliva using both methods were simul¬
taneous collected over five minutes in 26 healthy volun¬
teers .
Figure 4.1 - Carlsson-Crittenden cup
Parotid salivary flow was stimulated by 5% citric acid,
given by disposable pipette to the floor of the mouth in
0.5 ml aliquots each minute, to a total of two mis. A
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Carlsson-Crittenden cup was positioned over a parotid
duct on one cheek. (This simple device has an outer ring
with connected to an aspiration tube so that gentle
suction may be applied to maintain cup position over the
parotid duct orifice, and an inner collection cup, again
connected to an aspiration tube through which the parotid
saliva can be collected - see figures 4.1 and 4.2.
Figure 4.2 - Carlsson-Crittenden cup head in detail
A cotton-wool ball was positioned over the contralateral
parotid duct as described above. Saliva collected by the
cotton-wool was retrieved from the absorbent material by
placing the material into the barrel of a 20 ml syringe,
replacing the plunger and compressing the cotton-wool.
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This forced absorbed saliva from the cotton-wool and out
|
of the syringe. Parotid salivary samples were stored at
-20oC without any treatment or preservative until assay.
Some minor problems were experienced with cup slippage
away from the parotid orifice, especially in subjects
with bulky n>asseter muscles, but generally collection was
straightforward. Total protein and total IgA concentra¬
tions were assayed in the samples. Both total
protein .









Parotid salivary protein concentration when collected by
Carlsson-Crittenden cup and cotton wool simultaneously.
P=0. 00001, (jpaired t-test) .
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Parotid salivary IgA concentration when collected by
Carlsson-Crittenden cup and cotton wool simultaneously.
P=0.00001, (paired t-test).
concentration (p=0.00001), shown in figure 4.3, and total
IgA concentration (p=0.00001), shown in figure 4.4, were
decreased in the parotid saliva collected by cotton-wool
when compared with the saliva collected by cup.
Specificity of ELISA.
To ensure that the ELISA used was specific for
immunoglobulins and antibodies in the parotid saliva,
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standard serial dilution and absorption experiments were
carried out. Serial dilution of the samples resulted in a
parallel decline in activity (figure 4.5). Serial absorp¬
tion of the antibodies also led to a stepwise and paral¬
lel reduction in activity (figure 4.6). Both of these
experiments confirmed the specificity of the assay.
Figure 4.5 ELISA specificity - serial dilutions
Saliva dilution
Effect of serial dilution on optical density reading for
IgA anti-gliadin antibody activity in samples of parotid
saliva from five subjects.
Since small amounts of mucus are present in parotid
saliva, and IgA has been shown to be associated with
mucus, a variety of physical and chemical treatments were
administered to unfiltered fresh parotid saliva in an
attempt to increase measurable protein and IgA.
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Figure 4.6 ELISA specificity - absorption study
Gliadin concentration in pg/ml
per ml of saliva
Optical density readings for IgA anti-gliadin antibody
activity of parotid saliva after absorption against
increasing concentrations of gliadin.
A range of concentrations of the detergent polyoxyethyl-
enesorbitan (Tween, Sigma Chemical Co, Poole, Dorset), of
the mucolytic dithiothreitol (DTT, Sigma Chemical Co.),
and ultrasonification for different lengths of time, were
used on the parotid saliva. The effect of filtration or
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centrifugation, to remove any solid or mucus particles,
on the measured protein and IgA was also assessed. No
treatment increased measured total protein or IgA concen¬
trations, but assay interference occurred with 0.1M DTT,
resulting in unmeasurably high optical density (OD)
readings (figures 4.7 and 4.8). Removal of mucus and
solid particles by filtration or centrifugation did not
alter measured IgA concentration (figure 4.8).














i 1 1 1 1 i 1 1 i 1 1
0.05 0.1 0.5 1.0 5.0 0.1 0.5 1.0 2 5 10
Untreated Tween (%) DTT (M) Sonication
controls (minutes)
Measurable protein concentration after treating saliva
with detergent (Tween), dithiothreitol (DTT), and sonica¬
tion. Key- ND = not detected, over = reading above scale.
70
Technical developments and experiments

















i 1 1 1











Measurable IgA concentration after treatment of saliva by
a detergent (Tween), dithiothreitol (DTT), and sonica¬
tion. Saliva with (solid) and without mucus or solid
particles (clear) was also compared.
Contamination
To assess if contamination of parotid saliva by other
fluids could occur during the collection period, 5 mis of
cochineal food colouring was pipetted into the oral
cavity and a standard collection of saliva carried out.
The salivary specimens were assessed by spectrophotometer
for evidence of colouration, and compared with known
serial dilutions of cochineal. Rinsing the mouth with
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cochineal revealed no evidence of contamination of parot¬
id saliva collected by Carlsson- Crittenden cup down to a
dilution of <10-5 on 10 occasions.
Assay reliability
The reproducibility and variation of ELISA analysis of
serum and salivary total immunoglobulins and specific
antibodies was assessed. For saliva IgA, IgM, and IgG
immunoglobulin and antibodies were studied, and for serum
IgA immunoglobulin and IgA isotype-specific antibodies
were tested. For each immunoglobulin and antibody in both
fluids, twelve specimens were assayed, each aliguoted
into eight wells on a single ELISA plate to assess in-
plate variation. For each of these eight samples the mean
OD reading of each sample was determined and the range of
OD readings expressed as a percentage variation from this
mean. The results from the 12 samples were combined to
give a mean percentage variation with a range.
In a separate experiment twelve samples were assayed in
duplicate on three separate plates, and the mean OD
reading for each sample determined on each plate. For
each sample the mean variation between the plates was
then calculated and expressed as a percentage. The per¬
centage variations determined both within and between
plates are shown in tables 4.1 and 4.2, and were within
acceptable limits.
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Percentage deviation from average OD reading
(mean + range)
total anti-gli anti-ova anti-J5LG
3 .1 7 . 3
(1.9-4.4) (4.2-8.9)


















(2.0-4.7) (2.8-8.3) (5.9-16.9) (2.5-6.4)
Twelve specimens of each isotype were aliquoted into 8
separate wells on the same plate for both saliva and serum.
Table 4.2 Between-plate variation of ELISA




details total anti-gli anti-ova anti-BLG
Saliva - IgA 5.8 11.1 8 . 4 6.9
- IgG 4.4 12 . 2 7.0 7.8
- IgM 6.9 9.1 9.4 9.1
Serum - IgA 5.2 7.1 13.4 5.5
Mean variation between three plates for 12 specimens tested
in duplicate on each plate.
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LAVAGE
Introduction
Patients attending the gastrointestinal unit who were
about to undergo barium enema examination or colonoscopy,
or who suffered from constipation, were offered bowel
preparation with an alternative method of cleansing to
the standard regime of sodium picosulphate and co-dan-
thromer. The lavage solution employed for this purpose
was a polyethyleneglycol (PEG) electrolyte lavage solu¬
tion. PEG 3350, a mixture of different-sized molecules
with a mean molecular weight between 3200 and 3700, and
sulphate are the osmotic agents in the lavage solution.
The solution is available commercially in the USA (and
has now become available in the U.K. during the writing
of this thesis) as "Golytely" and is used freguently and
successfully as a method of cleansing the colon for
colonoscopy, barium enema, and as a bowel preparation
prior to abdominal surgery (Davis et al , 1980).
Formulation of lavage
The polyethylene glycol electrolyte lavage solution was
formulated by the Hospital Pharmacy and contained
Potassium chloride BP 0.75g, Sodium chloride BP 1.45g,
Sodium bicarbonate BP 1.63g, Sodium bisulphate BP 5.68g
and PEG 3350 59.1 g/L, with a resultant osmolality of
approx. 260 mosmol/L.
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Lavage protocol
Following an overnight fast, lavage was commenced at 8.30
am. Subjects were asked to drink the lavage solution at
a rate of 250 mis every 15 minutes for a period of 4
hours, making the total volume consumed 4 litres. In
patients in whom lavage was used as a bowel preparation,
one sachet of sodium picosulphate ("Picolax"), was given
later the same day to remove excess fluid from the colon
which might interfere with radiographic studies.
Specimen processing
Since human intestinal secretions contain large amounts
of proteases, the specimens were treated with protease
inhibitors to preserve their immunoglobulin content.
The method of specimen processing described was adapted
from that developed by Elson and colleagues for use in
the mouse (Elson et al 1984). Stool collection was com¬
menced once the stools became liquid and free of faecal
material. Approximately 200 mis were collected and
filtered through cheesecloth into 50 ml polypropylene
tubes. Soybean trypsin inhibitor (Sigma Chemical Co.)
lmg/ml in phosphate-buffered saline (PBS) was added to
each tube to a final concentration of 10% (W/Vj, followed
by addition of 1.0m ethylene-diamine-tetracetic acid
(EDTA) to 5% (W/V) in PBS. Tubes were then centrifuged
at 550 g for 10 minutes.
The supernatant was transferred into clean centrifuge
tubes and 1% 100 mM phenylmethylsulfonylfluoride (PMSF)
in 95% alcohol was added to 1% (W/V). Tubes were then
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centrifuged at 2200 g for 30 minutes. The supernatant
was taken and PMSF was again added to a total of 1%
(W/V), followed by the addition of 1% (W/V) Sodium azide
in PBS. After 15 minutes gentle mixing, 5% (W/V) heat-
inactivated fetal calf-serum was added. Samples were
. . OP •
divided into aliguots and stored at -70 until assay.
In 10 subjects, the initial sample was divided into 3
aliguots, one being treated immediately, and the other
addition of protease inhibitors delayed for 1 and 2
hours, respectively, in the other 2. In 14 subjects, 2
serial specimens were collected and analysed for IgA
content.
Measurement of PEG levels in lavage samples
PEG was guantified by the method of Malawer (Malawer and
Powell, 1967), a modification of the turbidimetric analy¬
sis of Hyden (Hyden, 1955).
Results
Subject acceptance
Of 78 subjects who began lavage, 75 subjects were able to
provide samples suitable for analysis. Two subjects could
not tolerate the procedure, and one specimen was found to
be mainly urine on analysis. Subject acceptance was
reasonable; the solution was more acceptable if chilled
and taken with lemon juice. In some patients who did not
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tolerate the lavage, in whom it was necessary to complete
the preparation fully, a naso-gastric tube was passed to
administer the solution. The only side-effects were
abdominal bloating and nausea. Occasionally vomiting of
the fluid led to abandonment of the lavage, but generally
it also could be easily accomplished in an out-patient
setting. A medical presence was generally not required,
supervision being conducted at a distance. The gastroin¬
testinal unit investigation suite nursing staff became
extremely adept at administering the lavage fluid to
subjects and only occasionally was it necessary to intro¬
duce a naso- gastric tube for that purpose.
Immunoglobulin content
The time from the start of lavage to the passage of clear
stool specimens suitable for analysis ranged from 1 - 5
hours. Assay of the PEG showed little variation in con¬
centration (figure 4.9). Immunoglobulins and antibodies
were barely detectable if solid faecal material was still
present at the time of specimen collection, and it seemed
necessary to ensure that faecal effluent was clear before
samples were obtained. Initially, all stools were col¬
lected, until assay of these serial specimens demonstrat¬
ed that, once a clear effluent was produced, there were
no further significant changes in IgA concentrations,
suggesting that a steady state had been reached (figure
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4.10), and therefore that sample timing was not crucial.
Delay in the addition of protease inhibitors of one or
two hours resulted in a variable (0-92%) loss of IgA
activity (figure 4.11). This loss of immunoglobulin
content due to delay in the addition of protease inhibi¬
tors has been noted by others, who also found that the
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IgA concentration in two consecutive lavage samples in 14
subjects, after effluent became clear.
inhibitors did not interfere with assay by ELISA, which
was sensitive and showed minimal variation (Gaspari et
al, 1988). The initial PEG concentration of 59 g/L in the
ingested fluid would be reduced to 47.5 g/L by the addi¬
tion of protease inhibitors etc. Since the percentage of
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gut secretion in the liquid faecal effluent is determined
by a simple formula, (100 - the sample PEG concentration
[g/L] -5- 47.5 [g/L]), the samples were therefore a mean
78.5% PEG-electrolyte solution and 21.5% gut secretions.
Figure 4.11 Effect of delay in addition of protease
inhibitors to IgA concentrations in lavage fluid.
Comments
The choice of PEG-electrolyte solution as the lavage
fluid was straightforward. With minimal net water and
electrolyte absorption or secretion, potential problems
of fluid overload in susceptible patients are avoided
(Davis et al, 1980), although others have suspected some
fluid absorption as reflected by increased urinary vol¬
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study, greater than 97.3% of PEG from healthy volunteers,
and more than 96.5% of PEG from patients, was recovered
from the gut (Shields et al, 1968), and only 0.04-0.06%
of a total PEG dose administered orally was recovered in
urine (DiPiro et al, 1986). Previously reported side-
effects of mild nausea and abdominal distension or dis¬
comfort (DiPiro et al, 1986; Gaspari et al, 1988) were
also encountered in this study, but although a small
number of subjects were unable to retain the lavage
solution, the majority tolerated it well.
ELISA protocols
After the dilution-ranging studies, all other studies of
specificity and reproducibility were performed for each
assay respectively, using the protocols specified in
appendices (v)-(vii).
ELISA standards
For all ELISA's of total immunoglobulin concentrations, a
colostral IgA standard was used (SPS 101; Human Protein
Reference Unit, Royal Hallamshire Hospital, Sheffield),
double diluted out as detailed in the appendices.
81
CHAPTER FIVE: THE PHYSIOLOGY OF SALIVARY IMMUNO¬
GLOBULINS AND ANTIBODIES TO FOOD PROTEIN ANTIGENS
Introduction
In order to ensure that the results obtained from
salivary samples were relevant and representative it was
necessary to answer a number of questions. The aims at
this stage were to determine if parotid salivary
immunoglobulin and antibody levels varied significantly
throughout the day. This was necessary to determine
whether or not a random salivary sample, taken for
example in an out-patient clinic, was representative of
salivary immunity throughout the 24 hour period.
Secondly, it was necessary to determine whether or not
total protein concentration and salivary flow rate had
significant influence on salivary immunity and would
therefore be important to measure. Thirdly, the influence
of dietary antigen intake and alcohol consumption were
assessed in order to determine if these factors would
need to be taken into account when interpreting results.
Approach and results
Circadian rhythms.
Eight healthy adult volunteers were studied over a six¬
teen hour period in a single day, with parotid salivary
samples taken at intervals throughout that time. The
first sample was taken after an overnight fast, the
second after a standard breakfast and so on, and the last
sample prior to midnight. Samples were assayed for total
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IgA, IgM, and IgG, and for IgA antibodies to gliadin. The
variation in these samples was assessed statistically
using the Kruskal-Wallis test. There were significant
fluctuations in both total immunoglobulin concentrations
and in IgA anti-gliadin antibody levels throughout the
day (p<0.0025 IgA; p<0.005 IgM; p<0.00025 IgG; p<0.001
IgA antigliadin antibody), figures 5.1 and 5.2. The most
consistent change was seen after meals, with a fall in
immunoglobulin concentrations and antibody level.
Influence of eating.
In a further, separate, experiment specifically aimed at
studying the effects of a meal, paired salivary samples
were obtained after an overnight fast and 30 minutes
later, after a standard breakfast. Samples were assayed
for IgA concentration (n=ll), and total protein
concentration (n=13). These experiments confirmed a fall
in IgA concentration (p=0.0023), figure 5.3, and showed a
non- significant increase in total protein concentration
(p=0.075), figure 5.4 (paired t-test). Pure parotid sali
vary samples from 92 patients without gastrointestinal
disease were studied to determine the correlations be¬
tween total IgA, IgM, and IgG, total protein concentra¬
tion, and salivary flow rate. IgM concentration was
weakly but positively correlated with total protein
concentration (figure 5.5). There were no other signifi¬




A serendipitous observation on a healthy volunteer
suggested that alcohol ingestion might result in
profound changes in salivary antibody levels. Eight young
adult volunteers were studied to clarify this. Each
subject abstained from alcohol for five days, following
which they ingested 180 grams of alcohol taken as 440 mis
of gin, diluted freely with tonic water, over a six hour
period. After the alcohol challenge, subjects abstained
from alcohol for a further five days. Samples of pure
parotid saliva were obtained on days -2, -1, and days +1
and +2, and a cellobiose-mannitol small intestinal
permeability test performed on days 0 and +1. Salivary
samples were assayed for total IgA, IgM, and IgG, and for
antibodies to gliadin, ovalbumin, and Slactoglobulin of
all the three immunoglobulin classes. Random fluctuations
in antibody levels were seen, wider than observed in the
sixteen hour study of the variation of antibody levels in
healthy subjects. No consistent effects were noted
however. The cellobiose-mannitol ratio increased in one
of the eight volunteers, suggesting an increase in gut
permeability.
Influence of dietary antigens.
Pure parotid saliva and serum were obtained from 34
patients in whom the final diagnosis was of functional
bowel disease. Samples were tested for antibodies to
gliadin, ovalbumin, and Glactoglobulin of IgA, IgM, and
IgG classes. Comparisons of antibody levels were made
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between the patients who included milk or eggs or bread
in their diet and patients who excluded one or other of
these foods from their diet.
There were no significant differences in antibody levels,
either in saliva or serum, (figures 5.6-5.10, table 5.2).
Although data on dietary antigen intake is likely to be
fairly accurate for eggs (for ovalbumin), and for milk
(Blactoglobulin), this is probably not so for gliadin
since it is found not just in bread but in all foods that
contain flour, of which there are many. Thus it is likely
that subjects who did not eat bread still consumed glia¬
din, although they may have taken guantitatively less
than those who did include bread in their diets. Because
of this, data for anti-gliadin antibodies in serum has
not been analysed, and the data for anti-gliadin anti¬
bodies in saliva should be interpreted with caution.
Dietary antigen withdrawal.
To study the effects of withdrawing dietary antigens,
serial parotid salivary samples were collected from
eleven heterogeneous patients who were started on an
elemental diet for clinical reasons. Samples were
obtained prior to and during feeding solely with a
commercially available, chemically defined, diet (Elemen¬
tal 028, Scientific Hospital Supplies, Liverpool, U.K.).
The patients were being variously treated for coeliac
disease, Crohn's disease, or short bowel syndrome, and




Although antibody levels fell markedly in two patients,
there was no significant change overall, for example IgA
anti-gliadin antibody (figure 5.11). The results may
reflect the heterogeneity of both disease groups and
duration of study; also, other factors may need to be
taken account of, additional medical therapy for example.
Conclusions
There is great physiological variation in immunoglobulin
concentrations and antibody levels in pure parotid saliva
during the day, and generally speaking, eating a meal
reduces these parameters, especially after an overnight
fast. Neither alcohol, nor the amount of an antigen in
the diet appear to have any consistent effects on
immunoglobulin concentrations or antibody levels in
saliva. It seems reasonable in further studies on pure
parotid saliva to collect saliva after fasting, accepting
high individual variation, and allowing for the only
definite influence of eating meals. It does not seem




Figure 5.1 Daily variation of total immunoglobulin con¬






Each value expressed as a percentage of the mean daily
total for that individual. All immunoglobulins vary signif¬




Figure 5.2 Fluctuation in salivary IgA antigliadin anti¬
body levels.
Time (24 hour clock)
Fluctuation in salivary IgA antigliadin antibody levels
over 16 hours in healthy subjects, (n=8). Alterations were
significant, p<0.001 (Kruskal-Wallis test).
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Figure 5.3 Changes in IgA concentration in pure parotid








Changes in IgA concentration in pure parotid saliva, fast¬
ing (a.c.) and 30 minutes after a standard breakfast
(p.c.), p = 0.0023 (paired t-test).
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Figure 5.4 Changes in total protein concentration in pure
parotid saliva after a meal.
0.50
a.c. p.c.
Changes in total protein concentration in pure parotid
saliva, fasting (a.c.) and 30 minutes after a standard
breakfast (p.c.), p = 0.075, (paired t-test).
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Relationship between total protein content and IgM concen¬
tration in pure parotid saliva; n = 92, correlation (rs)
= 0.276, p = 0.008.
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Figure 5.6 Dietary egg, bread, and Bilk, and specific
salivary IgA antibody levels.





























IgA antibody levels (OD readings) to food protein antigens
in pure parotid saliva, comparing subjects omitting food
with those including food in diet. Caution in interpreting




Figure 5.7 Dietary egg, bread, and silk, and specific
salivary IgM antibody levels.
40 n





















IgM antibody levels (OD readings) to food protein antigens
in pure parotid saliva, comparing subjects omitting food
with those including food in diet. Caution in interpreting




Figure 5.8 Dietary egg, bread, and Milk, and specific



















IgG antibody levels (OD readings) to food protein antigens
in pure parotid saliva, comparing subjects omitting food
with those including food in diet. Caution in interpreting




Figure 5.9 Dietary egg, bread, and milk, and specific


















IgA serum antibody levels (OD readings) to egg and milk
derived proteins, comparing healthy subjects who include




Figure 5.10 Dietary egg and mlllc, and specific serum igM


































IgM and IgG serum antibody levels (OD readings) to egg and
milk derived protiens, comparing healthy subjects who
include with those who omit egg or milk from their diets.
No significant differences (Mann-Whitney test).
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Figure 5.11 IgA anti-gliadin antibody levels in pure
parotid saliva, and elemental diet.
Days
Change in IgA anti-gliadin levels (OD readings) in pure
parotid saliva in subjects beginning an elemental diet for




Table 5.1 Correlation of protein, salivary flow, IgA,
IgG, and XgM, in parotid saliva.
protein IgA IgG IgM
flow -0.119 -0.201 -0.129 -0.2
^
protein - 0.088 0.192 0.276
Rank correlation coefficients for various parameters within
a stimulated five minute sample of pure parotid saliva in
92 subjects. Key: * p=0.008 (Spearman's coefficient).
Table 5.2 Dietary egg, bread, and milk, and specific
antibody levels in parotid saliva.
antibody isotype
IgA IgG IgM
Food in diet Y N Y N Y N
Antibody to:
Ovalbumin 16.5 8.2 0.65 1.75 0 0.34
(21) (13) (18) (12) (18) (12)
[0.21] [0.09] [1.0]
Blactoglobulin 8.7 5.0 0.1 2.6 0 0
(19) (11) (19) (10) (17) (10)
[0.13] [0.077] [0.42]
Gliadin 3.15 3.0 2.5 6.0 0 0
(18) (15) (18) (15) (18) (15)
[0.89] [0.19] [1.0]
Dietary antigen levels subdivided according to the inclu¬
sion of the major parent food in the diet, Y, or not, N
(see chapter on methods). Median OD reading given, number
of subjects in round brackets (n), and p value in square
brackets, [x] (Mann-Whitney test).
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CHAPTER SIX: SALIVARY IMMUNITY IN COELIAC DISEASE AND
DERMATITIS HERPETIFORMIS
Introduction
Patients with coeliac disease or dermatitis herpetiformis
are known to have increased immunity to food protein
antigens in the systemic compartment of the immune
system. There have in the past been some studies using
insensitive techniques on antibody levels in intestinal
fluids (mainly on jejunal juice - see chapter two), and a
few more recent studies using sensitive ELISA
methodologies (LaBrooy et al 1986; Volta et al 1988).
These patients are an important target group, likely to
have up-regulated secretory immunity to these food
protein antigens which may be reflected in increased
antibody levels in pure parotid saliva. If this was
convincingly the case, there would be a potential use for
parotid saliva as a screening, diagnostic, or monitoring
tool.
Approach and results
Samples of pure parotid saliva and serum were obtained
from control subjects and from patients with untreated
and treated coeliac disease. All patients had recently
undergone jejunal biopsy, are described in detail in
chapter 3, and are summarised in table 6.1. Both pure
parotid saliva and serum were assayed for total immuno¬
globulin concentrations and for specific antibodies
of all three classes studied to gliadin, ovalbumin, and
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filactoglobulin.
Table 6.1 Subject details
Subject M F total age smokers
median (range)
controls 13 15 28 25.5 (14-34)
coeliac disease
- untreated 14 18 32 41.5 (16-78) 9
- treated 14 20 34 42.0 (15-72) 7
dermatitis herpetiformis
- ND, NH 8 4 12 58 . 0 (27-86) 2
- ND, P/SVA 8 3 11 64 . 0 (15-83) 2
- GFD, NH 11 8 19 49.0 (28-82) 7
- GFD, P/SVA 15 3 18 52.5 (26-77) 5
Age (years), sex, and smoking habits of subjects. Key: ND =
normal diet, GFD = gluten-free diet, NH = normal jejunal
histology, P/SVA = partial or subtotal villous atrophy.
An opportunity also arose to study a group of well-
characterised patients with dermatitis herpetiformis.
These subjects had been investigated for other purposes,
and had had a recent jejunal biopsy taken, and a dietary
history for gluten obtained, along with a nutritional
assessment, and some functional studies of small bowel
integrity. Some had had serum samples taken one or two
years prior to the present study, allowing comparisons
over long period of time to be made. Again, full details
of the group of subjects are included in chapter 3 and
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summarised in table 6.1. Samples of pure parotid saliva
and serum were obtained from these patients, and assayed
for total immunoglobulin concentrations and for specific
antibodies of all three classes studied to gliadin,
ovalbumin, and Slactoglobulin. The serum specimens were
assayed for specific antibodies to gliadin and ovalbumin,
and Blactoglobulin of the IgA and IgG classes; serum
total immunoglobulin concentrations have already been
reported (Gawkrodger et al, 1988).
Coeliac disease
Total immunoglobulins.
There were no differences in total immunoglobulin
trations in either saliva or serum when comparing
subjects to patients with untreated or treated
disease (data not shown).
Specific antibodies
-saliva.
IgA anti-gliadin antibody levels were significantly
elevated in the parotid saliva of patients with untreated
coeliac disease when compared with patients with treated
coeliac disease and control subjects, (table 6.2 and
figure 6.1), with values in treated coeliac disease
generally falling between those in untreated coeliac
disease and controls. There were no significant differ¬
ences in specific antibody levels to ovalbumin or
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Salivary antibody levels to gliadin (gli), ovalbumin (ova),
and B-lactoglobulin (BLG) in control subjects, patients
with untreated and treated coeliac disease. Values are
median (range) OD readings. Key: p = * = 0.013; # = 0.005;
** = 0.025, (Kruskal-Wallis test).
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Antibody levels (OD readings; bar = median) to gliadin in
pure parotid saliva in coeliac disease. Differences between
groups are significant (IgA - p=0,013; IgG - p=0.005;
Kruskal-Wallis test). Key: N = control, U = untreated
coeliac disease, T = treated coeliac disease.
Specific antibodies
- serum.
Serum antibodies were exactly as described in the
literature, with high anti-gliadin IgA and IgG antibodies
found in patients with untreated coeliac disease, with
low values in control subjects, and intermediate values
found in patients with treated coeliac disease (table 3).
There was a similar pattern with respect to IgA
antibodies to ovalbumin and to Blactoglobulin, and IgG
antibodies to Blactoglobulin (table 3).
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Serum antibody levels to gliadin (gli), ovalbumin (ova),
and B-lactoglobulin (BLG) in control subjects, patients
with untreated and treated coeliac disease. Values are
median (range) OD readings. Key: p = * <0.01, # <0.001,
(Kruskal-Wallis test).
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Dermatitis herpetiformis
Total immunoglobulins.
There were no differences in total parotid salivary
immunoglobulin concentrations between the groups of
patients with dermatitis herpetiformis who differed in
respect of jejunal histology and dietary gluten intake
(figure 6.2).



























Total immunoglobulin concentrations (bar = median) in
parotid saliva of patients with dermatitis herpetiformis,
with either normal jejunal histology or partial (PVA) or
subtotal villous atrophy (SVA), stratified according to
normal or gluten-free diet. No significant differences
between groups, (Kruskal-Wallis test).
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Specific antibodies
- saliva.
In general there were no significant differences in
specific salivary antibody levels, of any of the three
isotypes studied when comparing patients with and without
enteropathy irrespective of their be^.ng on a normal or on
a gluten-free diet (table 6.4). There were frequently
strong positive correlations between the levels of anti¬
body to different antigens in parotic saliva, and between
different isotypes of antibody to a single antigen,
(table 6.5).
- serum.
With respect to serum there were no differences between
antibody levels to any of the three antigens studied when
comparing all groups of patients (table 6.6). There were
frequently strong positive correlations between antibody
levels to one antigen and to another antigen, irrespec¬
tive of antibody isotype, (table 6.7), just as found in
saliva. In paired serum samples taken one to two years
apart, when there was no change in diet, antibody levels
remained remarkably constant (for example IgA anti-glia-
din antibodies, figure 6.3). When diet changed from a
normal, gluten-containing, one to a gluten-free diet, IgG
anti- gliadin antibody levels were significantly lower in
the second sample than one year previously, p=0.045,
(figure 6.4), however all other antibody levels remained
constant, (data not shown).
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Table 6.4 Salivary antibody levels in dermatitis
herpetiformis
Diet normal gluten-free
Jejunal histology N P/SVA M P/SVA
Antibody
IgA-anti
-gli 0.39 0.24 0.29 0.31
(0-0.59) (0-0.5) (0-1.01) (0.1-1.5)
-ova 0.22 0.2 0.42 0.53
(0-1.5) (0-1.25) (0.1-1.2) (0.1-1.5)
-5LG 0.22 0.1 0.15 0.5
(0-1.5) (0-0.41) (0-1.15) (0.1-1.5)
IgG-anti
-gli 0 0 0 0
(0-0.8) (0-0.13) (0) (0-0.15)
-ova 0 0 0.28 0.23
(0-1.5) (0-0.16) (0-1.4) (0-1.2)
-3LG 0 0 0 0
(0) (0-0.13) (0-0.1) (0-0.1)
IgM-anti
-gli 0 0 0.016 0.142
(0-0.28) (0-0.2) (0-0.26) (0-1.05)
-ova 0.02 0 0.07 0.08
(0-0.25) (0-0.19) (0-0.55) (0-1.5)
-I3LG 0 0 0 0
(0-0.1) (0-0.14) (0-0.31) (0-1.4)
Median OD (range) of pure parotid salivary antibody levels
in patients with dermatitis herpetiformis, according to
diet and histology. No significant differences between
groups, (Kruskal-Wallis test). Key: N = normal, P/SVA =
partial or subtotal villous atrophy.
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Table 6.5 Correlations of salivary antibody levels in
dermatitis herpetiformis
Clinical group gliadin ova BLG
IgA IgG IgA IgG IgA IgG






GFD, NH gliadin IgA
IgG
ova IgA
IgG .71" .59 .59
BLG IgA .57*
IgG .58*
ND, S/PVA gliadin IgA
IgG S
ova IgA .86"
^gG ## ##BLG IgA .92W¥ . 98yy
IgG .98




BLG IgA .61* . 71
IgG .65**
Spearman rank correlation coefficients between antibody
levels in saliva in patients with dermatitis herpetiformis,
stratified according to diet and jejunal histology. Only
statistically significant correlations between antibody
levels within saliva are shown for clarity. Key: ND =
normal diet, GFD = gluten-free diet, NH = normal jejunal
histology, P/SVA = partial or subtotal villous atrophy, * =
p = <0.05, ** = <0.02, # = <0.01, ## = <0.001.
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Table 6.6 Serum antibody levels in dermatitis
herpetiformis
Diet normal gluten-free
Jejunal histology N P/SVA N P/SVA
Antibody
IgA—anti
-gli 0.035 0 0.04 0.08
(0-0.29) (0-1.6) (0-0.79) (0-0.59)
-ova 0.17 0 0.15 0.17
(0-1.26) (0-0.38) (0-0.48) (0-1.3)
-6LG 0 0 0 0
(0) (0) (0) (0)
IgG—anti
-gli 0.18 0 0.1 0.1
(0-4.7) (0-1.26) (0-0.68) (0-1.5)
-ova 0.03 0 0.057 0.05
(0-1.02) (0-1.3) (0-1.5) (0-0.97)
-J3LG 0 0 0 0
(0) (0) (0) (0)
Median (range) of serum antibodies in OD readings in pa¬
tients with dermatitis herpetiformis stratified according
to diet and jejunal histology. No significant differences
between groups, (Kruskal-Wallis test). Key: ND = normal
diet, GFD = gluten-free diet, NH = normal jejunal histolo¬
gy, P/SVA = partial or subtotal villous atrophy.
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Table 6.7 Correlations of serum antibody levels in
dermatitis herpetiformis
Clinical group gliadin ova
IgA IgG IgA IgG
ND, NH gliadin IgA
IgG .805*
ova IgA .818* .907**
IgG .761
GFD, NH gliadin IgA
igG .14#
ova IgA *85^ *68#
IgG .69" .72" .76*
ND, S/PVA gliadin IgA
IgG .99*/
ova IgA .94** .93**
IgG .93** .92** .95**
GFD, S/PVA gliadin IgA
IgG -8#„„ „„
ova IgA .93** .85**
IgG .83 .75 .86##
Spearman rank correlation coefficients between antibody
levels in serum in patients with dermatitis herpetiformis,
stratified according to diet. Only statistically signifi¬
cant correlations between antibody levels within serum are
shown for clarity. Key: ND = normal diet, GFD = gluten-free
diet, NH = normal jejunal histology, P/SVA = partial or
subtotal villous atrophy, * = p = <0.05, ** = <0.02, # =
<0.01, ## = <0.001; ova = ovalbumin.
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Figure 6.3 Change in anti-gliadin antibody levels with














Serial serum IgA anti-gliadin antibody levels (OD readings,
405nm) taken one year apart in patients with dermatitis
herpetiformis with a normal jejunal mucosa, on a normal
diet. N = 14, no significant change in levels, (Mann-
Whitney test).
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Figure 6.4 Change in serua antigliadin antibodies with
change in diet.
Fall in serial serum IgG anti-gliadin antibody levels (OD
readings, 405nm) taken one year apart in patients with
dermatitis herpetiformis with villous atrophy, after chang¬
ing to a gluten-free diet. N = 14, p = 0.018, (Mann-Whitney
test).
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Conclusions and implications
As predicted salivary antibody levels were high in
untreated coeliac disease and fell in treated coeliac
disease, parallelling changes in serum antibody levels.
There was a lot of overlap in the levels however, and
this probably precludes the use of saliva as a diagnostic
tool in a clinical setting, or for monitoring therapy.
Surprisingly there was no detectable influence of jejunal
histology or dietary gluten intake on salivary antibody
levels in patients with dermatitis herpetiformis.
Antibody levels to gliadin (and to other antigens) were
maintained despite avoiding gluten on a gluten-free diet,
and despite mucosal healing which suggests good dietary
compliance, and that the persistent antibody levels were
not due to continued intake of (smaller amounts) of
antigen. These findings suggest that there is mucosal B-
cell memory for dietary antigens.
As expected total immunoglobulin concentrations in both
serum and saliva in control subjects, in patients with
coeliac disease, and in patients with dermatitis herpeti¬
formis, were similar. The frequency of strongly positive
correlations between levels of different antibodies in
saliva suggests non-specific activation of the humoral
immune response. This would suggest that the high
antibody levels seen are a secondary response rather than
being pathologically involved in the primary disease
process. This may also hold true for serum antibody
levels. The lack of any correlation in the absence of a
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co- existing or previous enteropathy suggests that a
breach of the mucosa is necessary at some stage to
initiate a systemic antibody response. The persistence of
virtually all serum antibodies, either on the same diet
or even after change to a gluten-free diet further
supports the hypothesis that there is B cell memory for
these protein antigens.
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CHAPTER SEVEN: IMMUNOGLOBULIN AND ANTIBODY LEVELS IN
LAVAGE FLUID
INTRODUCTION AND AIMS
Having established reliable methods for collection and
assay of intestinal fluid by gut lavage, healthy
individuals were used to answer specific questions. The
opportunity also arose to study a large number of
patients with coeliac disease. Since these patients are
known to have increased systemic immunity to food protein
antigens, it might be expected that they would also have
increased secretory immunity. Indeed some early studies
using insensitive methods (Douglas et al, 1970; Lancas¬
ter-Smith et al, 1974), and one or two more recent inves¬
tigations using ELISA on jejunal fluid (LaBrooy et al,
1986; Volta et al, 1988) support this theory. As many
such patients already attended the gastrointestinal unit
for investigation and treatment, some were invited to
undergo lavage and give saliva.
The specific questions posed were, firstly, what were the
concentrations of total immunoglobulins in lavage fluid?;
secondly, what proportion of IgA in lavage in health is
dimeric?; thirdly, could antibodies to food protein
antigens be detected in lavage fluid?; fourthly, did the
profound effects of smoking on parotid salivary immunity
extend to intestinal lavage fluid?; and finally, were
there abnormalities in immunoglobulin concentrations and




Healthy non-smoking and smoking volunteers were
approached and asked to undergo intestinal lavage.
Patients with untreated and treated coeliac disease
attending the gastrointestinal unit for investigation
were also invited to have intestinal lavage. In addition
the opportunity to study a group of patients with
inactive ulcerative colitis also arose. These patients
had already had gut lavage as part of a separate study,
on bacterial and candidal antibodies, undertaken by
ourselves in collaboration with Dr. E.D. Srivastava
(University Hospital of Wales, Cardiff). Samples of
intestinal fluid from these patients were therefore
available for assay.
The details of the administration, collection, and
treatment of the lavage fluid are given in chapter four.
All samples were assayed for total IgA, IgM, and IgG, and
for isotype-specific antibodies to gliadin, ovalbumin,
and Blactoglobulin. In addition, samples from healthy
volunteers were assayed for dimeric (secretory) IgA. This
assay was set up towards the end of the thesis, and was





The normal range of total immunoglobulins is shown in
table 7.1. IgA was found in the highest concentration,
with small but detectable concentrations of IgM and IgG
present. In patients with untreated and treated coeliac
disease there were no differences in IgA or IgG concen¬
tration, but IgM was significantly increased in both
patient groups when compared with healthy volunteers,
(table 7.1).
The proportion of IgA in healthy volunteers which was
dimeric was a median of 92% (range 82.3-100).
Table 7.1 Lavage fluid immunoglobulin concentrations
IgA IgM IgG
Controls 139.7 5.3 1.0
(n=25) (7.9-403) (0-37) (0-12.2)
Coeliacs
untreated 146.2 17.5* 2.7
(n=15) (10.7-487) (2.1-100) (0.1-34.9)
treated 90.8 25.7* 0.9
(n=19) (8.8-621) (0-192.2) (0.1-11.4)
Median (range) of total immunoglobulin concentrations in
ug/ml in intestinal lavage fluid. Key: * = significantly




Antibodies to gliadin, ovalbumin, and Slactoglobulin, of
all three isotypes tested, were regularly detected in
healthy subjects, and were usually at low levels. IgA and
IgM specific antibodies to all three food protein
antigens were increased in patients with coeliac disease;
antibody levels in treated patients were often
intermediate between those in healthy volunteers and
those in patients with untreated coeliac disease. There
were no differences in IgG antibodies (table 7.2).
Smoking.
In both healthy volunteers and in patients with inactive
ulcerative colitis, smoking decreased total IgA
concentrations, but these changes did not reach statisti¬
cal significance, (figure 7.1). There were no differences
in total IgM or IgG concentrations, nor in specific
antibody levels, when comparing non-smokers with smokers.
Only three subjects smoked more than twenty cigarettes
daily (two controls, one patient).
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Figure 7.1 Lavage IgA concentrations and smoking


















Total IgA concentrations (median) in lavage fluid in
healthy controls and in patients with inactive ulcerative
colitis, subdivided by smoking habits. No significant
differences between groups, (Kruskal-Wallis test). Key:
NS = non-smokers, S = smokers.
CONCLUSIONS AND IMPLICATIONS
A normal range for total immunoglobulin concentrations
and specific antibody levels in gut lavage fluid has been
established. Total IgA is largely dimeric in the lavage
fluid of healthy individuals. Total IgM concentrations,
and specific IgA and IgM antibodies are increased in
coeliac disease, not only to gliadin but also to
ovalbumin and Blactoglobulin. Smoking may decrease IgA in













































































Median (range) of antibody levels (OD readings) in intesti¬
nal lavage fluid. Key: # = significantly different from
both treated patients and controls, * = significantly
different from control subjects, p<0.05 for both compari¬
sons, (Mann-Whitney test).
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CHAPTER EIGHT: RELATIONSHIPS OF ANTIBODIES AND OF
IMMUNOGLOBULINS IN SECRETIONS AND IN SERUM.
INTRODUCTION
The mucosal and systemic immune systems are distinct and
separate (Chapter 2). Within the overall immune re¬
sponse of an individual possible direct or inverse rela¬
tionships between secretions, either for isotype pattern,
or specific antibodies, have been little examined.
Animal models suggest that after feeding of antigen there
is induction of mucosal antibodies, and active down-
regulation of systemic immunity (Challacombe, 1983).
Thus, generally there seems to be an inverse correlation.
In contrast, after parenteral injection of antigen, serum
antibody formation usually follows without secretory
antibodies (Baumann et al 1985; Smith et al 1986) . This
is probably due to a lack of any effect rather than
active suppression of the secretory antibody response.
Although there is much evidence that all areas of the
mucosal immune system are linked (thus, the appellation
"common mucosal immune system"), the relationships be¬
tween antibody levels in various secretions are uncer¬
tain. The small number of studies so far have given
conflicting results (see Chapter 2). The aims of this
section were
1. By comparing salivary with serum total immunoglobulin
concentrations, and antibody levels, to establish
whether there is a direct or inverse relationship between
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the gut associated lymphoid tissue and the systemic
immune system, or, possibly, no relationship at all.
2. To extend this question to the relationship between
whole gut lavage and serum, and jejunal aspirate and
serum.
3. To assess the value of saliva as a mirror of immune
events in more distal gut secretions by comparing saliva
to whole gut lavage, and saliva to jejunal aspirate, and,
for completeness, comparing jejunal aspirate to whole gut
lavage.
APPROACH
Using data from four groups of subjects described in
Chapter 3 and for whom details are shown in Table 1, non-
parametric correlation coefficients were determined for
immunoglobulin concentrations and specific antibody
titres in the four fluids under study within each group.
As this necessitated multiple statistical analyses on the
correlations only those correlations with a probability
of less than 1% (p<0.01) were taken to be significant.
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Table 8.1 Subject details
Subject M F total age (yrs)
(n) (n) (n) median (range)
Controls
ser/sal vs - lav 9 16 25 53 JU (21-92)
- asp 13 15 28 25.5 (14-84)
Coeliac disease
Untreated
ser vs - sal 14 18 32 41.5 (16-78)
ser/sal vs - asp 12 14 26 39.5 (16-78)
- lav 6 9 15 43 (28-62)
Treated
ser vs - sal 14 20 34 42 (15-72)
ser/sal vs - asp 9 13 22 42 (15-72)
- lav 8 11 19 46 (16-72)
Dermatitis herpetiformis
NH, GFD 10 11 21 52 (27-82)
P/SVA, ND 12 7 19 54 (15-83)
P/SVA, GFD 17 4 21 52 (26-80)
Heterogeneous subjects
10 14 24 45 (22-72)
Demographic details of subjects . Key - ser = serum , sal
saliva, lav = lavage, asp = jejunal aspirate, ND = normal
diet, GFD = gluten-free diet, NH = normal jejunal histolo¬
gy, S/PVA = subtotal or partial villus atrophy. Controls
having jejunal aspirate younger than other groups, *
p<0.05, (Mann-Whitney test), no other significant differ¬
ences.
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RESULTS
The main results are shown diagrammatically in Table 8|. 2.
Overall there were few highly significant correlations.
With regards to the comparison of serum and parotid
saliva significant correlations were present and the
relationships were usually direct and positive. Such
correlations were seen most frequently when there was, or
had been, an enteropathy present. Additionally, in
these patients there were positive correlations between
antibody levels in serum and antibody levels in both
lavage and jejunal fluids.
Serum IgG antibodies (within a clinically cohesive group
of patients) correlated positively with salivary IgG
antibodies and also with salivary IgA antibodies to the
same antigen. Positive correlations were most noticealble
in patients with untreated coeliac disease with villus
atrophy, and in patients with treated dermatitis herpeti¬
formis with a normal jejunal mucosa. Conversely, no sfuch
correlations were demonstrable in patients with trealted
coeliac disease and patients with dermatitis herpetifor¬
mis with villus atrophy (Table 8.3).
Generally, within an individual, pure parotid salivary
immunoglobulin concentrations and specific antibody
levels did not reflect those in jejunal aspirate or whole
gut lavage fluid. Although a few significant correlations
emerged there was no overall pattern apparent. There
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Table 8.2 Correlations of immunoglobulins and of antibodies
between serum, saliva, aspirate, and lavage fluid
XgA IgM IgG
I 1 1 1 ll 1 1 1 II d I I I
ser
j sal ^ asp ^ lav tot gli Big ova tot gli Big ova tot gli Big ova
controls




























Rank correlation coefficients (with p values <0.05) between total
immunoglobulin concentrations, and between specific antibodies in
serum (ser), saliva (sal), jejunal aspirate (asp), and lavage (lav).
Comparisons being made as shown by asterisks joined by solid lines
in left-hand column. Aspirate and lavage were only available for
comparison in the heterogeneous group (table 4). Key: tot = total
immunoglobulin, gli= gliadin, ova = ovalbumin, Big = Blactoglobulin,
NH = normal jejunal histology, S/PVA = subtotal or partial villous
atrophy, ND = normal diet, GFD = gluten-free diet, * = p<0.01.
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were a couple of weakly positive correlations between
immunoglobulins or antibody levels which failed to reach
the statistical criterion of p<0.01, when comparing
jejunal aspirate and lavage fluid, although this hetero¬
geneous group mainly consisted of patients with untreated
coeliac disease (Table 8.4).
Table 8.3 Correlation between serum IgG and salivary IgA






NH, GFD 0.609* 0.603*
S/PVA, ND
S/PVA, GFD
Spearman rank correlation coefficients (with p values
<0.05) between serum IgG and salivary IgA specific anti¬
bodies to gliadin (gli), ovalbumin (ova), and
Blactoglobulin (Big). Key: * = p <0.01, NH = normal jejunal
histology, S/PVA = sub-total or partial villous atrophy, ND
= normal diet, GFD = gluten-free diet.
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Table 8.4 Correlations between saliva, aspirate, and
lavage
secretion IgA IgM IgG






Spearman rank correlation coefficients (with p values
<0.05) for total immunoglobulins (tot), and specific anti¬
bodies to gliadin (gli), ovalbumin (ova), and
Blactoglobulin (Big) in saliva (sal), jejunal aspirate
(asp), and gut lavage (lav) in heterogeneous group of
subjects, (n=24). No correlations with p value <0.01 were
found.
CONCLUSIONS
Most commonly there were no relationships between total
immunoglobulin concentrations or between antibody levels
when comparing parotid saliva and serum. On the infre¬
quent occasion where a relationship was apparent, gut
mucosal damage often was, or had been, present. Such a
relationship was usually direct (positive). Similarly,
the correlations between serum and either jejunal aspi¬
rate or lavage fluid were infrequent. Parotid saliva did
not seem to reflect, in an individual at least, immune
events in jejunal aspirate or in gastrointestinal lavage
fluid.
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CHAPTER NINE: THE EFFECTS OF SMOKING ON SALIVARY
IMMUNITY
Introduction
Cigarette smoking is not only known to have profound
effects on the immune system, but in addition there is
strong epidemiological evidence that smoking has a role
in certain inflammatory and malignant oro-gastro-
intestinal diseases. To investigate a possible effect of
smoking on mucosal immunity saliva which had been
collected in Edinburgh by Dr. Magdy Riad for other
purposes (see chapter 3) from healthy smokers, healthy
non-smokers, and patients with epithelial head and neck
tumours was obtained and analysed. Results from these
Scottish patients and healthy subjects revealed
significant differences between the various groups. To
confirm this data and in addition to avoid the possible
confounding effects of concurrent alcohol consumption,
prospective studies were then performed in Egyptian, non-
drinking, healthy subjects and patients with head and
neck tumours. To assess whether or not the alterations in
immunoglobulins were unique to head and neck tumours,
tumours local to the salivary glands, a group of patients
with tumours in other regions was studied.
In some patients in the initial Edinburgh study who had
recently completed a course of radiotherapy very high
levels of total IgM were detected. To fully assess the
influence of radiotherapy on immunoglobulin and specific
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antibody levels, a prospective study of patients undergo¬
ing a course of treatment in Edinburgh was undertaken.
The studies on parotid salivary fluid demonstrated pro¬
found effects on immunoglobulin concentrations, and
therefore parotid gland specimens were subseguently
examined to assess plasma cell numbers.
SUBJECTS AND METHODS
Edinburgh healthy subjects and patients
Numbers of subjects and clinical details are given in
chapter 3, and in tables 3.5 and 3.6 in that chapter. Due
to the retrospective nature of this phase of the study
alcohol intake was not recorded, smoking history was
incomplete for the non-smokers (never smoked or ex-
smokers?) and the groups were not age or sex matched. The
patients in the prospective arm of the study undergoing
radiotherapy had the same standard course of treatment as
those in the retrospective arm (see chapter 3). Six of
the 14 patients were current or ex-smokers, with 8 stat¬
ing that they had never smoked.
Cairo healthy subjects and patients
Clinical details of these subjects are given in chapter
3, tables 3.2-3.4. Of the Cairo volunteers and patients
the mean age of the smokers and non-smoking controls was
not significantly different (p-0.682). Similarly, the
tumour patients and the age- and sex-matched controls
were not different in terms of age (p=0.596). The irradi¬
ated group were somewhat older, mean 59 years, than both
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the control, 52 years, and the tumour patients, 53 years,
(p—0.0004 vs controls; p=0.0033 vs tumour patients; all
tests Mann-Whitney). These patients had tumours in var¬
ious sites in the head and neck (table 3.7, chapter 3)
which did not differ significantly between groups, (chi-
squared =0.699, 2 df, p=0.71).
There were no differences in the sex distribution between
any group of Egyptian subjects, (chi-squared = 3.164,
7df, p=NS).
Clinical procedures.
Collection of saliva was bilateral and simultaneous for
two minutes (Cairo) or unilateral for five minutes
(Edinburgh group), but otherwise followed the protocol
outlined in chapter 4.
The assays of salivary total proteins and immunoglobulin
concentration are described in appendices (i) and (v).
Salivary electrolytes were analysed on a standard SMAC
II.
PLASMA CELL NUMBERS IN PAROTID GLANDS.
Subjects and methods.
Parotid gland specimens were obtained from cadavers
undergoing post-mortem at the Western General Hospital
with the co-operation of Dr Margaret Mclntyre, consultant
pathologist. Initial immunoperoxidase staining of the
first few specimens revealed marked background staining
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which seemed likely to be due to autolytic artifact.
Therefore, fresh, per-operative specimens were obtained
from patients undergoing parotidectomy for parotid adeno¬
ma, in co- operation with Professor AGD Maran of the
department of Otolaryngology. Only normal parotid tissue
was examined. Each specimen was processed as described in
appendix (iii). Counts of isotype-specific plasma cells
were made under a magnification of x400, and were enu¬
merated per ten high power fields. Each specimen was
assessed in a blind manner, and each was counted twice,
again blindly. A comparison of the plasma cell counts
between smokers and non-smokers was made.
RESULTS
SALIVA.
1. Edinburgh - retrospective study.
The results are shown in table 9.1. There were no differ¬
ences between the disease control groups of patients with
inactive thyroid disease, anorexia, bulimia, and obesity,
and the control group, and all these subjects were con¬
sidered together as a large control population for sta¬
tistical analysis. Salivary IgA concentrations were
decreased in smokers, and in patients with head and neck
tumours, both before and after irradiation. Conversely,
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Table 9 .1 Salivary immunoglobulin concentrations
Subjects
non-smokers smokers tumour irradiated
patients patients
(n=114) (n=28) (n=27) (n=30)
IgA 145192 44141* 80161* 87149*
IgM 0.2610.4 1.0410.5* 0.0810.2 3.219.2
IgG 3.719.5 0.0710.1 I I
Mean (±sd) salivary immunoglobulin concentrations in ug/ml
in the Edinburgh subjects. Key: * = significant difference
from control values, p<0.0005 in all cases, (Mann-Whitney
test). I = insufficient saliva.
IgM concentrations were increased in smokers, and in
patients with head and neck tumours, with a few extremely
high values in the post-irradiation group. These results
must be interpreted with caution as the age and sex
distribution was distinctly different from the healthy
subjects and disease controls, who were a heterogeneous
group.
2. Edinburgh - prospective study: head and neck tumours.
There were no significant changes in total immunoglobulin
or specific antibody levels with the course of radio¬
therapy (results not shown).
3. Cairo
Healthy smokers had significantly lower salivary IgA
concentrations (Figure 9.1), and higher salivary IgM
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Parotid salivary IgA concentrations in Cairo subjects.
Key: * = significant difference between appropriate
control groups and smokers and patients (p<0.00001 vs
healthy smokers; p<0.00001 vs tumour patients; p<0.00001
vs irradiated tumour patients, Mann-Whitney test). Bars
show mean ± standard error.
(Figure 9.2), when compared with non-smokers. There was
no influence of smoking on salivary IgG concentration,
(figure 9.3). There was a strong inverse correlation
between salivary IgA concentration and the number of
cigarettes currently smoked daily (10-60), (Figure 9.4);
however, no such relationship existed for salivary IgG,
or IgM concentrations. Salivary flow rates were weakly
but significantly correlated positively with the number
of cigarettes smoked daily (r=0.291, p=0.044, Spearman
correlation coefficient) but no relationship existed









































Parotid salivary IgM concentrations in Cairo subjects.
Key: * = significant difference between appropriate con
trol groups and smokers and patients (p<0.00001 vs
healthy smokers; p<0.00001 vs tumour patients; p<0.00001
vs irradiated tumour patients; Mann-Whitney test). Bars
show mean ± standard error.
Salivary IgA concentrations in ex-smokers of at least 20
cigarettes daily, who had given up smoking two years
prior to sampling, were higher than in healthy current
smokers, and after five years of non-smoking IgA concen¬
trations had returned to those comparable with those of
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Parotid salivary IgG concentrations in Cairo subjects.
Bars show mean ± standard error. No significant differ¬
ences between groups, (Kruskal-Wallis test).
non-smokers (Figure 9.5). The effects of stopping
smoking on salivary IgM concentrations were less consist¬
ent. Values were similar to those for non-smokers after
2 years abstinence (p=0.641, Mann-Whitney test, figure
9.6), but at 5 years were significantly higher again than
in non-smokers (p=0.0004, Mann-Whitney test).
The findings were identical when the patients with head
and neck tumours (the majority being smokers, or recent
ex-smokers) were compared with the non-smoking controls
(Figures 9.1 - 9.3). Again, salivary IgA concentration
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Relationship between daily cigarette consumption and
salivary IgA concentration, r = -0.68, p<0.00001,
(Spearman correlation coefficient).
was markedly decreased and IgM concentration increased,
IgG being normal, when compared with values for matched
non- smoking controls. No differences were seen between
the groups of patients who were untreated, and those who
had undergone radiotherapy, (figures 9.1-9.3).
In contrast to the patients with upper aero-alimentary
tract tumours, IgM concentrations were just significantly
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higher between the group with tumours outwith the upper
aero-alimentary tract and age- and sex-matched controls,
28.47 ± 3.55ug/ml vs 26.04 ± 6.3ug/ml (p=0.04, Mann-
I
Whitney test). There were no differences in IgA or IgG
concentrations (data not shown).



































Parotid salivary IgA concentrations in ex-smokers of 20
cigarettes daily, after 2 (p=0.0001), and after 5
(p=0.633) years abstinence compared to healthy non-smok¬
ers, (Mann-Whitney test). Current smokers are shown
for comparison - *.
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Salivary protein and electrolyte concentrations.
Identical results were found in both centres with no
differences in salivary protein and electrolyte
concentrations between any of the groups.
Plasma cell numbers in parotid glands
There were no differences in isotype-specific plasma cell
numbers in parotid glands when comparing glands from non-
smokers with those from smokers, (data not shown).




































Parotid salivary IgM concentrations in ex-smokers of 20
cigarettes daily, after 2 (p=0.64) and 5 (p=0.0004) years
abstinence compared to healthy non-smokers, (Mann-Whitney




The influence of smoking on parotid salivary immunoglobu¬
lin concentrations was striking, especially when twenty
or more cigarettes were smoked daily. Parotid salivary
IgA was decreased in a dose-dependent and reversible
fashion, whereas IgM was increased. There was no influ¬
ence on IgG. The findings were independent of alcohol
consumption and age. Similarly, salivary IgA was de¬
creased and IgM increased in patients with head and neck
tumours, most of whom did or had smoked. There was no
consistent effect of radiotherapy. In patients with
tumours outwith the upper aero-alimentary tract, there
was a marginal increase in parotid salivary IgM concen¬
tration.
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CHAPTER TEN: INFLAMMATORY BOWEL DISEASE
Introduction and aims
Some in vitro studies on blood and intestinal cells in
patients with inflammatory bowel disease suggest that
there may be a primary immunodeficiency in the gut that
may predispose individuals to these diseases (James et
al, 1985; MacDermott et al, 1981; Verspaget et al, 1988).
Serum IgA deficiency is also associated with Crohn's
disease (Bergman et al, 1973; Soltoft et al, 1972). One
of the main aims of this thesis was to determine if there
was evidence of mucosal immunodeficiency in patients with
inflammatory bowel disease. Two specific guestions which
were addressed follow on from this main aim; firstly, are
there alterations in secretory immunity in parallel with
disease activity?, and secondly, are there differences in
gut secretory immunity when comparing patients with
Crohn's disease to patients with ulcerative colitis?.
Approach
In order to answer these guestions, samples of saliva and
intestinal lavage fluid were obtained from healthy
volunteers and from patients with active and inactive
Crohn's disease who were already attending the
gastrointestinal unit for investigation by colonoscopy or
barium enema. These patients were offered bowel prepara¬
tion by lavage. The opportunity again arose to study
samples of lavage fluid (but not saliva) from the group
of patients with inactive ulcerative colitis who had had
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lavage for a separate project as detailed in chapter 9.
Parotid saliva and intestinal fluid were collected from
subjects as previously detailed, and assayed for total
immunoglobulin concentrations and IgA, IgM, and IgG
antibodies to gliadin, ovalbumin, and Blactoglobulin.
RESULTS
Saliva.
Total immunoglobulin concentrations were similar in
healthy controls and in patients with inactive and active
Crohn's disease (table 10.1). IgA and IgG specific anti¬
bodies to all three antigens were increased in parotid
saliva from patients with inactive and active Crohn's
disease compared with healthy subjects (table 10.1).
Lavage.
Total immunoglobulin concentrations were similar in
intestinal lavage fluid in healthy volunteers and in
patients with inactive Crohn's disease, and in patients
with inactive ulcerative colitis. Total immunoglobulin
concentrations, of all three isotypes studied, were in¬
creased in patients with active Crohn's disease. By far
the most striking elevation was of IgG (table 10.2).
Specific antibody levels to food antigens in lavage were
no different from controls or from patients with inactive
or active Crohn's disease. In patients with inactive
ulcerative colitis however, IgG antibodies were increased
when compared with control subjects (table 10.2).
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Table 10.1 Salivary immunoglobulins and antibodies in
inflammatory bowel disease
Total Ig GKE BLG OVA
IgA
controls 165.8 0.024 0.008 0.013
(66-607) (0-0.154) (0-0.12) (0-0.13)
Crohn's
inactive 149.4 0.11 * 0.25 * 0.076 ^
(24-423) (0.05-9.7) (0.14-0.49) (0.01-0.78)
182.2 0.1 * 0.11 * 0.12 *
(69-477) (0.02-0.75) (0.02-0.54) (0.02-1)
IgM
controls 1.1 0.053 0.143 0.005
(0-556) (0-0.3) (0.03-0.3) (0-0.34)
Crohn's
inactive 1.12 0.048 0.034 * 0.014 ^
(0-0.59) (0.01-0.11) (0.01-0.09) (0.01-0.31)
active 1.84 0.025 0.035 * 0.029 *
(0.44-37) (0-0.76) (0-0.17) (0-0.5)
IgG
controls 3 000
(0-11.7) (0-0.076) (0-0.029) (0-0.017)
Crohn's
inactive 1.06 0.003 * 0.002 0.002 *
(0.17-11.5) (0-0.024) (0-0.016) (0-0.01)
active 1.29 0.001 * 0.001 # 0.002 #
(0.16-34.6) (0-0.038) (0-0.07) (0-0.03)
Total immunoglobulins and antibodies (median + range) in
pure parotid saliva from controls (n=22), and patients
with inactive (n=7) and active (n=17) Crohn's disease.
















































































































Total immunoglobulins and antibodies (median + range) in
lavage fluid from controls (C, n=22), patients with
inactive (CD-I, n=7) and active (CD-A, n=17) Crohn's
disease, and patients with inactive ulcerative colitis
(UC, n=30). Key: p = * <0.025, # <0.05, for values





The generally normal or increased total immunoglobulin
concentrations and specific antibody levels, with the odd
exception, in both inactive Crohn's disease and inactive
ulcerative colitis suggest that there is no secretory
immunodeficiency in these two diseases. High total immu¬
noglobulin concentrations in gut lavage fluid in active
Crohn's disease may be due to plasma leakage across the
inflamed mucosa, or may be derived from the increased
numbers of plasma cells present in the inflamed mucosa,
or to a combination of both pathologies. Different re¬
sults for parotid saliva and intestinal lavage in pa¬
tients with Crohn's disease further supports previous
observations in this thesis that parotid saliva does not
reflect immune events which occur more distally in the
gastrointestinal tract.
There were significant differences in total IgG concen¬
trations in lavage fluid when comparing patients with
inactive and active Crohn's disease, but the small number
of patients with active disease precludes meaningful
correlation of IgG and disease activity.
There do appear to be differences between inactive ulcer¬
ative colitis and inactive Crohn's disease, with in¬
creased IgG specific antibodies to the food antigens in
patients with ulcerative colitis. No comparisons can be
made for active disease, since no patients with active
ulcerative colitis were studied. There have been few
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studies on secretory intestinal immunity and only two of
salivary immunity in inflammatory bowel disease, (see
chapter 2). These two studies were conducted by the same
group, and in whole saliva found an increase of IgA, IgG
and IgM in patients with Crohn's disease (Crama-Bohbouth
et al, 1984), and an increase in IgA and IgG in ulcera¬
tive colitis (Crama-Bohbouth et al, 1989). They noted
gingival inflammation in the patients with ulcerative
colitis, but no macroscopic differences in the oral
mucosa between control subjects and patients with Crohn's
disease. In parotid saliva, there were no significant
differences in immunoglobulin concentrations in either
study, and treatment with corticosteroids decreased
immunoglobulin concentrations (although not significant¬
ly) . The absence of any significant difference in parotid
saliva accords with the results from this study.
There are no comparable studies on immunoglobulin
concentrations in gut fluid in patients with inflammatory
bowel disease. There were no differences in jejunal
aspirate immunoglobulin concentrations between a
heterogeneous group of patients with Crohn's disease and
controls (Jones et al, 1976), but IgG concentration was
increased in the freeze-dried faeces of patients with
inactive ulcerative colitis (Haneberg and Aarskog, 1975).
This latter result is at variance with the data from this
study, but the experiments are not really comparable.
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CHAPTER ELEVEN: GENERAL DISCUSSION
Introduction
Since there has been no systematic study of gastrointes¬
tinal secretory immunity in man, this thesis sought to
develop, evaluate, and apply protocols for the study of
gut secretions. Saliva was assessed in its own right as a
mucosal secretion, and the relationships of saliva to
serum, and to gut lavage as a more distal gastrointesti¬
nal secretion were also studied. It was hoped that saliva
would be representative of more distal gut secretions and
could therefore be used as a means of studying the secre¬
tory immunity of the gut. This proved not to be the case
- in fact there seems to be no easy way to investigate
gut immunity.
In addition to the study of healthy volunteers and pa¬
tients without organic gastrointestinal disease to look
at basic gut secretory immunity, groups of patients
likely to have abnormalities of gastrointestinal immunity
were also assessed. Increased secretory immunity to food
protein antigens was indeed present in patients with
coeliac disease and dermatitis herpetiformis. Further¬
more, study of these patients answered questions on the
relationships between antibodies and between immunoglobu¬
lins in serum and secretions. During early work, it
became apparent that the effects of smoking on secretory
immunity especially deserved further study. Finally, to
clarify previous reports of immunodeficiency in inflamma-
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tory bowel disease, preliminary studies of such patients
were undertaken. There was no evidence of secretory
immunodeficiency in these studies.
Subjects.
Patients with functional bowel disorders (including those
with the irritable bowel syndrome) were used in the
thesis as normal control subjects, those with diseases
likely to have an immunological component being excluded.
Although most clinicians and immunologists do not believe
that patients with irritable bowel syndrome have any
immune abnormality, some would disagree and cite an
immune reaction to food as aetiological. This question
was not specifically addressed in this thesis, but is
under study at present. For the purposes of this thesis
these patients were assumed to be immunologically normal
and included in control groups.
Patients with coeliac disease and dermatitis herpetifor¬
mis are fairly easy to classify objectively, for example
in terms of gut pathology, disease site, or current diet,
and form fairly cohesive "experimental" groups. Thus,
these patients were well documented for the purposes of
this thesis. Unfortunately this cannot be said for pa¬
tients with inflammatory bowel disease, particularly
Crohn's disease. These subjects were much more heteroge¬
neous in terms of disease extent, activity, and treatment
(often with immuno-modulatory drugs) than the other
groups studied. This part of the thesis is a preliminary
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study which lays a foundation for future, extended,
enquiry.
In view of the we11-documented and profound effects of
nutritional status on immunity, future studies of mucosal
immunity should include an assessment of nutritional
status, and the influence of nutrition and "pure" malnu¬
trition (such as might be found in anorexia nervosa or
after extensive small bowel resection for ischaemia) on
secretory immunity should be specifically addressed. A
whole programme of research is needed to assess this
broad and complex issue. One patient group who would be
ideal for study are those with coeliac disease. These
patients, when newly presenting, have villus atrophy in
association with nutritional abnormalities ranging from
marked malnutrition to no nutritional deficiency at all.
Furthermore, most will improve markedly on a gluten-free
diet.
Unfortunately, the limited literature on the effects of
nutrition on secretory immunity has concerned heterogene¬
ous groups of subjects, in whom malignancy or chronic
infection/infestation may have been the primary problem
(Cheatham et al, 1984; Watson et al, 1985 - see review in
chapter two). To repeat, studies on homogeneous groups
of subjects with pure malnutrition are needed.
Expression of results.
A persistent problem with no easy solution is the ques¬
tion of how best to express antibody levels obtained by
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ELISA when there is no weight-based, quantified, standard
available. Ideally, isotype-specific antibody should be
obtained by passing serum or a secretion known to have
high antibody levels over a sepharose gel column or on
agarose beads, coated with the specific antigen to allow
antibody extraction. The antibody could then be eluted by
washing, and a pure protein preparation obtained which
could then be used as a standard, and against which test
sample antibody levels could be expressed in micrograms,
nanograms, or picograms, as appropriate. This exercise is
technically feasible, although time-consuming and expen¬
sive; if further work is to be carried out using the same
antigens and antibodies, it would be valuable to invest
time and expense in obtaining the standards.
In the absence of such a standard the best compromise,
adopted in this thesis and by many working in secretory
immunity, is to express antibody levels as optical densi¬
ty (OD) readings, given as a percentage of the OD reading
of a high positive control sample. Multiple aliquots of
the high positive control sample are set aside so as to
allow valid comparisons between various batches of test
samples. A major reason for expressing results as a
percentage of a control sample is that optical density
readings are not linearly related to specific antibody
levels. A further corollary of this is that a comparison
between antibodies of differing specificities is not
possible. To allow valid comparisons between samples it
is important to standardise the assay conditions as much
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as possible, since significant variations in results can
occur between assays, and preferably one should make
comparisons only between samples run in the same batch.
Needless to say, a control group should always be used.
Using these methods, and means of expressing results, the
assays' reproducibility and variation were within accept¬
able limits, 3.1-13.4% (tables 1 and 2, chapter 4).
The main alternative method of expressing antibody levels
would be by diluting out each sample until a standard
level of activity (measured spectrophotometrically) had
been reached. However this would multiply the number of
assays involved, and, since each of the many samples was
already being assayed for twelve parameters, this alter¬
native was considered to be impractical.
It is important to state that it is critical to use non-
parametric statistical methods when analysing specific
antibody levels expressed as OD readings, since, as




Specimen processing and storage.
- Saliva.
Most investigators have found that saliva (especially
parotid) is stable when stored frozen, even without any
other means of preservation. There may be slight deterio¬
ration of proteins over time, but this seems to be of
• DP •
little consequence when a temperature of -70 is used,
and when storage time does not exceed three months. Most
assays for this thesis were done within this timespan,
• oP
and all specimens were stored at -70 . Formal assess¬
ment of the effects of storage and freezing were there¬
fore not carried out.
- Lavage fluid.
The necessity of immediate addition of protease inhibi¬
tors to gut lavage fluid in order to preserve immunoglob¬
ulins was amply demonstrated in this thesis. Again, the
fluid was stored at -70oC, and assayed promptly. There¬
fore no formal study of the effects of prolonged storage
was undertaken. The processing and protocol for protease
inhibition was taken directly from other investigators,
who had given our laboratory their protocol, based on
extensive work, some eighteen months prior to publication
of the paper (Gaspari et al, 1988). It would be sensible
to re-examine the need for each stage of the protocol,
which at present uses multiple protease inhibitors and
repeated centrifugation, in an attempt to simplify the
process. As it stands at present it is somewhat lengthy
and complex. It would certainly be worth comparing sim-
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pier treatment regimes, with just one or two anti-pro-
teases, for future studies.
Although most subjects found the drinking of the lavage
fluid acceptable, many found the taste to be very salty.
A reduced sodium preparation is now available, and should
be a better alternative, especially if healthy volunteers
(with less incentive to comply) are to be involved
(Fordtran et al, 1990).
Salivary physiology.
It is obvious from the literature that analysis of mixed
saliva is a less than perfect secretion by which to study
secretory immunity. Previously, methods of salivary
collection have been poor and the simple experiments in
this thesis have shown that data on secretory immunity
derived from mixed saliva is of questionable value. It is
absolutely essential to take account of age and smoking
habits. For example, one of my successors, in collabora¬
tion with me, studied an aged population. Despite contra¬
dictory literature on whole saliva, there was not a
single paper on pure parotid saliva, and we found a
striking effect of age on salivary immunity, by using
simple, straight-forward, methodology.
The original premise for this thesis was that food, time,
and alcohol would have to be controlled for when collect¬
ing saliva, because of their likely influence on salivary
immunoglobulin and antibody levels. In fact meals were
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the only consistent influence, and then only transiently;
thus the only absolute recommendation for future work
would be to sample after a short fast. There was a marked
variability in the concentrations of immunoglobulin and
levels of specific antibody over the 18 hour period
studied. The fall in these parameters after meals might
be explained by acinar or cellular depletion conseguent
on the high salivary flow which occurs during eating (a
washout effect), levels rising slowly after eating, until
the next meal. The high protein concentration in saliva
after food may be due to induction of digestive enzyme
synthesis and release upon eating. The disparity between
the fall in immune parameters and the increase in total
protein may be due to a differential capacity for synthe¬
sis or storage, or, if digestive enzymes were responsible
for the increased protein, that immunoglobulin release is
not stimulated by eating, whereas enzymes are. There are
probably many various influences on these parameters; the
only one definitely identifiable was, as stated above,
that of eating a meal, particularly breakfast. The best
solution seemed to be to take samples after an overnight
fast, or at least one hour after a meal, to permit com¬
parison of the results.
I had proposed that a large dose of oral alcohol would
lead to gut damage and an increase in gut permeability,
which would in turn eventually stimulate B cells to
produce more antibody, this being measured as a change in
salivary antibody levels. However, the effect of a large
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acute dose of alcohol on salivary antibody levels was
inconsistent although wide fluctuations in antibody
levels were observed, more so than in the 18 hour study.
Both smokers and non-smokers were included, since the
influence of smoking had not been appreciated at the
time, and this heterogeneity may have confounded inter¬
pretation of the results. The sugar permeability test
only detected a change in gut permeability in one non¬
smoking volunteer, whose antibody levels rose dramatical¬
ly. The permeability test may not have been sensitive
enough to detect more subtle changes in mucosal perme¬
ability in the other subjects, as the size of the mole¬
cules used limits the range of sensitivity of the inves¬
tigation. However, large doses of alcohol were used, and
any real and physiologically significant alteration in
salivary immunity seems unlikely. It would be valuable
to assess the acute and chronic effects of alcohol on
intestinal secretions, especially in those with alcohol-
related diarrhoea.
Lavage physiology.
For the purposes of this thesis, the first clear samples
of effluent obtained at gut lavage were taken to be
representative of lavage. Indeed the serial study of two
consecutive samples found that a steady state, in terms
of IgA concentration, was reached in lavage fluid once
the fluid had become clear. This work is at present being
repeated and extended to include several serial samples.
In the future, repeat lavages need to be performed on
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several days, and after longer periods of time to assess
the physiological dynamics of the fluid and the reproduc¬
ibility of the technique. Lavages could also be performed
prior to, and after excluding specific antigens from the
diet for a period of time. Similarly, subjects taking an
elemental diet could be investigated to determine whether
or not gut fluid, like parotid saliva, maintains antibody
levels in the absence of dietary antigen stimulation.
Kinetics of antibody levels.
Specific questions concerning the influence of dietary
antigen on levels of salivary antibodies were addressed
using a variety of approaches. Healthy patients were
divided into those including and those excluding bread or
eggs or milk in their diet. Groups of patients with derma¬
titis herpetiformis both on a normal, gluten- containing,
and a gluten-free diet were studied. Finally, a heteroge¬
neous group of patients begun on an elemental diet were
assessed. Generally, antibody levels to dietary antigens
were similar, irrespective of either dietary antigen
intake or mucosal integrity. This suggests that, at least
for food protein antigens, salivary antibody levels are
maintained in the absence of dietary antigen stimulation
for at least one year.
There are a number of points that need to be kept in mind
when interpreting these results. Firstly, avoidance of
certain dietary antigens may not be complete. Secondly,
only the study of subjects taking an elemental diet was
prospective, bringing recall bias into account for the
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retrospective studies. Thirdly, the prospective study of
subjects on elemental diet was heterogeneous in terms of
disease, concomitant therapy, and duration of diet.
However, despite these qualifications, the uniformity of
results suggest that the findings are valid.
Animal studies of antigen-stimulated mucosal antibody
production suggest that the quantity and number of doses
are critical determinants of not only the magnitude but
also of the quality of response. It must be remembered
that these experiments were conducted in genetically
identical, immunologically naive, animals and it may be
inappropriate to extrapolate the results to man. The
kinetics of antibody production have not been studied in
this thesis, nor have non-protein antigens. Experiments
with other antigens of different origin and of antigens
entirely novel to subjects would give valuable informa¬
tion. It may be that quite different patterns of antibody
levels would result if, for example, bacterial antigens
(associated with highly immunogenic lipopolysaccharides)
were used to stimulate a response. Certainly, other
antigens are as relevant as food antigens in terms of
disease.
Coeliac disease and dermatitis herpetiformis.
Other groups have been assaying saliva for anti-gliadin
antibody levels as a test for coeliac disease. These
studies have made two suppositions; firstly they have
assumed that salivary antibodies reflect distal gut
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antibodies, and secondly that anti-gliadin antibody
levels in distal gut secretions can distinguish between
healthy subjects and patients with coeliac disease.
Unfortunately neither of these suppositions have been
either thoroughly tested nor proven.
One of the main aims of this thesis was to determine if
the first hypothesis was correct and that salivary anti¬
bodies and immunoglobulins did reflect distal gut secre¬
tions. To accomplish this, the results from gut lavage
were taken as the "gold standard". Then, antibody levels
and immunoglobulin concentrations from parotid saliva
were compared with those obtained from lavage. Data from
saliva generally did not correlate with that from gut
lavage, nor did it correlate with data obtained from
jejunal aspirate.
The study of parotid saliva from coeliac patients also
allowed comparison with control subjects to see if these
groups could be separated by measuring antibody levels in
saliva or gut lavage. If this had been the case, salivary
antibody levels or immunoglobulin concentrations might
have been of use in diagnosis or follow-up of patients
with coeliac disease. Finally, samples of secretions from
these patients permitted an assessment of the effects of
mucosal damage on antibody levels to dietary antigens.
Although salivary antibody levels were higher in coeliac
disease than in control subjects, the degree of overlap
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between the groups prevents saliva from being used as a
diagnostic marker. The persistence of salivary antibody
levels in patients with coeliac disease and dermatitis
herpetiformis on a gluten-free diet, even when complete
mucosal healing has occured, also precludes the use of
saliva for monitoring dietary adherence, mucosal healing,
and relapse in these conditions.
It is not apparent why salivary antibody levels in derma¬
titis herpetiformis are similar whatever the state of the
mucosa. It might be proposed that if there has never been
an enteropathy present that antibody levels would be low
but this did not appear to be the case. Transient previ¬
ous abnormality cannot be excluded, and sensitive histo¬
logical techniques (for example quantitative morphometry,
intra-epithelial lymphocyte counts, and crypt cell mitot¬
ic rates) were not employed to detect subtle forms of
enteropathy. However other work from this laboratory
supports an abnormality of secretory immunity in dermati¬
tis herpetiformis, independent of any enteropathy (O'Ma-
hony et al, 1990). It is of interest that, despite the
fact that gliadin is the "toxic" antigen, there was
strong positive correlation between antibody levels to
all antigens, even irrespective of isotype. This suggests
that the mucosal antibodies are produced as part of a
generalised secretory response, secondary to a primary




In gut lavage there were not only significant differences
in antibody levels to gliadin but also to ovalbumin and
Blactoglobulin between controls and patients with both
treated and untreated coeliac disease. These differences
were not present in parotid saliva. In addition, total
IgM and IgG concentrations were increased in the lavage
fluid of untreated coeliac patients. Interestingly in¬
creased numbers of IgM and IgG plasma cells have been
reported in the jejunal mucosa of patients with coeliac
disease (Lancaster-Smith et al, 1974; Scott et al, 1984).
It might be reasonable to attribute these high antibody
and immunoglobulin levels to increased secretory immunity
in an area of inflamed and damaged gut mucosa. The in¬
creased IgG in untreated disease might be explained by
plasma leakage from the inflamed mucosa although it must
be said that IgA is not proportionately increased as
might be expected, and an increase in mucosal IgG plasma
cells has previously been demonstrated, (Lancaster-Smith
et al, 1974; Wood et al, 1987), suggesting that a "leak"
may be too simplistic an explanation and that a local
increase in production may be present. Furthermore,
although in treated patients the lavage IgG concentration
was not different from controls, IgM concentrations
remained high.
Other work of great interest from our laboratory, re¬
ferred to above, found that jejunal aspirate total IgM
concentrations and IgM antibodies to gliadin, ovalbumin,
and Blactoglobulin are high not only in patients with
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untreated coeliac disease, but also in patients with
dermatitis herpetiformis with a normal jejunal mucosa, as
assessed by standard histology, intra-epithelial lympho¬
cyte counts, and quantitative morphometry. Jejunal aspi¬
rate total IgA and IgG concentrations were also in¬
creased, but not as markedly as IgM (O'Mahony et al,
1990). A two stage model of coeliac disease is proposed,
in which inappropriate gluten sensitivity is quite com¬
mon, genetically restricted, and expressed in the gut
(and also in the kidneys and skin) via T-cell mediated
immunity as a spectrum of functional and histological
abnormalities. Expression of the full intestinal lesion
is dependent on a second factor (of which a number are
proposed) to drive the enteropathy from latent to overt.
Relationships between antibody levels in various fluids
Data from both animal work and human studies has demon¬
strated the existence of a common mucosal immune system.
Thus it be expected that one mucosally derived secretory
fluid would be representative of another. A major aim of
this thesis was to define whether or not this was the
case. At the start of this thesis I knew from the litera¬
ture that antibodies to mouth commensal bacteria were
detectable in parotid saliva (Gregory and Allansmith,
1987; Smith and Taubman, 1987), and that that specific
antibodies to gut pathogens (and other orally adminis¬
tered bacteria) could be found in saliva either after
natural infection or immunisation (Clancy et al, 1983;
Carlsson et al, 1985; Jertborn et al, 1986). It was also
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apparent that there was generally little or no salivary
antibody response after parenteral immunisation (Baumann
et al, 1985; Waldman et al, 1986) . Additionally, from the
rare previous studies addressing the question, there did
not seem to be any clear relationships between antibodies
induced in both saliva and intestinal fluid by gut infec¬
tion (Jertborn et al, 1986; Stoll et al 1986), nor had
anyone described salivary immune responses to either a
primary systemic or a localised, non-mucosal, infection.
In the thesis I sought to formally study these points.
The results from my experiments did not substantiate the
hypothesis that one mucosally derived secretory fluid was
representative of another. With respect to comparisons
between serum and saliva, current theory suggests that
there is either an inverse or no relationship between
antibody levels. The findings of this thesis suggest
mainly no relationship, but when one is present the
correlations are direct and positive. This was true for
both antibodies of the same isotype and also for serum
IgG and salivary IgA antibodies. In fact, the positive
correlations between salivary IgA and serum IgG anti¬
bodies in patients with coeliac disease and dermatitis
herpetiformis suggest activation of both the salivary and
systemic immune systems in parallel.
Furthermore, although parotid saliva differs from jejunal
aspirate, both in the way it encounters antigen and
secretes fluid into the gut (via a duct), it is unlikely
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that these differences wholly account for the lack of
correlation between saliva and aspirate, since, despite
the fact that the data is taken from an heterogeneous
group of subjects, antibody titres in aspirate and gut
lavage did not correlate either. One explanation for
this may be differences in local antigen concentrations.
Thus, relationships between immunoglobulins or specific
antibodies in mucosal secretions were rare, and most of
the significant correlations were between immunoglobulins
or antibodies in serum and in a secretion. Direct corre¬
lations were most often found when mucosal damage was, or
previously had been, present. This suggests that when
the mucosal barrier is breached, loss of tolerance may
occur, and both the systemic and mucosal immune system
may be stimulated to a greater or lesser extent.
My further studies since the completion of this thesis
have demonstrated a five to ten-fold rise in both total
and secretory IgA and in specific antibody levels to
Streptococcus mutans species (pathogenic oral bacteria)
following tonsillitis and peri-tonsillar abscess. There¬
fore, although the parotid glands have been shown to be
part of the common mucosal immune system they may also
reflect the systemic immune response, and, taken all
together, my work suggests that the parotids are an area
of interface between the two systems. After all, unlike
the majority of the mucosal associated lymphoid tissue
the parotid glands have not been shown to take up anti-
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gens directly from the exterior, and may not even encoun¬
ter antigen directly at all, the stimulus to antibody
production possibly arising from circulating lymphocytes
which have migrated from an area of antigen challenge.
What are the likely mechanisms involved in parotid sali¬
vary antibody production?. It is unlikely to be local
antigen leading to direct stimulation, or to plasma leak
into parotid saliva. It is most likely to be circulating
B cells, from the gut or oral mucosa, or from local lymph
nodes and bone marrow in the case of systemic infection
which gives rise to the specific salivary antibody re¬
sponse. Migration of T cells leading to B cell maturation
and activation could also be involved, as could T cell
signals, either directly or via cytokines. Studies of
circulating lymphocytes and parotid salivary cytokines
would be two ways of investigating the mechanism.
So lavage fluid has been extensively investigated in many
subjects, along with parotid saliva. In fact, the assump¬
tion that saliva is a good representative of mucosal
secretions is not borne out either by this thesis or by
the current literature. Naively at the beginning of this
thesis I had hoped salivary immunity would be proportion¬
al to distal gut immunity, and that I would be able to
use saliva to investigate important guestions relating to
distal gut immunity and to oral tolerance. However,
although there were significant differences both in
salivary and in lavage antibody levels between groups of
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well-characterised patients with coeliac disease, and
although patterns of antibody levels for these groups in
saliva often parallelled those in gut lavage, for an
individual saliva could not be used to predict gut lavage
antibody levels.
Smoking and mucosal immunity.
Much work has been conducted on systemic immune status
but, surprisingly, the influence of smoking on mucosal
immunity has been relatively neglected. Smoking is
strongly associated with epithelial tumours of the upper
oro-gastro-intestinal tract (Kleinsasser, 1983). The
incidence of ulcerative colitis is much lower in smokers
than in non-smokers or ex-smokers (Tobin et al, 1987;
Boyko et al, 1987; Vessey et al, 1986). A recent report
that smokers have reduced numbers of antigen-presenting
cells in the cervical epithelium is of interest (Barton
et al, 1988).
A striking and reproducible influence of cigarette smok¬
ing on salivary immunoglobulins was demonstrated in these
investigations. In healthy smokers, the concentration of
IgA in pure parotid saliva was reduced, and that of IgM
increased, when compared with non-smokers. For IgA, this
effect was strongly dose dependent, and reversible;
salivary IgA concentrations were similar to those for
non- smokers in a group of healthy subjects who had
stopping smoking at least five years before. Differences
in parotid salivary immunoglobulin concentrations between
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healthy non- smokers and patients with head and neck
cancer might be attributed solely to the smoking habits
of the latter. Such a relationship may be blurred by the
fact that many smokers are heavy alcohol drinkers (Fla-
mant et al, 1964), and alcohol consumption may increase
serum (and therefore possibly salivary) IgA levels
(Sherlock, 1989). Alcohol is an independent risk factor
for squamous cell cancer of the head and neck (Broitman
et al, 1983). This complicating factor of alcohol was
avoided by using non-drinkers in the second, case-con¬
trolled phase of the study in which identical results
were obtained.
The similarity of the findings between healthy smokers
and patients with epithelial head and neck tumours proba¬
bly reflects the fact that most people who develop these
neoplasms smoke. Although many patients in the untreated
tumour group and in the post-radiotherapy group had
stopped smoking at the time of sampling, most commonly at
the time of diagnosis, sufficient time may not have
elapsed to allow any potential normalisation of salivary
immunoglobulin levels. However, the majority of patients
in the prospectively studied group from Edinburgh under¬
going radiotherapy said that they had never smoked. It
may be that the salivary immunoglobulin alterations seen
are a secondary phenomenon, reflecting immune disturbance
secondary to tumour. The negative findings in the pa¬
tients with tumour elsewhere would suggest, if that were
the case, that there must also be a local component to
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this. An attractive alternative explanation is that
mucosal immunodeficiency may predispose to tumour forma¬
tion, as others have proposed (Kleinsasser, 1983).
I am aware of four previous reports of salivary
immunoglobulins in smokers (Watanabe et al, 1983; Hersey
et al, 1983; Bennett and Reade, 1982; Olson et al, 1985),
relating to small numbers of selected patients, and using
whole saliva. Even in the absence of oral sepsis or
obvious radiation damage, contamination with crevicular
fluid is likely to influence results. This is highlighted
by the discrepant results in the literature on the
influence of smoking on immunoglobulin content of mixed
saliva. Bennett and Reade found that salivary IgA con
centration was low in 8 elderly, edentulous male smokers,
in contrast to Watanabe et al who reported high mixed
salivary IgA levels in a group of smokers and drinkers,
and in head and neck cancer patients. Hersey et al
reported a striking decrease in salivary IgG (probably
derived from crevicular fluid or inflammatory exudates)
in a small group of healthy smokers who stopped smoking.
Olson et al found no change in whole salivary IgA when
smokers stopped smoking and took nicotine or placebo
chewing gum. The use of pure parotid saliva for assay is
therefore particularly important in patients with head
and neck tumours and after radiotherapy, when there may
be immunosuppression and oropharyngeal superinfection.
Studies of serum and circulating leucocytes have been
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used to determine the effects of smoking on systemic
immunity. Smokers have increased polymorphonuclear
neutrophil counts, decreased natural killer cell
activity, an increase in total T cell numbers with a
decrease in the Thelper/suppressor cell ratio in heavy
smokers (reviewed by Holt, 1987). The decrease in
cells in both blood and broncho-alveolar lavage has been
noted by more than one group, and shown to be reversible
on stopping smoking (Costabel et al, 1986; Miller et al,
1982). In smokers, serum IgA, IgG, and IgM are generally
lower by 10-20% than in non-smokers (Gerrard et al, 1980;
Holt, 1987), with higher levels of serum IgD and IgE in
smokers (Holt, 1987). Smokers have a generally decreased
systemic response to antigens encountered at the nasal
and respiratory mucosae (Andersen et al, 1982; McSharry
et al, 1985), although at the mucosal level conflicting
results have been reported for total IgA in broncho-
alveolar lavage fluid, with a decrease (Gotoh et al,
1983) and a three to four-fold increase (Velluti et al,
1983) reported; at the nasal mucosa a decrease in local
antibody levels in smokers is reported (Rylander et al,
1982). In a group of patients with head and neck tumours
high whole salivary IgA levels were shown to correlate
with tumour load, and decrease towards normal after
successful treatment (Brown et al, 1975).
The increase in IgM levels might be interpreted as a
compensatory rise. This concept is a little naive; IgM
has very different properties to IgA, and its higher
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concentrations may reflect immunopathology rather than
simple compensation. It is probably unnecessary to con¬
firm the self reported cigarette consumption; there is no
reason to suppose that any errors in reporting would vary
between light, moderate or heavy smokers, and others have
shown self-reported smoking habits to be reliable (Wil¬
liams and Gillies, 1984).
Although no statistically significant difference between
smokers and non-smokers was found in gut lavage fluid It
may be that, due to too many light smokers and too few
subjects, a type II error has occurred. A larger study of
heavier smokers of more than twenty cigarettes daily
should be undertaken to clarify the issue. Although no
consistent effect of alcohol was demonstrated on parotid
salivary immunity it would be sensible to exclude heavy
drinkers from such a study.
Unfortunately, there were too few patients with inactive
and active Crohn's disease to assess the influence of
smoking on mucosal immunity in this condition. This would
be of great interest, given the association of smoking
with Crohn's disease, the findings of the thesis, and
postulated immunodeficiency present in these patients
(MacDermott et al, 1986; Verspaget et al, 1988).
Thus it has been demonstrated that smokers have a dose-
dependent and probably reversible humoral mucosal immuno¬
deficiency, as reflected either directly or otherwise by
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salivary IgA concentrations. Studies of mucosal immunity
at other surfaces are necessary and should include inves¬
tigation of T cell factors and other regulatory mecha¬
nisms. It would be valuable to assess the effect of
smoking on the quality and magnitude of the mucosal
response to novel antigens. It would also be valuable to
use bacterial antigens, and not to confine the work to
dietary protein antigens as previously, since the former
may be more directly relevant to gastrointestinal pathol¬
ogy. If changes in secretory immunoglobulins reflect
abnormalities of other, as yet unexplored components of
mucosal immunity, new avenues of pathogenesis of smoking-
related diseases may emerge.
Inflammatory bowel disease.
Information on immunity in patients with inflammatory
bowel disease is becoming more and more important as the
numbers of patients increase and as the high morbidity
becomes apparent, especially in the young (Barton et al,
1989; Barton and Ferguson 1990). I had proposed that
there might be a primary mucosal secretory immunodeficin-
ecy which could be quite localised and very specific. My
studies in this thesis were only the early phase of a
larger study on this topic, but certainly found no evi¬
dence of mucosal secretory immunodeficiency, although
others had previously suggested that immunoglobulin
production by lamina propria lymphocytes was decreased
(see chapter two; also - MacDermott et al, 1981; Verspa-
get et al, 1988). In fact in parotid saliva there were
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generally increased levels of antibodies to food protein
antigens, with no alteration in total immunoglobulin
concentrations.
Although a different pattern of antibodies and immuno¬
globulin was apparent in lavage in patients with inflam¬
matory bowel disease, again there was no evidence of
immunodeficiency. Total immunoglobulin concentrations
were increased in fact, and strikingly so in respect of
IgG, with no difference in specific antibody levels.
Again this increase might be explicable on the basis of a
plasma leak, and further work since the completion of
this thesis by co-workers in this laboratory suggests
that this is the case (O'Mahony, personal communication).
However others have shown high numbers of IgG plasma
cells in the gut of Crohn's patients (Brandtzaeg and
Baklien 1976; Bookman and Bull, 1979; Kett et al, 1987),
and indeed increased synthesis of IgG (Bookman and Bull,
1979; McClelland et al, 1976; Verspaget et al 1988),
although this has been disputed (MacDermott et al, 1981)
and qualitative differences in IgG subclass distribution
have been shown (Kett et al, 1987; Scott et al, 1986).
The markedly elevated lavage fluid IgG concentrations
have been confined to patients with active Crohn's dis¬
ease, and seem to be a marker of early inflammatory
activity when other features such as radiographic studies
are normal. As such, lavage fluid IgG concentrations are
now being used in clinical situations in this hospital.
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Secretory immunodeficiency predisposing to or as a result
of inflammatory bowel disease has not been excluded by
the results from these studies however. For example,
others have suggested that IgA subclasses may differ in
these patients (MacDermott et al, 1986). This was not
addressed in this thesis.
Further study of secretory immunity in inflammatory bowel
disease would be of value. It would be important to
assess the secretory immune response to novel antigens in
dynamic studies. It would also be valuable to use bacte¬
rial antigens, and not to confine the work to dietary
protein antigens as previously, since the former may be
more directly relevant to gastrointestinal pathology.
SUMMARY
New approaches to the investigation of mucosal humoral
immunity in man have been explored. Pure parotid saliva,
jejunal juice, and intestinal fluid obtained by whole gut
lavage have been used to describe some areas of basic
physiology of secretory fluids. Comparison of serum,
parotid saliva, jejunal aspirate, and intestinal fluid
immunoglobulin concentrations and specific antibody
levels has allowed correlations between these fluids to
be made and their relationships determined. Investigation
of patients with coeliac disease and dermatitis herpeti¬
formis has shown that, as in serum, there is up-
regulation of secretory immunity. A striking influence of
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smoking on salivary immunity has been established. Final¬
ly, no evidence of mucosal immunodeficiency in patients
with inflammatory bowel disease has been demonstrated.
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(i) Pierce protein assay.
A standard protein solution of known concentration
(2mg/ml) was made up with bovine serum albumin in dis¬
tilled water, and serial dilutions of this solution were
made to give standards with a range of protein concentra¬
tions from 0.2 - 1.2 mg/ml. Pierce reagent A (sodium
carbonate, sodium bicarbonate, bichinchoninic acid [BCA],
and sodium tartrate, in 0.IN sodium hydroxide) were added
to reagent B (4% copper sulphate.5H2O) in a ration of
50:1. One tenth of a millilitre of the diluted standard
or test solution (saliva) was pipetted into a test tube.
Carbonate buffer was used as a blank reference. Then, 2.0
mis of Pierce working reagent (A + B) were added to each
tube for testing and to the blank, and mixed well. The
tubes were incubated at 37oC for 30 minutes then cooled
to room temperature. The absorbance of the samples at
562nm was then read against the blank on a standard
spectrophotometer (Dynatech Microelisa Autoreader M580),
subtracting the value of the blank. The known standard
dilutions were then plotted against absorbance, and
standard curves constructed to calculate the protein
concentration of each test sample. Serial dilution curves
were constructed to determine the optimum dilution of the
test samples of saliva.
(ii) ELISA for serum antibodies to food proteins.
ELISA plates (Microelisa M129B, Dynatech, Billingshurst,
Sussex) were coated with 5 ug/ml of antigen (gliadin or
ovalbumin or BLG) dissolved in carbonate buffer at pH
9.6, using 125 ul to coat each well. The coated plates
were incubated overnight at 4oc, then washed three times
with 0.9% NaCl with 0.05% Tween (Sigma chemicals ltd.,
Poole, Dorset), and blocked with 0.9% NaCl with 0.05%
Tween 20 and 1% adult bovine serum (Scottish antibody
production unit, Carluke, Lanarkshire). To measure anti¬
bodies in serum, serum was diluted 1:200 to measure IgG
antibodies, and 1:100 to measure antibodies of the IgM
and IgA isotype.
To each well in duplicate pairs, 125 ul of diluted sample
was added, using a high positive serum as a control, and
the plates were again incubated overnight at 40<~*. After
incubation, the plates were washed with 0.9% NaCl with
0.05% Tween , and then blocked with 0.9% NaCl with 0.05%
Tween 20 and 1% adult bovine serum. Following this, each
well was treated with 125 ul of 1/5000 affinity-purified,
alkaline phosphatase-conjugated, goat anti-human IgA,
IgG, or IgM (Northeast biomedical laboratories, Uxbridge,
Middlesex) diluted in blocking solution. The plates were
washed with 0.9% NaCl with 0.05% Tween , and blocked with
0.9% NaCl with 0.05% Tween 20 and 1% adult bovine serum
before the addition of lmg/ml of paranitrophenylphosphate
(PNP) substrate (104-105, Sigma) in 10% diethanolamine
(DEA) buffer. The resultant colour reaction was read on
ELISA reader at OD 405 nm, allowing the OD value of the
high positive control to develop to 1.000. The arithmetic
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mean of the OD reading of each paired test sample was
expressed as a percentage of the OD reading of the high
positive control.
(iii) Immurioperoxidase staining of parotid glands.
The parotid gland specimens obtained at post-mortem or
per- operatively were fixed for a minimum of 24 hours in
10% buffered formal saline. Using a Histokinette machine
the specimens were immersed in increasing concentrations
of alcohol from 70% upto 100%, followed by chloroform and
then paraffin wax, in which they were mounted. The mount¬
ed specimens were cooled on ice to reduce paraffin wax
crystallisation and stored dry until processing. Prior to
processing the blocks were once more cooled on ice and
sections 3 um thick were cut on a microtome, slides being
previously coated with poly-L-lysine 0.01% to assist
adhesion. Sections were dried in an oven at 37 for 20
minutes and were then ready for staining.
For staining, sections were de-waxed by immersion in
Histoclear for five minutes on two occasions. Dehydration
of the specimen was accomplished by soaking in absolute
alcohol (IMS 99) for 5 minutes on two occasions. After
this they were treated with 1% hydrogen peroxide in
methanol for 20 minutes to block endogenous peroxidase,
immersed in tap water once and in tris buffered saline
(TBS) at pH7.6 twice , for 5 minutes each stage. After a
soak in normal donkey serum with TBS for 10 minutes to
help prevent non- specific binding, the areas around the
specimens were drained and dried, and the primary anti¬
body was applied for 60 minutes. To detect IgA-positive
cells for example, sheep IgA anti-human IgA was used.
This was followed by rinse and then two 5 minute immer¬
sions in TBS, after which the secondary antibody (e.g.
donkey IgG anti-sheep IgA) was applied for 60 minutes. A
further rinse and two 5 minute immersions with TBS were
followed by coating the specimens for another 60 minutes
with sheep peroxidase-antiperoxidase to combine with the
anti-sheep antibody, after which they were rinsed and
immersed in TBS in a similar manner to previously. Diami-
nobenzidine was added for 5-10 minutes to develop the
brown/black colour reaction, then the specimens were
soaked in TBS followed by tap water, each for 5 minutes,
before treatment with haematoxylin for 5 minutes to stain
up cell nuclei. Soaking in tap water was followed by a 10
second immersion in 1% acid alcohol to remove excess
haematoxylin, and then another 2 minute rinse with tap
water followed before "blue" in lithium carbonate was
added which turned the haematoxylin from red to blue and
in doing so stabilised the reaction.
The specimens were then washed in tap water for 5 minutes
prior to dehydration for three 30 second periods in 70%
alcohol, absolute alcohol, and finally isopropanol.
Treatment with Histoclear for 30 seconds, followed by
immersion for 5 minutes raised the refractive index and
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improved resolution. Finally the sections were mounted in
the synthetic resin DPX (RA Lamb, North Acton, London). A
positively stained cell appeared brown or black, and the
nuclei blue.






IBM PS/2 30 286
Hewlett-Packard laserjet III printer
Software
Amstat 1, lg, 2a-d statistical programmes
dBASE III Plus data storage, retrieval, and sorting
Minitab statistical programme
Wordstar version 4.1 word-processing
Dynatech EIA-soft ELISA interpretation
The Amstrad PCW8512 and Amstat statistical programmes
provided all the necessary analyses, but were limited in
terms of flexibility. Data entered onto a storage and
retrieval system could not be transferred to the statis¬
tics programme and had to be re-entered. Once entered,
the data points were not available for the necessary
manipulations without substantial re-entry of much of the
data again. The system was very slow at calculation, and
frequently "dumped" large columns of data, when the
limited memory was exceeded. The system could not safely
handle more than 10 columns approximately 40 points long.
Minitab on the other hand could import data, with some
awkward manipulation, from dBASE III Plus and rapidly
analyse large files of data with ease. Again, manipula¬
tion was needed to obtain paired t-tests, and non-para¬
metric correlation and significance values.
Initial data storage and statistical analysis was done on
the Amstrad computer using the Amstat statistical soft¬
ware programmes. It was soon apparent that the limited
flexibility and capacity of this system could not handle
the necessary tasks. Fortunately the IBM and IBM-compati¬
ble DCS machines, along with dBASE III Plus and Minitab
became available. They offered high capacity data stor¬
age, flexibility and selectivity of data access, and the
necessary RAM to rapidly perform all the tasks required,
and were used thereafter.
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(v)- ELISA for total salivary immunoglobulins
- IgA, IgG, IgM, and for secretory IgA
Standards.
Colostral IgA (Sigma) and human serum immunoglobulin (SPS
101, Human Protein Reference Unit, Royal Hallamshire
Hospital, Sheffield) were used as standards. The initial
dilution of the secretory IgA standard was 0.5 ug/ml,
whilst for the IgG and IgM standards, the initial dilu¬
tion was 3 ug/ml.
Method.
Immulon I ELISA plates (Microelisa M129A, Dynatech) were
coated with a 1/5000 dilution of affinity-purified goat
anti-human immunoglobulin Fc alpha or gamma or mu anti¬
body (Northeast Biomedicals) in 0.1 M carbonate buffer,
pre- diluted 1:1 with distilled water, at pH 9.6-8, using
125 ul per well. The coated plates were incubated over¬
night at 4°C, and then washed three times with 0.05%
Polyoxyethylene sorbitan monolaurate (Tween 20) in 0.9%
NaCl, and blocked with 1% adult bovine serum diluted in
the same. Saliva was diluted 1:10, and then double dilut¬
ed down to 1/100 to measure IgG and IgM; to measure IgA
the initial dilution was 1:100, followed by double dilu¬
tions down to 1/6400. All dilutions were made with block¬
ing agent, and 125 ul of each diluted sample were added
to wells in duplicate.
The plates were incubated overnight at 4°C, then washed,
and treated with 125 ul of 1/5000 affinity-purified,
alkaline phosphatase-conjugated, goat anti-human IgA,
IgG, or IgM. (Northeast biomedicals) in blocking solu¬
tion, and washed again. Then lmg/ml of PNP substrate
(104-105, Sigma) in 10% DEA buffer was added, and the
subsequent colour reaction read on an ELISA reader at OD
405 nm. The OD of the highest concentration of the stand¬
ard was allowed to develop to give an OD reading of 1.000
before the plate was read. Immunoglobulin concentrations
in the test samples were calculated from the linear
portion of the test sample curves compared to a parallel
part of the standard curve.
(vi) ELISA for isotype-specific salivary antibodies to
gliadin, ovalbumin, and Blacrtoglobulin
ELISA plates (Microelisa M129B, Dynatech) with 5 ug/ml of
antigen (gliadin, or ovalbumin, or BLG) dissolved in
carbonate buffer at pH 9.6, using 125 ul of solution per
well, and incubated overnight at 4°C. After this, the
plates were washed three times with 0.9% NaCl with 0.05%
Tween, and blocked with 0.9% NaCl with 0.05% Tween 20 and
1% adult bovine serum. To measure antibodies in saliva,
the saliva was diluted 1:2 with diluent to measure IgG
and IgM, and diluted 1:5 to measure IgA. To each well in
duplicate was added 125 ul of diluted sample, using a
high positive serum sample as a control, and the plates
were incubated overnight at 4°C. After washing again,
plates were treated with 125 ul of 1/5000 affinity-puri¬
fied, alkaline phosphatase-conjugated, goat anti-human
IgA, IgG, or IgM (Northeast biomedicals) diluted in
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blocking solution, and were once more washed. PNP sub¬
strate at lmg/ml was added (104-105, Sigma) in 10% DEA
buffer, and the subsequent colour reaction read on an
ELISA reader at OD 405 nm, allowing the OD of the control
sample to develop to 1.000. The arithmetic mean of each
test sample OD reading was expressed as a percentage of
the control value.
(vii) . ELISA methodologies for lavage fluid
The ELISA protocols for measurement of total immunoglobu¬
lins and antibodies to foods in lavage fluid were the
same as for saliva, except for the dilution of the stand¬
ards when measuring total immunoglobulin concentration.
For lavage this was as follows - SPS 101 standard human
immunoglobulin reagent for IgM and IgG was initially
diluted to a concentration of 3 ug/ml for each immuno¬
globulin, and followed by doubling dilutions.
(vixi) Standards for ELISA
Initially the British working reagent for human serum
immunoglobulins IgG, IgA, and IgM 67/99 (National Insti¬
tute for biological standards, Potters Bar, Hertford¬
shire) , based on the World Health Organisation 1st inter¬
national reference preparation, was used as a standard
for all total immunoglobulin assays. Subsequently SPS 101
(Protein Reference Unit, Royal Hallamshire Hospital,
Sheffield) was used as a colostral standard. For total
immunoglobulin assays, the standard was double diluted
out, beginning at an initial dilution of 1.25ug/ml for
optimum assay conditions. For secretory IgA, the optimum
initial dilution was found to be 0.5ug/ml. Test samples
were also double diluted out, and the concentration of
immunoglobulin determined by comparing the curve of OD
readings to the standard curve, finding the parallel
values, and taking their arithmetic mean. This could be
performed automatically, but less reliably, by computer
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(x) GLOSSARY OF ABBREVIATIONS, TERMS AND SYMBOLS
BLG beta-lactoglobulin
BSA Bovine serum albumin
C. albicans Candida albicans
DEA diethanolamine
DTT dithiothreitol
E. coli Escherichia coli
EDTA ethylenediaminetetracetic acid
ELISA enzyme-linked immunosorbent assay
(immunoglobulins and antibodies)
ELISPOT enzyme-linked immunosorbent spot
assay (cells producing
immunoglobulins or antibodies)












PVA partial villus atrophy
S. mutans Streptococcus mutans
S. epidermidis Staphylococcus epidermidis
SVA subtotal villus atrophy
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DO SALIVARY ANTIBODIES TO DIETARY ANTIGENS REFLECT INAPPROPRIATE
STIMULATION OF GALT OR HYPERPERMEABILITY?
J R BARTON & ANNE FERGUSON
University of Edinburgh Gastrointestinal Unit,
Western General Hospital, Edinburgh, U.K.
INTRODUCTION
Since there is traffic of lymphocytes between mucosal
surfaces (1) antibodies in saliva may reflect the secretory
immune responses of the gastrointestinal tract (2). We are
examining the possible role of saliva in this context. In this
first phase, a detailed study of salivary immunoglobulins and
specific antibodies has been pursued. Pure parotid saliva is a
stable, clean, secretory fluid, easily obtained by non-invasive
means, requiring litle processing before analysis and in many
ways ideal for such investigation.
We selected patients likely to have abnormally permeable
gastrointestinal mucosae with, possibly, secretory antibodies to
common food proteins. We have also embarked on an investigation
of the effects of complete dietary exclusion of the relevant
foods on the levels of any antibodies present.
METHODS
Subjects studied were 142 normal volunteers, 14 patients
with active coeliac disease, and 12 patients with active small
intestinal Crohn's disease. Pure parotid saliva was collected
via a Car 1 sson-C r i t tenden cup for five minutes, with flow
stimulated by two mis. of 5% citric acid in aliquots. The volume
was measured by graduated pipette and saliva stored at -20°C.
The protein content was assayed by the Dowry method. Total
immunoglobulins IgA, IgG, and igM were determined by an ELISA
technique using a WHO reference immunoglobulin serum as standard.
Specific antibodies to gliadin (gli), ovalbumin (ova), and B-
lactoglobulin (BLG) , were also analysed by ELISA. Although IgA,
IgG, and IgM assays were used, we have, to date, limited data for
the IgG and IgM food antibodies in the controls population and
so only results of assays for IgA specific antibodies are
reported.
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ELISA results were assessed in relation to volume, flow
rate, salivary protein content, and (for the IgA-specific
antibodies) in relation to total IgA. Results per ml. are shown.
Statistical analysis was by using contingency tables, non-
parametric ranking and the Wilcoxon paired rank sum test.
RESULTS
Total immunoglobulins
IgA was present in 137/142 of control and all patient
samples, IgM in 97/124 and IgG in 32/155 control samples, in
10/12 and 3/10 of coeliacs, and 12/12 and 4/12 of Crohn's
patients, (p>0.05, NS).
Concentrations of IgA and IgG were not different, but in
contrast to previous reports (3,4), levels of IgM were
significantly increased in both patient groups, p = 0.0018 and
0.0001 for coeliac and Crohn's disease respectively, (fig. 1).
No differences with regard to age, sex, salivary volumes and flow














(n=l 12) (n=l2) (n=12)
IgG
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(n=i24) (n= 12) (n=l2)
IgM
Fig. 1 Total immunoglobulin levels in controls (A), coeliacs
(B), and Crohn's disease (C), * = significant difference.
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Implications
It is not certain what these markedly raised igM
concentrations represent. Are they a result of disordered
immunoregulation, such as a failure of B cell switching, perhaps
secondary to defective function? Are they due to the
nature of the antigen? Others have found an increase in the
number of IgM-producing plasma cells in the jejunal mucosa, and
of IgM in jejunal juice of coeliacs (5), and the increased
salivary immunoglobulins may reflect this. However the same
investigators found no difference in the levels of IgM in the
saliva of their subjects.
IgA anti-food antibodies
IgA antibodies to gliadin, ova and BLG were detectable with
similar frequency in all three groups. Antibody levels to all
three food proteins were significantly increased in Crohn's
disease (p = 0.0018 gli; 0.005 ova; 0.028 BLG), and to two of
















i jzisfsni. 1* ISt.
ABC ABC AB
Gliadin Ova 3 LG
Fig. 2 IgA anti-food antibody levels, (key as fig. 1)
* = significant difference, see text.
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Implications
Similar findings in patients with two quite distinct
diseases suggests a non-specific mechanism. The most likely
explanation is that this a secondary phenomenon following damage
to the gut wall, the subsequently increased permeability allowing
increased antigenic load to reach the gut lymphoid system. It is
unlikely that these antigens have a primary causative role in
Crohn's disease, although they may be involved in perpetuation of
inflammation after an initial insult. The precise relevance to
coeliac disease is unclear, and the presence of detectable
antibodies in many normal volunteers, although at lower titres,
argues against a pathogenetic role.
IgA anti-gliadin antibodies during elemental diet therapy
In this pilot study of five patients with active small
intestinal Crohn's disease, treatment with an elemental diet
(Elemental 028) for varying periods was accompanied by a fall in
IgA anti-gliadin antibodies, p = 0.004, Fig. 3. One patient
continued to take small amounts of normal food in addition to
the elemental diet; her readings remained unchanged. There was
no correlation with total IgA levels.
Fig. 3 Change in IgA anti-gliadin antibody levels, elemental




Withdrawal of gliadin from the diet resulted in a definite
though variable decrease in specific antibody levels in saliva.
Continued intake of small amounts of gliadin in one patient may
have prevented this fall. By such dietary manipulation a means
of determining the kinetics of the secretory immune response may
be available. Elemental diets have been shown to improve
patients with Crohn's disease, who demonstrate relapse after
reintroduction of a normal diet. Salivary antibodies to
enterically encountered antigens, even if not directly involved
in the pathogenesis, may reflect disease activity.
SUMMARY AND CONCLUSIONS
Increased levels of IgM, and IgA anti-food antibodies are
found in the parotid saliva of patients with coeliac disease and
Crohn's disease. In five patients with active Crohn's disease,
IgA anti-gliadin antibody levels fell during a period of
treatment with an elemental diet.
Pure parotid saliva can be readily used to measure total
immunoglobulins and isotope-specific antibodies to foods. Events
in saliva may mirror those in distal gastrointestinal secretions.
These preliminary results are encouraging and merit further
study; we are now comparing the patterns of antibodies in saliva
with those in serum and in gut irrigation fluid.
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Abstract
Cigarette smoking influences the risk of
orogastrointestinal disease in both protective
(ulcerative colitis), and inductive (squamous
tumours of the head, neck and oesophagus)
roles. In order to study the effects of smoking
on mucosal immunity, salivary immuno¬
globulins were measured in pure parotid saliva
from groups of healthy non-smokers, smokers,
and exsmokers and from patients with
epithelial head and neck tumours, both un¬
treated and after radiotherapy. Of the healthy
individuals, smokers had significantly lower
salivary IgA and higher IgM concentrations
than did non-smokers. The effect on IgA was
dose related, and reversible after cessation of
smoking. Likewise, in patients with head and
neck tumours (the majority being smokers),
salivary IgA concentration was reduced and
IgM increased when compared with non¬
smoking controls. Results were similar before
and after radiotherapy. This study provides
evidence of the effects of smoking on mucosal
immunity as evaluated by parotid salivary
immunoglobulins. Further studies of the in¬
fluence of smoking on secretory immunity are
indicated.
alcohol consumption, prospective studies were
then performed in Egyptian, non-drinking,
healthy subjects and patients with head and neck
tumours.
Methods
EDINBURGH HEALTHY SUBJECTS AND
PATIENTS
Healthy smokers and non-smokers were
recruited from volunteers, and disease controls
from patients attending clinics for obesity,
bulimia, and treated hypo and hyperthyroidism.
Patients with head and neck tumours were
recruited from the Otolaryngology clinics.
Patients who had received radiotherapy had been
treated with a standard 52-5 Gy course over four
weeks in 20 treatments. The field of irradiation
did not include the parotid glands. Because of
the retrospective nature of this phase of the study
alcohol intake was not recorded, smoking history
was incomplete for the non-smokers (never
smoked or ex-smokers?) and the groups were not
























There is strong epidemiological evidence that
smoking has a role in certain inflammatory and
malignant orogastrointestinal diseases.' The
incidence of ulcerative colitis is much lower in
smokers than in non-smokers or exsmokers.2-4
On the other hand smoking is strongly associated
with epithelial tumours of the upper orogastro¬
intestinal tract.1 It is likely to be of relevance to
these disease associations that cigarette smoking
has profound effects on the immune system, and
this has recently been reviewed.5 Much work has
been conducted on systemic immune status but,
surprisingly, the influence of smoking on
mucosal immunity has been relatively neglected.
A recent report that smokers have reduced
numbers of antigen presenting cells in the cervi¬
cal epithelium6 is of interest.
As part of a programme of research on human
mucosal immunity, we developed techniques for
the measurements of salivary immunoglobulin
concentrations by ELISA. In order to investigate
a possible effect of smoking on mucosal
immunity we applied these techniques to stored
saliva which had been collected in Edinburgh for
other purposes from healthy smokers, healthy
non-smokers, and patients with epithelial head
and neck tumours. Results from these Scottish
patients and healthy subjects revealed significant
differences between the various groups. To
confirm these data and in addition to avoid the
possible confounding effects of concurrent
CAIRO VOLUNTEERS AND PATIENTS
Healthy non-smokers, smokers, and ex-smokers
were recruited from clinical, laboratory and
ancillary staff, and from people attending for the
removal of ear wax at the Ain Shames University
Hospitals, Cairo, Egypt. In addition, all patients
with epithelial head and neck tumours who were
attending the Department of Otolaryngology in
TABLE I Subject numbers in each group from both centres.
?=status unknown (retrospective data - see text),
-=not investigated.
Edinburgh Cairo
Subjects M F Total M F Total
Healthy controls
Non-smokers 31 83 114 19 11 30
Smokers 19 9 28 27 20 47
Ex-smokers
-2yr - - - 11 10 21
Ex-smokers
-5yr - - - 10 7 17
Age+sex
matched for
Tumour patients - - - 18 10 28
Tumour patients
Untreated
Current smokers 13 4 17 14 4 18
Ex-smokers p p p 7 4 11
Non-smokers ? p p 0 1 1
Unknown 5 5 10 0 0 0
Total 18 9 27 21 9 30
Irradiated
Current smokers 0 0 0 7 2 9
Ex-smokers ? ? p 14 7 21
Non-smokers ? ? p 0 0 0
Unknown 26 12 38 0 0 0
Total 26 12 38 21 9 30
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these hospitals were invited to participate. These
patients received 50-60 Gy in 25-30 treatments
over five to six weeks. The field of irradiation
included the parotid glands. Healthy subjects
and patients did not take alcohol, and non¬
smoking groups were separately age and sex
matched for healthy smokers and for the tumour
patients. Of the patients with tumours (un¬
treated and irradiated respectively), 13 and 11
had tumour in the larynx, nine and eight in the
hypopharynx, and eight and 11 in the
oropharynx.
Of the Cairo volunteers and patients there
were 47 smokers mean age 29-8 years, range 21-
37 and 30 non-smoking controls, mean age 29-2
(21-36) (age comparison, U=665-5, p=0-682).
Mean age of 30 tumour patients was 52-7 (31-
64), and of 28 controls, mean 51-6 (34—61), with
again no difference between the test groups and
their controls in terms ofage (U= 366, p=0 • 596).
The irradiated group were somewhat older than
both the control and the tumour patients, mean
age 59-0 (48-73) (U= 187-5, p=0-0004 v con¬
trols; U=250-5, p=0-0033 v tumour patients).
These patients had tumours in various sites
which did not differ between groups (x2=0-699,
2 df, p=0-71).
There were no differences in the sex distribu¬
tion between any group of Egyptian subjects,
(X2=l-82,4df,p=0-7712).
CLINICAL PROCEDURES
Full informed consent was obtained in every
case. For each subject details of age, sex, weight,
smoking history, general health and, if appro¬
priate, tumour site were recorded. Before collec¬
tion of saliva the oral cavity was examined for
evidence of local sepsis (gingivitis, pharyngitis,
tonsillitis, dental abscess: if any of these condi¬
tions were present, the person was excluded
from the study). Parotid saliva was then obtained
using a simple modification of a Carlsson-Crit-
tenden cup (J Harvey, Lochgilphead, Argyll,
Scotland). The secretion of parotid saliva was
stimulated by 5% citric acid given in four 0-5ml
aliquots: collection of saliva was bilateral and
simultaneous for two minutes (Cairo) or uni¬
lateral for five minutes (Edinburgh group).
Sample volumes were measured by graduated
pipette, and the samples stored at —70°C until
analysis. Flow rates were calculated from the
volume in millilitres divided by the collection
period in minutes, divided by the number (one
or two) of parotid ducts from which saliva was
collected.
ASSAY TECHNIQUES
Salivary concentrations of IgA, IgG, and IgM
were assayed by a double sandwich ELISA
technique. Briefly, microtitre plates M129A
(Dynatech, Billingshurst, Sussex) were coated
with one in 5000 goat antihuman IgA, IgG, and
IgM. The plates were washed five times with
0-9% salinewith 0-05% Tween 20 (Sigma, Poole,
Dorset), blocked for 20 minutes with the wash¬
ing solution with 1% adult bovine serum (Scot¬
tish antibody production unit, Carluke, Lanark¬
shire), then pure parotid saliva was applied at a
1:2 dilution for IgG and IgM and a 1:5 dilution
for IgA, 125 pi being added to each well, and left
for approximately eight hours at 20°C. After
further washing five times, alkaline phosphatase
conjugated goat antihuman IgA, IgG, and IgM
(Northeast Biomedical Laboratories, Uxbridge,
Middlesex) was added and incubated overnight
at 4°C. Again after washing five times, para-
nitrophenyl phosphate at a concentration of 1
mg/ml in 10% diethanolamine buffer was added.
As a standard control, World Health Organisa¬
tion human serum immunoglobulin (1st inter¬
national reference preparation, National Insti¬
tute for Biological Standards, Potters Bar, Herts)
was used. The plates were read at optical density
405 nm on a Dynatech Microelisa Autoreader
MR580. Total protein was measured using the
Pierce method. Electrolytes were analysed on a
standard SMAC II.
STATISTICAL ANALYSIS
The Mann-Whitney U test, Wilcoxon's paired
rank-sum test, and Spearman's rank correlation





The results are shown in Table II. Salivary IgA
concentrations were decreased in smokers, and
in patients with head and neck tumours, both
before and after irradiation. Conversely, IgM
concentrations were increased in smokers, and in
patients with head and neck tumours, with a few
extremely high values in the postirradiation
group. These results must be interpreted with
caution as the age and sex distribution was
distinctly different from the healthy controls.
Cairo
Healthy smokers had significantly lower salivary
IgA concentrations (Fig 1), and higher salivary
IgM (Fig 2), when compared with non-smokers.
There was no influence of smoking on salivary
IgG concentration, Figure 3. There was a strong
inverse correlation between salivary IgA concen¬
tration and the number of cigarettes currently
smoked daily (10-60), (Fig 4); however, no such
relationship existed for salivary IgG, or IgM
concentrations. Salivary flow rates were weakly
but significantly correlated positively with the
number of cigarettes smoked daily (r= 0-291, p=
TABLE II Salivary immunoglobulin concentrations in the
Edinburgh subjects. *= significant difference from control
values, p<0-0005 in all cases. I=insufficient saliva.
Subjects
Tumour Irradiated
Non-smokers Smokers patients patients
(n=114) in—28) II Nj (n—30)
IgA 145(92) 44(41)* 80(61)* 87 (49)*
IgM 0-26 (0-4) 1-04(0-5)* 0-077(0-2) 3-2(9-2)
lgG 3-7(9-5) 0-07 (0-1) I I















Healthy Matched healthy Tumour Tumour patients
non-smokers smokers controls for tumour patients post-radiotherapy
(n=30) (n=47) patients (n=28) (n=30) (n=30)
Figure 1: *=significant difference between appropriate control groups and smokers and patients
(U=84, p<0 00001 v healthy smokers; U=2, p<0-00001 v tumourpatients;
U=9, p<0-00001 v irradiated tumourpatients). Bars show mean (standard error).
0-044) but no relationship existed between
salivary immunoglobin concentrations and flow
rate.
Salivary IgA concentrations in exsmokers of at
least 20 cigarettes daily, who had given up
smoking two years before sampling, were higher
than in healthy current smokers, and after five
years of non-smoking IgA concentrations were
similar to those of non-smokers (Fig 5). The
effects of stopping smoking on salivary IgM
concentrations were less consistent. Values were
similar to those for non-smokers after two years'
abstinence (U=267, p=0-641, data not shown),
but at five years were significantly higher than in
non-smokers (U=91, p=0-0004).
There were identical findings when the
patients with head and neck tumours (the
majority being smokers, or very recent ex-
smokers) were compared with the non-smoking
controls (Figs 1-3). Again, salivary IgA concen¬
tration wasmarkedly decreased and IgM concen¬
tration increased, IgG being normal, when com¬
pared with values for matched non-smoking
controls. No differences were seen between the
groups of patients who were untreated, and those
who had undergone radiotherapy, Figures 1-3.
Identical results were found in both centres
with no differences in salivary protein and elec¬
trolyte concentrations between any of the groups.
Discussion
We have shown a striking and reproducible
influence of cigarette smoking on salivary
immunoglobulins. In healthy smokers, the con¬




Healthy Healthy Matched healthy Tumour Tumour patients
non-smokers smokers controls for tumour patients post-radiotherapy
(n=30) (n=47) patients (n=28) (n=30) (n=30)
Figure 2: *=significant difference between appropriate control groups and smokers and patients
(U=250, p<0-00001 v healthy smokers; U=113, p<0-00001 v tumour patients; U=ll,
p<0 00001 v irradiated tumour patients). Bars show mean (standard error).
reduced, and of IgM increased, when compared
with non-smokers. For IgA, this effect is
strongly dose dependent, and reversible; salivary
IgA concentrations were similar to those for non-
smokers in a group of healthy subjects who had
stopping smoking at least five years before.
Differences in parotid salivary immunoglobulin
concentrations between healthy non-smokers
and patients with head and neck cancer might be
attributed solely to the smoking habits of the
latter. Such a relationship is blurred by the fact
that many smokers are heavy alcohol drinkers,7
and because alcohol consumption (in the
absence of hepatic cirrhosis) increases salivary
IgA concentrations (Barton and Ferguson, un¬
published observations) and is an independant
risk factor for squamous cell cancer of the head
and neck.8We avoided this latter factor by using
non-drinkers in the second, case controlled
study in which identical results were obtained.
Nevertheless in future studies it will be necessary
to exclude other environmental factors such as
drugs, and genetic factors which influence
immunoglobulin levels.
The similarity of the findings between healthy
smokers and patients with epithelial head and
neck tumours probably reflects the fact thatmost
people who develop these neoplasms smoke.
Although many patients in the untreated tumour
group and most patients in the postradiotherapy
group had stopped smoking at the time of
sampling, most commonly at the time of
diagnosis, sufficient time may not have elapsed
to allow any possible normalisation of salivary
immunoglobulin levels.
We are aware of four previous reports of
salivary immunoglobulins in smokers,'~12 but
they relate to small numbers of selected patients,
and whole saliva was used. Even in the absence of
oral sepsis or radiation damage, mixed saliva is
contaminated with crevicular fluid, similar in its
immunoglobulin content to serum, and is there¬
fore unsuitable as material for the study of
mucosal immunity.13 This is highlighted by the
discrepant results in the literature on the
influence of smoking on immunoglobulin con¬
tent of mixed saliva. Bennett found that salivary
IgA concentration was low in eight elderly,
edentulous male smokers," in contrast with
Watanabe who reported high mixed salivary IgA
levels in a group of smokers and drinkers, and in
head and neck cancer patients.' Hersey reported
a striking decrease in salivary IgG (probably
derived from crevicular fluid or inflammatory
exudates) in a small group of healthy smokers
who stopped smoking.10 Olson found no change
in whole salivary IgA when smokers stopped
smoking and took nicotine or placebo chewing
gum.12 The safe and simple collection of pure
parotid saliva provides a clean and stable secre¬
tory fluid for assay. This is particularly impor¬
tant in patients with head and neck tumours and
after radiotherapy, when there may be immuno¬
suppression and oropharyngeal superinfection.
Studies of serum and circulating leucocytes
have been used to determine the effects of
smoking on systemic immunity. Smokers have
increased polymorphonuclear neutrophil
counts, decreased natural killer cell activity, an
increase in total T cell numbers with a decrease
Mucosal immunodeficiency in smokers, and in patients with epithelial head and neck tumours 381
50-i
t i-8-it
Healthy Healthy Matched healthy Tumour Tumour patients
non-smokers smokers controls for tumour patients post-radiotherapy
(n=30) (n=47) patients (n=28) (n=30) (n=30)
Figure 3: Bars show mean (standard error). No significant differences between groups,
(U=566, p=0-144, healthy smokers v controls).
in the T helper/suppressor cell ratio in heavy
smokers. In smokers, serum IgA, IgG, and IgM
are generally lower by 10-20% than in non-
smokers, with higher concentrations of serum
IgD and IgE in smokers.5 Smokers have a
generally decreased systemic response to
antigens encountered at the nasal and respiratory
mucosae,1415 although at the mucosal level
conflicting results have been reported for total
IgA in bronchoalveolar lavage fluid, with a
decrease16 and a three to four-fold increase17
reported; at the nasal mucosa a decrease in local
antibody levels in smokers is reported.18 In a
group of patients with head and neck tumours
high whole salivary IgA concentrations were
shown to correlate with tumour load, and
decrease towards normal after successful treat¬
ment."
The increase in IgM concentrations might be
interpreted as a compensatory rise. This concept
is a little naive; IgM has very different properties
to IgA, and its higher concentrations may reflect
immunopathology rather than simple compensa¬
tion. We have not yet addressed the mechanism
whereby cigarette smoking alters the immuno¬
globulin profile of saliva. Intuitively, we favour
the concept that smoking impairs T cell
immunoregulation of B cell differentiation and
maturation, and propose to pursue this hypo¬
thesis in the first instance. Alternatively, the
alterations may be mediated via the afferent limb
of immunity, gut antigen presenting cells as

















Figure S: IgA concentrations in ex-smokers of20 cigarettes daily, after 2 (U= 102-5,
p=0-0001), and 5 (U=214, p=0-633)years abstinence compared with controls. Current
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Figure 4: Relationship between daily cigarette consumption
and salivary IgA concentration, r=—0-68, p<0-00001.
lium.6 Both this study and our own suggest a
mechanism other than direct toxicity, as the
cervix and parotid gland are distant from the
local effects of cigarette smoke. It is probably
unnecessary to confirm the self reported
cigarette consumption; we have no reason to
suppose that any errors in reporting would vary
between light, moderate or heavy smokers, and
others have shown self reported smoking habits
to be reliable.20
Thus we have shown that smokers have a dose-
dependant and probably reversible humoral
mucosal immunodeficiency, as reflected either
directly or otherwise by salivary IgA concentra¬
tions. Studies of mucosal immunity at other
surfaces are necessary and should include inves¬
tigation of T cell factors and other regulatory
mechanisms. If changes in secretory immuno¬
globulins reflect abnormalities of other, as yet
unexplored components of mucosal immunity,
new avenues of pathogenesis of smoking related
diseases may emerge.
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REGULATION OF ANTIBODIES TO FOOD PROTEINS WITHIN THE COMMON
MUCOSAL IMMUNE SYSTEM: LACK OF CORRELATION BETWEEN ANTIBODY
TITRES IN SALIVA AND INTESTINAL FLUID
JR Barton, S O'Mahony, Anne Ferguson.
University of Edinburgh Gastrointestinal Unit and Western
General Hospital, Crewe Road, Edinburgh EH4 2XU
Previous workers have studied saliva on the assumption that
immunological changes reflect events in other gastrointesti¬
nal secretions. We tested this hypothesis by comparing total
immunoglobulin levels and specific antibody titres in saliva
and intestinal fluid obtained by gut lavage from 20 healthy
subjects. An ELISA technique was used to measure total
immunoglobulins and and specific antibody levels of the
IgA, IgG, and IgM isotypes to three common food proteins,
gliadin, ovalbumin and beta-lactoglobulin. No correlations
between saliva and lavage fluid concentrations of IgA or IgM
existed, although a positive correlation was found for IgG
which was present in trace amounts in the secretions. Anti¬
body titres in saliva and intestinal fluid did not correlate
for any isotype. However in the case of IgM, comparison of
saliva with serum, and lavage with serum showed significant
positive correlations. This study suggests that saliva does
not reflect immune events in intestinal secretions, that the
gut must be studied directly, and that regulation of IgM
antibody may not be segregated with respect to mucosal and
systemic compartments, in contrast to IgA antibodies as is
clearly demonstrated.
Introduction
Study of the gastrointestinal mucosal immune system in man
has been hindered by practical and ethical problems of
access. Investigators have tended to use in vitro studies of
isolated tissue specimens obtained from patients at endosco¬
py or operation which may not be representative. The secre¬
tory aspects of gut mucosal immunity have been relatively
neglected. The existence of a common mucosal immune system
suggests that other mucosal secretions may reflect immuno¬
globulin and specific antibody status in gut secretions. To
determine if parotid saliva is representative of gastroin¬
testinal secretions, we assayed immunoglobulins and anti¬
bodies in serum, saliva, and intestinal fluid obtained by
whole gut lavage.
Materials and methods
Twenty subjects were recruited for the study, and comprised
healthy volunteers and patients with an eventual diagnosis
of functional abdominal problems. The subjects were given
the PEG-electrolyte solution (osmolality 260 mosmol/L) and
asked to drink at a rate of 1 litre per hour, to a total of
4 litres consumed. The stools were discarded until a clear
fluid was passed. Approximately 100-200mls were then col¬
lected and immediately treated with soybean trypsin inhibi¬
tor, EDTA, phenylmethylsulphonylfluoride, sodium azide and
fetal calf serum to inactivate proteases and to prepare a
suitable fluid for analysis. This was aliquoted and stored
at -700c until assay. Assay of total IgA, IgG, and IgM, and
isotype-specific antibodies of these classes to three food
protein antigens, gliadin, ovalbumin, and beta-lactoglobulin
was carried out using an ELISA technique. The results for
antibody levels were expressed as a percentage of a high
positive control.
Results
No correlations existed for antibody titres to the food
antigens between saliva and intestinal lavage in any iso-
type. Antibody titres of the IgM isotype in saliva and
intestinal fluid were reflected by serum antibody levels
(saliva vs serum antigliadin r=0.31, p=0.011, n=20; antiova
r =0.49, p=0.001, n=18; lavage vs serum antiova r =0.6,
p=0.013, n=9). Concentrations of total IgG were weakly
correlated in saliva and intestinal fluid (r=0.452, p=0.03),
but no such relationship existed for IgA or IgM. There was
no correlation in either fluid between total immunoglobulin
levels and specific antibody titres.
Discussion
Despite the existence of a common mucosal immune system,
this study failed to find any correlation in healthy sub¬
jects between two mucosal secretions for either specific
antibody titres, or total immunoglobulin concentrations with
the exception of IgG. We feel that although antigen- specif¬
ic effector and memory cells can be found throughout the
mucosal immune system after antigen challenge, that final
antibody levels may be largely determined by local antigen
concentrations. This study suggests that saliva does not
reflect immune events in intestinal secretions, that the gut
must be studied directly, and that regulation of IgM anti¬
body may not be segregated with respect to mucosal and
systemic compartments, in contrast to IgA antibodies as is
clearly demonstrated.
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Direct investigation of intestinal humoral
immunity requires collection of intestinal
secretions or mucosal biopsy specimens, or
both. A non-invasive technique of gut lavage,
with a polyethyleneglycol electrolyte lavage
solution as a means of collecting intestinal
secretions for immunoglobulin and antibody
studies, was evaluated. Fifty patients were
studied - 25 immunologically normal patients
or volunteers, 15 patients with untreated
coeliac disease, and 10 patients with active
Crohn's disease. Protease inhibitors were
added promptly to samples to prevent pro¬
teolysis of immunoglobulin content. Treated
lavage samples were assayed by enzyme linked
immunosorbent assay for immunoglobulin and
antibody content. Studies of serial lavage
specimens showed that early, faecally con¬
taminated specimens contained negligible
quantities of immunoglobulin, but once the
specimens became clear a steady state was
reached, with little variation in immuno¬
globulin content between serial specimens and
with a uniform dilution (around 20%) of the
ingested polyethyleneglycol. Gut lavage fluid
IgA was predominantly secretory, comprising
92%, 81-6%, and 76-7% respectively of the total
IgA gut lavage fluid content in the control,
coeliac, and Crohn's groups. High values of
total IgM and IgA and IgM antigliadin anti¬
bodies were detected in the coeliac group, and
high values of IgG in the Crohn's disease
group. This method ofgut lavage is not only an
effective bowel cleanser, but also a non¬
invasive means of obtaining intestinal secre¬
tions for the study of humoral immunity in
gastrointestinal disease.
The mucosal immune system is largely indepen¬
dent of the systemic immune system. Therefore,
for investigation of local immunity in gastro¬
intestinal disease, the gut must be studied
directly. Human research in this area has been
hampered by difficulty of access to intestinal
secretions. Gaspari and colleagues recently des¬
cribed a non-invasive gut lavage and sample
processing technique that they performed in 12
healthy volunteers.1 Human intestinal secretions
contain large amounts of proteases,23 and they
found that loss of immunoglobulin content due
to proteolysis could be prevented by treating
specimens with protease inhibitors. We have
further evaluated this technique, studying
immunoglobulin content and specific antibody
(antigliadin) activity in both healthy subjects
and patients with gastrointestinal conditions
(coeliac disease and Crohn's disease) where




Gut lavage was performed in 50 subjects.
Twenty five were immunologically normal
patients (16 women, nine men, median age 52,
range 21-92 years) who underwent lavage as a
bowel preparation for barium enema or colono¬
scopy, or who volunteered when invited. (No
organic pathology was found in these patients,
and final diagnosis in most was functional bowel
disorder.) Fifteen subjects were patients with
untreated coeliac disease (nine women, six men,
median age 43, range 28-62 years), all of whom
had had a recent jejunal biopsy specimen show¬
ing subtotal or severe partial villous atrophy.
Ten patients with active Crohn's disease were
also studied (four women, six men, median age
27, range 18-92 years).
LAVAGE SOLUTION
The lavage solution is a polyethyleneglycol
electrolyte lavage solution. This is available
commercially in the USA (Golytely) and is
widely used as a method of cleansing the colon
for barium enema and colonoscopy.4 The lavage
solutionwas formulated by the hospital pharmacy
and contained 59-1 g polyethyleneglycol 3350 (a
mixture of different sized molecules with a mean
molecular weight between 3200 and 3700),5
potassium chloride BP 0-75 g, sodium chloride
BP 1-45 g, sodium bicarbonate BP T63 g, and
sodium bisulphate BP 5-68 g, made up to 1 litre
with a resultant osmolality of 260 mOsm/1.
LAVAGE PROTOCOL
After an overnight fast, lavage was begun at 8 30
am. Patients were asked to drink the lavage
solution at a rate of 250 ml every 15 minutes for a
period of four hours, making the total volume
consumed 4 litres. The solution was found to be
more palatable ifconsumed chilled and flavoured
with a little lemon juice. In patients in whom
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lavage was used as a bowel preparation, one
sachet of sodium picosulphate (Picolax) was
given later in the afternoon of the same day.
SPECIMEN PROCESSING
Stool collection was begun once the material
passed per rectum became liquid, clear, and free
of faecal material. Approximately 200 ml were
collected and filtered into 50 ml polypropylene
tubes. Specimens were centrifuged twice and
treated with protease inhibitors as described by
Gaspari et aid Treated samples were aliquoted
and stored at —70°C. In four subjects, early
faecal specimens were collected and processed
along with later clear specimens. In 10 subjects,
the first clear specimen was divided into three
aliquots - one was treated immediately, but
treatment was delayed for one and two hours
each in the other two to determine the time
course of sample deterioration due to proteoly¬
sis. In 14 subjects, two serial clear specimens
were collected to determine whether immuno¬
globulin content varied between specimens.
ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA)
Total IgA, IgM, and IgG; secretory IgA. Assays
were performed in 96 well microtitre ELISA
plates (Dynatech). All reactants were added in
volumes of 0-125 ml per well and all washes were
done three times using saline with 0-05% Tween
80 added. For the assay of total IgA, wells were
coated with 100 ng/ml affinity purified goat
antihuman IgA (Northeast Labs) in 0T M
carbonate buffer, pH 9-6, and were incubated
overnight at 4°C and washed. After washing,
serial twofold dilutions ranging from 1250-19-35
ng/ml of a human colostral IgA standard (Sigma)
and serial dilutions of treated lavage samples
(initial dilution 1/100) were added to the coated
wells. Plates were incubated overnight at 4°C and
washed. Goat antihuman IgA conjugated with
alkaline phosphatase (Northeast Labs) diluted
(in saline with 1% fetal calf serum and 0-05%
Tween 80) to a predetermined optimal level was
added and plates were incubated for three hours
at 20°C. After washing, paranitrophenyl-









Figure 1: Polyethyleneglycol (PEG) concentrations (g/l) in
treated lavage samples (n=25).
diethanolamine (DEA) buffer, pH 9-8, was
added. Plates were read at an optical density
of 405 in an MR580 microELISA reader
(Dynatech). A standard curve was constructed;
the IgA content of any given sample was deter¬
mined by taking the mean IgA content of those
two sample dilutions whose optical density fell
within the range of the standard curve. The
method used to determine total IgM and IgG was
similar; human reference serum (Protein
Reference Unit, Sheffield) was used as a
standard, and the initial sample dilution was
1/25.
The assay for secretory IgA" was similar to that
for total IgA; wells were coated with a goat
antihuman secretory piece (Atlantic Anti¬
bodies), the same human colostral IgA was used
as a standard.
Antigliadin antibodies. The assay was similar to
that described above. Wells were coated with
crude gliadin at a concentration of 5 ug/ml.
Serum from a patient with untreated coeliac
disease was used as a positive standard, and
lavage samples were added in duplicate dilutions
of 1/2 (this dilution gave optimal optical density
readings). Plates were read when the standard
reached an arbitrary optical density of 1-0;
antibody levels are given in the form of optical
density readings expressed as percentages of the
optical density of the standard.
MEASUREMENT OF POLYETHYLENEGLYCOL
VALUES IN LAVAGE SAMPLES
Polyethyleneglycol was quantified by the
method of Malawer and Powell,7 a modification
of the turbidimetric analysis ofHyden.8
STATISTICAL ANALYSIS
Differences in IgA content of serial lavage speci¬
mens were analysed with the paired t test.
Differences in immunoglobulin and antibody
values between patient groups were analysed




Mean (SD) polyethyleneglycol concentration in
the processed samples of 25 subjects was 37-3
(3-4) g/l. The initial concentration of 59-1 g/l in
the ingested lavage fluid would be reduced to
47-5 g/l by the addition of protease inhibitors,
etc; thus, the liquid stools were comprised on
average of 78-5% polyethyleneglycol lavage
solution and 21-5% gastrointestinal secretions.
There was little variation about the mean (Fig 1).
IMMUNOGLOBULIN CONTENT IN SERIAL
SPECIMENS
Early faecally contaminated specimens con¬
tained low concentrations of IgA compared with
later clear specimens (Table I). Once the speci¬
mens became clear, there was no significant
difference in IgA content between serial speci¬
mens (Fig 2).






Figure 2: IgA concentrations (\xg/ml) in serial lavage
specimens (n= 14).
Time (h)
Figure 3: Effect ofdelay in addition ofprotease inhibitors on
lavage fluid IgA content.
(p<0-0002 v control subjects, p<0-02 v Crohn's
patients), with similar values in control subjects
and Crohn's patients.
PROTEASE INHIBITION
Delays of one and two hours in the addition of
protease inhibitors resulted in loss of IgA content
varying from 0 to 92% (Fig 3).
IMMUNOGLOBULIN AND ANTIBODY VALUES IN THE
PATIENT GROUPS
Mean immunoglobulin values are shown in
Table II. No significant difference in IgA values
was found between the three groups. High IgM
values were found in the coeliac group (p<0-02 v
control subjects) and in the Crohn's patients
(p<0-05 v control subjects), with no significant
difference between the coeliac and Crohn's
groups. High IgG values were found in the
Crohn's patients (p<0-00001 v control subjects;
p<0-0005 v coeliac group).
Antigliadin antibody values are shown in
Figure 4. High IgA antigliadin antibody values
were found in the coeliac patients (p<0-002 v
control subjects, p<0-01 v Crohn's patients),
with similar values in control subjects and
Crohn's patients. High IgM antigliadin antibody
values were also found in the coeliac patients
table i IgA concentration (|iglml) in early faecal specimens
compared with clear lavage specimens





table ii Lavage fluid immunoglobulin concentrations
(mean (SE)) in fig/ml
Group IgA IgM IgG
Control (n—25) 136-9(20-6) 9-26(2-02) 2-38(0-72)
Coeliac (n= 15) 173-6(33-8) 23-66(6-69)* 5-57(2-42)
Crohn's (n= 10) 176-1(58-0) 17-82(4-5)* 28-93(6-75)*
*Values significantly higher (p<0-05) compared with controls.
SECRETORY IgA CONTENT
The mean (range) percentage of lavage fluid total
IgA expressing secretory component was as
follows: control subjects: 92-0% (82-3-100-0);
coeliac patients: 8T6% (57-8-98-7); and Crohn's
patients: 76-7% (64-0-91-3).
Discussion
Investigation of intestinal humoral immunity
presents major logistic problems. Some investi¬
gators have extrapolated information from
studies of peripheral blood and saliva as repre¬
sentative of immune events in the gut. Although
this approach may be valid in certain instances -
for example, in the study of IgA secreting B cells
after enteral infection or immunisation9 - for
definitive studies of intestinal immunity, the gut
must be studied directly. For example, we have
found no correlation between systemic and
mucosal (salivary and jejunal aspirate) antibodies
in coeliac disease (unpublished observations).
The gut lavage method described is safe, non¬
invasive, and useful for bowel cleansing and
treatment of constipation.10 The technique is
well tolerated by most patients. We have now
carried out gut lavage in over 100 subjects, and
the procedure was abandoned in only two
patients, who were unable to consume the
volume of liquid required. Polyethyleneglycol
electrolyte lavage solutions are not absorbed and
have minimal effects on fluid and electrolyte
balance.1112 Other investigators have used saline
lavage for collection of intestinal secretions,13 but
this is contraindicated in patients with cardiac,
renal, and hepatic disease.
Processing of specimens is crucial to success in
subsequent laboratory assays. Several studies
have shown that human intestinal secretions
contain large amounts of protease,14 and that the
addition of protease inhibitors prevents appreci¬
able immunoglobulin loss1 and improves antigen
stability for ELISA.3 We and others' have shown











Coeliac Crohn's Controls Coeliac Crohn's Controls
Figure 4: Lavagefluid IgA and IgM antigliadin antibody values.
that delay in addition of protease inhibitors to
secretions obtained by this method may result in
significant loss of immunoglobulin content.
Results of total IgA content of serial specimens
indicates that once the patient passes clear fluid
per rectum, a steady state is reached, with no
difference in immunoglobulin content between
subsequent specimens. Analysis of semiliquid
early faecal specimens, however, showed neglig¬
ible quantities of IgA compared with that found
in clear specimens. This must cast doubt on
attempts to assess mucosal immunity by studies
on faeces.
These preliminary studies on patients with
coeliac disease and Crohn's disease have shown
substantial qualitative differences between
patient groups in patterns of isotype specific
immunoglobulins, and these findings are being
confirmed in continuing definitive investiga¬
tions. Specific antibodies can also be readily
measured, as we have shown with gliadin and
others have shown with cholera toxin B subunit.1
It could be argued that increased intestinal
permeability in patients with coeliac disease and
Crohn's disease may allow serum leakage of
immunoglobulin and antibody into the gut
lumen. It is quite possible that at least some
lavage fluid immunoglobulin is serum derived,
but we have shown that lavage fluid IgA is
predominantly secretory in the three patient
groups.
The finding of high values of lavage fluid IgG
in the Crohn's group could reflect altered intesti¬
nal immunoglobulin production in this condi¬
tion;15 however, as there is no specific mucosal
transport system for IgG, it is more likely that
the IgG is serum derived, leaking across the
inflamed mucosa.
This technique has great potential for in vivo
determination of immunoglobulins and antibody
in the gut, and can be applied to a wide range of
studies of secretory immunity in health and
disease.
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We examined humoral immunity in coeliac
disease as expressed in serum (systemic
immunity), and in saliva, jejunal aspirate, and
whole gut lavage fluid (mucosal immunity).
The aims were to define features of the secre¬
tory immune response (IgA and IgM con¬
centrations and antibody values to gliadin and
other food proteins measured by enzyme
linked immunosorbent assay (ELISA)) in
active disease and remission, and to establish
whether secretions obtained by relatively non¬
invasive techniques (saliva and gut lavage
fluid) can be used for indirect measurements of
events in the jejunum. Serum, saliva, and
jejunal aspirate from 26 adults with untreated
coeliac disease, 22 treated patients, and 28
immunologically normal control subjects were
studied, together with intestinal secretions
obtained by gut lavage from 15 untreated and
19 treated patients with coeliac disease and 25
control subjects. Jejunal aspirate IgA and IgM
and gut lavage fluid IgM concentrations were
significantly raised in patients with untreated
coeliac disease; the lavage fluid IgM concen¬
tration remained higher in patients with treated
coeliac disease than in controls. Serum and
salivary immunoglobulin concentrations were
similar in the three groups. Patients with
untreated coeliac disease had higher values of
antibodies to gliadin compared with treated
patients and control subjects in all body fluids
tested; these were predominantly of IgA and
IgG classes in serum, and of IgA and IgM
classes in jejunal aspirate and gut lavage fluid.
Values of salivary IgA antibodies to gliadin
were significantly higher in untreated coeliacs,
though antibody values were generally low,
with a large overlap between coeliac disease
patients and control subjects. In treated
patients, with proved histological recovery on
gluten free diet, serum IgA antigliadin anti¬
body values fell to control values, though
serum IgG antigliadin antibody values
remained moderately raised. In contrast, there
was persistence of secretory antigliadin anti¬
bodies in treated patients (particularly IgM
antibody) in both jejunal aspirate and gut
lavage fluid. Antibody responses to betalacto-
globulin and ovalbumin were similar to those
for gliadin, including persistence of high intes¬
tinal antibody values in patients with treated
coeliac disease. There was a positive correla¬
tion between antibody values in jejunal
aspirate and gut lavage fluid, but not between
saliva and jejunal aspirate; thus salivary anti¬
bodies do not reflect intestinal humoral
immunity.
Systemic humoral immunity in coeliac disease
has been the subject of intensive investigation.
Numerous studies have established that patients
with untreated coeliac disease have high values of
circulating antibodies to wheat derived proteins
such as gliadin, and that antibody values fall after
a period of treatment with a gluten free diet.1"4
Estimation of serum IgA antigliadin antibody is
now routinely used both as a screening test for
coeliac disease and as a means of assessing dietary
compliance.
In contrast, information on mucosal immunity
in coeliac disease is patchy. There have been
many studies of mucosal lymphoid cells56 and
there is circumstantial evidence of a local cell
mediated immune response to gluten.78 Several
studies have carefully mapped the numbers of Ig
producing plasma cells in the jejunal mucosa of
patients with untreated and treated coeliac
disease,910 showing that untreated patients have
increased numbers of IgA and IgM (and to a
lesser extent, IgG) jejunal plasma cells. In the
1970s, the presence of intestinal antibodies to
food antigens was recognised by a relatively
insensitive precipitin technique," but there are
only two studies published,1213 both in children,
on the isotype of antibodies to dietary antigens in
intestinal secretions, and these give conflicting
results.
The general objectives of this study were
twofold. In relation to coeliac disease, our aim
was to characterise, in vivo, intestinal humoral
immunity. Total immunoglobulins and specific
antibodies to gliadin and to two antigens which
are not toxic in coeliacs were measured in three
different mucosal secretions. Untreated and
treated patients with coeliac disease were studied
to determine whether abnormalities of secretory
immunity are permanent and intrinsic to the
coeliac diathesis or are only present in active
disease. Separately, and of relevance to the
clinical investigation of mucosal immunity, we
studied the relations between systemic and intes¬
tinal antibodies, and we examined our data to
establish whether patterns of immunoglobulins
and antibodies in jejunal fluid are mirrored in
other secretions which can be obtained without
intubation. The salivary glands are considered
part of the common mucosal immune system,14
and we therefore studied pure parotid saliva. We
also used a whole gut lavage technique for the
non-invasive collection of intestinal secretions.15
Methods
PATIENTS STUDIED AT THE TIME OF JEJUNAL
BIOPSY
Specimens of saliva, jejunal aspirate, and serum
were collected at the same time as jejunal biopsy
on 76 occasions in 69 patients. There were 41
patients with coeliac disease (seven studied
twice), (23 women and 18 men; median age 42
years, range 15-78) and 28 control patients (14
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women, 14 men, median age 35 years, range
14-75). Control subjects had jejunal biopsy to
exclude coeliac disease - jejunal histology in
these patients was normal, no other significant
pathology was found, and a final diagnosis of
functional bowel disease was made. Twenty six
of the patients with coeliac disease were un¬
treated and histological examination of the
jejunal biopsy specimens showed subtotal or
severe partial villous atrophy. Seven of these and
a further 15 patients with treated coeliac disease
(all with previous diagnostic biopsy specimens)
underwent biopsy again while on a gluten free
diet. The median period on gluten free diet was
three years (range 3 months - 17 years). Eleven
had entirely normal jejunal histology (all of these
had been taking a gluten free diet for at least two
years), and 11 had minor histological changes -
for example increased intraepithelial lympho¬
cytes (most patients in this group had been
taking a gluten free diet for less than one year).
PATIENTS STUDIED BY WHOLE GUT LAVAGE
Gut lavage was carried out in 15 untreated coeliac
disease patients, 19 with treated disease, and 25
control patients. These included 10, eight, and
two patients respectively from each group who
had also had collection of jejunal aspirate. The
median period on a gluten free diet in patients
with treated coeliac disease undergoing gut
lavage was eight years (range 3 months - 19
years). Eleven of the patients on a gluten free diet
had in the past shown a clinical and histological
response to the diet, but did not undergo biopsy
again at the time of this study. Gut lavage was
carried out in 25 control patients (16 women and
nine men, median age 52, range 21-92 years).
These subjects were either healthy volunteers or
patients with functional bowel disorder.
SPECIMEN COLLECTION AND PROCESSING
Saliva: parotid salivary flow was stimulated with
5% citric acid sublingually in four 0-5 ml aliquots
over five minutes, and collected via a Carlsson-
Crittenden cup placed over the parotid duct,
with gentle aspiration to maintain position and
suction. We collected stimulated saliva only.
Jejunal aspirate: samples were collected from a
point just distal to the duodenal-jejunal junction,
through the tubing of the Crosby capsule, before
taking the biopsy specimen. The protease
inhibitor phenylmethyl sulphonylfluoride
(PMSF, Sigma) 100 mM in 95% alcohol (20 pi
perml of aspirate) was added before aliquoting.16
Serum was obtained from all patients.
Gut lavage: the lavage fluid used was a poly¬
ethylene glycol (PEG) based electrolyte lavage
solution (Golytely). After an overnight fast,
patients drank this solution at a rate of 250 ml
every 15 minutes for a period of four hours,
making the total volume consumed four litres.
Specimen collection began once the material
passed per rectum became liquid, clear, and free
of faecal material. Approximately 200 ml was
collected and filtered into 50 ml polypropylene
tubes; specimens were centrifuged and treated
with protease inhibitors as described by Gaspari
et al.'5
All the above specimens were aliquoted and
stored at —70°C.
ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA)
Reference materials and reporting of results
For assays of immunoglobulins in the various
secretions, serial twofold dilutions of a standard
preparation were used to produce a standard
curve. For example, for IgA assays dilutions
ranging from 1250—19-35 ng/ml of a human
colostral IgA standard (Sigma) were used in each
test run. Serial dilutions of test samples (varying
in initial dilution depending on the type of
specimen) were also assayed. Only when the
optical density results of at least two of these
sample dilutions fell within the range of the
standard curve was the assay considered techni¬
cally satisfactory. The IgA content of the sample
was then determined by taking the mean IgA
content of these two sample dilutions. For total
IgM and IgG in secretions human reference
serum (Protein Reference Unit, Sheffield) was
used as a standard.
In the assays of specific antibodies, experi¬
ments were carried out to define optimal test
conditions for each antigen, isotype, and secre¬
tion. Serum from a patientwith untreated coeliac
disease, previously recognised as having high
titres of antibodies of all isotypes to a wide
variety of dietary antigens, was used as a
reference standard. The reference specimen and
test specimens were studied at suitable dilutions,
varying for the different assays, and the plates
were read when the optical density for the
standard reached 10. Results for test specimens
are expressed as optical density readings, % of
this standard. Results are thus expressed as non-
parametric data; antibody values are not directly
proportional to the antigen binding capacity of
the sample. This is a feature of all such assays.
Immunoglobulins (jejunal aspirate, gut lavage fluid,
and saliva)
Assays were performed in 96 well microtitre
ELISA plates (Dynatech). All reactants were
added in volumes of 0-125 ml per well and all
washes were done three times using saline with
0-05% Tween-80 added. For the assay of total
IgA, wells were coated with 100 ng/ml affinity
purified goat antihuman IgA (Northeast Labs) in
0-1 M carbonate buffer, pH 9-6, and incubated
overnight at 4°C and washed. After washing,
serial twofold dilutions of standard and samples
(initial sample dilution 1/100) were added to the
coated wells. Plates were incubated overnight at
4°C and washed. Goat antihuman IgA con¬
jugated with alkaline phosphatase (Northeast
Labs) diluted (in saline with 1% fetal calf serum
and 0-05% Tween-80) to a predetermined
optimal value was added and plates were in¬
cubated for three hours at 20°C. After washing,
paranitrophenylphosphate (PNPP, Sigma)
1 mg/ml in 10% diethanolamine (DEA) buffer,
pH 9-8, was added. Plates were read at optical
density 405 in an MR580 microELISA reader
(Dynatech). The IgA content of any given
sample was determined as described above.
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The method used to determine total IgM and
IgG in secretions was similar; initial sample
dilution was 1/25.
Serum immunoglobulins were measured by
autoanalyser using an immunoturbidimetric
method.
Food antibodies
The assay was similar to that described above.
Immulon 2 (129B) ELISA plates (Dynatech)
were used. Wells were coated with antigen
(gliadin, betalactoglobulin and ovalbumin) at a
concentration of 5 jig/ml. Betalactoglobulin and
ovalbumin were supplied by Sigma; gliadin was
supplied by Dr Stefan Strobel. Reference stan¬
dard and samples were added in duplicate dilu¬
tions to the coated wells. The following sample
dilutions were used: serum: 1/100 (IgA and IgM)
and 1/200 (IgG); jejunal aspirate: 1/10; gut lavage
fluid: 1/2; saliva: 1/2. An appropriate dilution of
standard was included in each assay; these
dilutions gave optimal optical density readings.
We established that these antibodies were
specific by incubating samples with the relevant
table i Immunoglobulin concentrations (median (range)) in serum (mg/ml), jejunal aspirate,
gut lavage fluid, and saliva (uglml)
Ig Untreated Treated Control
class coeliacpatients coeliac patients subjects
Serum IgA 2-4 (1-3-3-8) 2-0(0-7-3-3) 1-8(0-9-4-1)
IgM 11 (0-3-3-4) 0-9(0-3-3-1) 1-3(0-3^4-5)
IgG 10-5(5-6-15-7) 10-7(5-4-20-1) 9-5(7-3-15-9)
Jejunal aspirate IgA 290*(25-2282) 140-7(20-1558) 102-5(22-9-540-6)
IgM 29-8*+ (1-9-357-9) 9-6(0-174-4) 4-5(0-39-5)
IgG 23-9* (3-261-8) 11-8(0-3-271-4) 7-3(1-2-29-3)
Gut lavage fluid IgA 146-2 (10-7—487-5) 90-8(8-8-621-8) 139-7(7-9-403)
IgM 17-5* (2-1-100-1) 25-7* (0-192-2) 5-3(0-37)
IgG 2-7(0-1-34-9) 0-9(0-1-11-4) 1-0(0-12-2)
Saliva IgA 123-8(48-6-454) 118-1 (32-2-838-2) 165-8 (66-5-606-9)
IgM 1-2(0-1-138-9) 1-4(0-1-12-4) 1-1(0-1-3-6)
IgG 1-3(0-25-1) 0-9(0-1-10-6) 0-5(0-34-3)
immunoglobulin concentration significantly higher (p<0-05) than in control subjects.
-{-Immunoglobulin concentration significantly higher (p<0-05) than in treated coeliac disease patients.
table ii Serum food antibody values (median (range))
Untreated Treated Control
Ig coeliac patients coeliac patients subjects
Antigen class (n=26) (n=22) (n=28)
Gliadin IgA 43-7*t (4-6-150) 5-8(0-3-41-9) 5-3(0-44-5)
IgM 43-0(19-3-95-4) 38-6(10-5-87-6) 47-9(16-1-108-8)
IgG 82-4*1(9-8-137-4) 41-6* (6-8-107-4) 21(0-105-2)
BLG IgA 14-7*f (1-4-150) 6-6* (2-1-87-5) 3-3 (0-2-36-4)
IgM 33-6(9-125-5) 38-7(11-3-94-6) 27-4(3-5-82-2)
IgG 94-7* (5-150) 70-2(8-6-150) 30-9(0-131-8)
OVA IgA 18-8* (2-6-150) 14-8(4-8-60-6) 11-4(0-9-35-9)
IgM 31-1 (4-87) 37-8(9-5-123-4) 30-0(5-7-102-6)
IgG 64-4(2-6-150) 63-4* (8-4-150) 27-6(3-6-150)
*Antibody values significantly higher (p<0-05) than in control subjects.
-{-Antibody values significantly higher (p<0-05) than in treated coeliac disease patients.
BLG=betalactoglobulin; OVA=ovalbumin.
TABLE in Jejunal aspirate antibody
Untreated Treated Control
Antigen
Ig coeliac patients coeliac patients subjects
class (n=26) (n= 22) (n=28)
Gliadin IgA 26-5*f (0-7-134-5) 4-0* (0-3-34-2) 1-1 (0-13-3)
IgM 80-5*+ (0-1-150) 19-6* (2-1-114-4) 1-9(0-11-7)
BLG
IgG 1 -8*f (0-23-4) 1-0* (0-4-8) 0-2(0-2-2)
IgA 25-3* (0-6-150) 9-2 (1-1110-9) 5-0(0-1-60-8)
IgM 16-4* (0-150) 9-2* (1-1-78-3) 1-6(0-11-7)
OVA
IgG 4-5* (0-104) 1-6(0-35-1) 1-0(0-7-7)
IgA 15-8* (4-150) 19-6*(1-5-66-5) 4-2(0-100-5)
IgM 18-7* (0-97) 8-4* (0-1-52.5) 1-1 (0-17-7)
IgG 1-3* (0-26-2) 1-1 (0-11-7) 0-5 (0-26-5)
*Antibody values significantly higher (p<0-05) than in control subjects.
"{"Antibody values significantly higher (p<0-05) than in treated coeliac disease patients.
BLG=betalactoglobulin; OVA = ovalbumin.
antigen and showing that the antibody was
specifically absorbed out. In a study of 20
samples, the within plate optical density coeffi¬
cient of variation was 7-3%, and the between
plate optical density variation was 111%. If the
optical densities of the duplicate sample dilu¬
tions varied by >15%, the assay was repeated.
STATISTICAL METHODS
Differences in antibody values and immuno¬
globulin content were analysed using the Mann-
Whitney U test. For correlations, Spearman's
test was used.
Results
IMMUNOGLOBULIN CONCENTRATIONS (TABLE i)
Serum
No significant differences were observed.
Jejunal aspirate
Untreated coeliac disease patients had signifi¬
cantly higher jejunal aspirate concentrations of
IgA, IgM, and IgG compared with controls, and
higher IgM compared with patients with treated
coeliac disease. Values for treated coeliac disease
patients were not significantly different from
those of control subjects.
Gut lavage fluid
IgM content was significantly higher in both
untreated and treated coeliac disease patients
than in control subjects .
Saliva
No significant differences were observed.
ANTIBODIES TO FOOD PROTEINS
Serum (Table II)
Untreated coeliac disease patients had high
values of serum IgA antigliadin antibody, with
values for treated coeliac disease patients similar
to control values. High values of serum IgG
antigliadin antibody were found in both un¬
treated and treated coeliac disease patients, with
significantly higher values in the untreated
patients. There were no significant differences
between patient groups in values of serum IgM
antibodies. Patterns of serum antibodies to OVA
and betalactoglobulin were generally similar to
those for antigliadin antibody, as detailed, with
statistical information in Table II. Untreated
patients had high values for IgA and IgG anti-
betalactoglobulin antibody and IgA anti-
ovalbumin antibody. Serum IgA anti-betalacto-
globulin and IgG antiovalbumin antibody values
were higher in treated patients than in control
subjects.
Jejunal aspirate (Table III)
There was very little antibody detected in jejunal
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Figure I: Jejunal aspirate
IgA and IgM antigliadin
antibody values. (Median









A Treated coeliac patients with minor jejunal histological changes









Figure 2: Gut lavage fluid IgA and IgM antigliadin antibody
values. (Median antibody levels shown as horizontal bars.)
aspirates from control subjects, but as detailed in
Table III, for all three isotypes and all three
antigens studied, antibody values were signifi¬
cantly higher in jejunal aspirates from untreated
patients than from control subjects (p values all
<0-02). For antigliadin antibodies, values in
treated coeliac patients were intermediate
between untreated coeliac disease patients and
control subjects and significantly different from
both. When antibody values in the 11 treated
patients with entirely normal jejunal histology
were compared with those in control subjects,
IgA antigliadin antibody values were not signifi¬
cantly higher. Conversely, IgM antigliadin anti¬
body values remained significantly raised
(p<0-005) in this group. Antibodies to betalacto-
globulin and ovalbumin showed a greater over-
table iv Gut lavage fluid antibody values
Untreated Treated Control
Ig coeliac patients coeliac patients subjects
Antigen class (n—15) (n=19) (n=25)
Gliadin IgA 53-6*+ (2-2—137-8) 9-2* (0-4-72-9) 2-2 (0-57-9)
IgM S6-9*f (8-150) 17-9* (0-2-150) 3-1(0-88-7)
IgG 0-4* (0-2-19) 0-6(0-3) 0-2(0-6-5)
BLG IgA 7-9* (1-8-85-5) 8-4(0-6-76-5) 3-5(0-1-71-2)
IgM 5-6* (0-14-5) 5-3* (0-53) 0-1 (0-22-6)
IgG 0-7(0-21) 0-4(0-8-1) 0-4(0-4-4)
OVA IgA 15-0* (3-7-39-3) 14-7* (0-5-46-8) 4-8(0-76)
IgM 6-6* (0-8-33-3) 3-6* (0-46-3) 0-9(0-20-6)
IgG 0-3* (0-1-3) 0-0(0-61-2) 0-0(0-3-6)
*Antibody values significantly higher (p<0-05) than in control subjects.
fAntibody values significantly higher (p<0-05) than in treated coeliac disease patients.
table v Salivary antibody values
Untreated Treated Control
Ig coeliac patients coeliac patients subjects
Antigen class (n=26) (n=22) (n—28)
Gliadin IgA 5" 1 *t (0-1—29-6) 4-2(0-12-5) 3-0(0-11-7)
IgM 5-1(0-150) 5-4 (0-35-9) 2-4(0-15-5)
IgG 0-3* (0-17-9) 0-0(0-4-6) 0-0(0-7-6)
BLG IgA 8-3* (1-9-53-7) 8-3* (0-46-5) 5-3(0-29-8)
IgM 1-0(0-28-3) 1-2(0-14-4) 0-8(0-11-9)
IgG 0-4(0-5-8) 0-0(0-18-8) 0-0(0-2-9)
OVA IgA 15-8(1-9-92-9) 13-2(0-6-34) 14-3(3-4-30-2)
IgM 1-2(0-34-1) 1-4(0-16-7) 1-3(0-13-3)
IgG 0-0(0-13) 0-0 (0-3-1) 0-0(0-1-7)
*Antibody values significantly higher (p<0-05) than in control subjects,
fAntibody values significantly higher (p<0-05) than in treated coeliac disease patients.
BLG= betalactoglobulin; OVA=ovalbumin.
lap between values in coeliac disease patients and
control subjects, but again high IgM antibody
values persisted in the treated patients.
Jejunal aspirate IgA and IgM antigliadin
antibody values are shown in Figure 1.
Gut lavage fluid (Table IV)
As in jejunal aspirate, high values of IgA and
IgM antibodies to gliadin were found in both
untreated and treated coeliac disease patients
compared with control subjects, with signifi¬
cantly higher antibody values in the untreated
compared with the treated patients. High values
of IgA and IgM antibodies to betalactoglobulin
and ovalbumin were found in untreated patients;
high values of IgA and IgM anti-ovalbumin and
IgM anti-betalactoglobulin antibodies persisted
in the treated coeliac disease patients.
Gut lavage fluid IgA and IgM antigliadin
antibody values are shown in Figure 2.
Saliva (Table V)
Salivary antibody values were generally low,
with large overlaps beween patient groups. Un¬
treated coeliac disease patients had higher values
of IgA and IgG antigliadin antibodies compared
with control subjects; only IgA antigliadin anti¬
body values were higher than in the treated
patients. Higher values of IgA anti-betalacto-
globin antibody were found in both untreated
and treated coeliac disease patients compared
with control subjects.
SERIAL STUDIES IN COELIAC DISEASE PATIENTS
Seven coeliac disease patients who had a clinical
and histological response to a gluten free diet
were studied before and after treatment. Serial
changes in serum IgA antigliadin antibody and
jejunal aspirate IgA and IgM antigliadin anti¬
bodies are shown in Figure 3. Whereas serum
antibody values fell significantly (p«F05) with
treatment, there was no significant change in the
values of intestinal antibody despite histological
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Figure 3: Serial changes in
values of serum antigliadin 1 • 5 -,
antibody and jejunal
aspirate IgA and IgM
antigliadin antibodies in 7
coeliac disease patients
before and after treatment
with gluten free diet. ^
ND=normal diet; ra





recovery on a gluten free diet. There was, in fact,
a trend towards higher values of IgM antibody
after treatment. It should be noted that these
seven patients had been taking a gluten free diet
for six months or less, which may account for the
fact that they behaved differently from the
treated coeliac disease patients as a whole, who
had significantly lower jejunal aspirate antibody
values compared with untreated coeliac disease
patients.
CORRELATIONS BETWEEN ANTIBODY VALUES IN
JEJUNAL ASPIRATE, GUT LAVAGE FLUID, SERUM,
AND SALIVA (TABLE Vl)
IgA antigliadin antibody values were compared
in the various body fluids tested. In the untreated
coeliac disease patients, we found a positive
correlation between antibody values in serum
and jejunal aspirate (r=0-68, p<0-0001) but in
the treated coeliac disease patients this correla¬
tion was not maintained as they had high values
of jejunal aspirate antibody, whereas serum
antibody values were low or absent. In the
control group, there was a positive correlation
(r=0-59, p<0-001) between antibody values in
serum and saliva. No correlation was found
between salivary and jejunal aspirate antibody
values in any of the three groups.
Both jejunal aspirate and gut lavage fluid had
been collected from 20 patients (from all three
patient groups). A positive correlation (r=0-79,
p<0-01) was found between antibody values in
jejunal aspirate and gut lavage fluid.
mentwith a gluten free diet. It is possible that the
intestinal IgA antigliadin antibody and minor
histological changes could both be due to con¬
tinued ingestion of small amounts of gluten.
Conversely, intestinal IgM antibody values
remained higher than in control subjects, even in
patients with completely normal jejunal mucosa
who had been taking a gluten free diet for some
years. It is likely that minute amounts of gluten
(complete compliance to a gluten free diet is
difficult to achieve in adults) maintains a local
immune response rather than a systemic one.
Our finding of a persistent IgM antibody res¬
ponse parallels the finding of a relatively high
fraction of IgM plasma cells in treated coeliac
disease patients.9
We found high values of serum IgA and IgG
antigliadin antibody in untreated coeliac disease
patients. In the treated patients, serum IgA
antigliadin antibody values were similar to those
in controls but serum IgG antigliadin antibody
values, though significantly lower than in the
untreated coeliac disease patients, remained
significantly higher than in control subjects.
These findings agree with those of other
reports.1718
Concentrations of IgA, IgM, and IgG were all
high in jejunal aspirates from untreated coeliac
disease patients. Counts of jejunal plasma cells
and in vitro immunoglobulin production in
coeliac disease are higher than in control subjects
for all isotypes,10 supporting the view that the
immunoglobulins (at least IgA and IgM) in
coeliac intestinal secretions are produced locally.
Discussion
Intestinal antigliadin antibodies in coeliac
disease patients were mainly in the IgA and IgM
classes, and significant amounts of IgM antibody
persisted in the secretions of treated coeliac
disease patients with entirely normal jejunal
histology. Secreted IgA antibody was detected
only in the subgroup of treated coeliac disease
patients with minor histological abnormalities,
most of whom had had less than a year's treat¬
table vi Correlation between IgA antigliadin antibody
values in serum, jejunal aspirate, and saliva
Serum and Serum and Saliva and
Group saliva aspirate aspirate
Untreated coeliac disease r=0-021 r=0-68 r=0-293
(n=26) (NS) (p<0-0001) (NS)
Treated coeliac disease r=0-392 r-0-04 r-0-323
(n=22) (NS) (NS) (NS)
Control subjects r=0*593 r=-0193 r=0-071
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It is likely that most of the jejunal IgG is plasma
derived as the numbers of IgG secreting plasma
cells are low even in untreated coeliac disease.'
We should point out that immunoglobulin
measured in jejunal aspirate was total immuno¬
globulin and not specific secretory IgA and IgM.
It is possible that at least some of the jejunal IgA
and IgM is serum derived (coeliac disease is a
protein losing disorder). We are currently
characterising jejunal immunoglobulins and
antibody in terms of molecular weight and
percentage of total Ig which contains a secretory
component. An increase in the intestinal fluid
immunoglobulin content was not accompanied
by equivalent changes in serum immuno¬
globulins; in fact, the serum IgM content was
noticeably low in some untreated coeliac disease
patients.
We have not yet assessed the contribution of
specific antigliadin antibody to the increase in
intestinal immunoglobulin content in coeliac
disease. Falchuk and Strober," using an affinity
chromatography technique, reported that
approximately half of the net increase in IgA and
IgM synthesis (in an in vitro model of gluten
challenge) was due to synthesis of antigliadin
antibody. Conversely, in a more recent report of
in vitro secretion of antigliadin antibody by
coeliac jejunal mucosal biopsy specimens,20
Ciclitera et al calculated that antigliadin antibody
accounted for 2 -1%, 12-1%, and 4-1% of the total
concentrations of IgA, IgM, and IgG
respectively.
In any event, enhanced intestinal antibody
production in coeliac disease is not limited to
gluten derived proteins: we found high values of
intestinal antibody to betalactoglobulin and oval¬
bumin in untreated coeliac disease patients, with
persistence of IgM antibody to these proteins in
treated patients. Antibodies to these food pro¬
teins were less specific to coeliac disease than
antigliadin antibodies. It has been suggested that
high values of serum antibody to these proteins
in untreated coeliac disease is simply the result of
increased intestinal permeability to antigens.
Although ELISA is now accepted as the
standard assay technique for measuring anti¬
bodies to food proteins in coeliac disease, several
different ELISA methods have been described,
and different reference preparations are used by
each group of investigators. The method we used
is essentially similar to that of Savilahti et al,' and
we used crude gliadin as antigen for the ELISA
(rather than say, alphagliadin), as Skerrit et al21
have shown that sera and intestinal aspirates
from coeliac patients contain antibodies which
bind to several different gliadin subunits. We
have not ascribed levels of 'positivity' or 'nega¬
tivity' to antibody values; such arbitrary designa¬
tions are of some value in screening tests used in
clinical practice but not in prospective research
investigations.
Although untreated coeliac disease patients
had statistically higher values of salivary IgA and
IgG antigliadin antibodies compared with con¬
trols, salivary antibodies were generally low with
a large overlap between patients and controls.
Furthermore, there was no correlation between
jejunal aspirate and salivary antibody values.
Our results do not suggest that antibody tests on
saliva have any diagnostic or screening potential.
On the other hand, gut lavage offers a
relatively non-invasive alternative to intubation
for the collection of intestinal secretions for
immunoglobulin and antibody studies. Anti¬
body findings in gut lavage fluid were broadly
similar to those in jejunal aspirate, with a positive
correlation for IgA antigliadin antibody values in
those patients studied by both techniques.
Immunoglobulin concentrations, however,
differed considerably in jejunal aspirate and gut
lavage fluid; all three immunoglobulin isotypes
were raised in jejunal aspirate in the untreated
coeliac disease patients, whereas only IgM was
significantly raised in gut lavage fluid. Gut lavage
fluid is likely to contain secretions from not only
the small bowel but also gastric juice, bile,
pancreatic secretions, and colonic secretions. In
this respect, it is not a homogeneous fluid, unlike
jejunal aspirate, which reflects events in the
jejunum only, and is thus more likely to
represent accurately local immune phenomena
in coeliac disease. Fluid flow rate is another
factor that may influence Ig values in exocrine
secretions; this may partly account for dif¬
ferences in findings in jejunal aspirate and gut
lavage fluid.
The relevance of gluten reactive intestinal
B cells and antibodies to the pathogenesis of
coeliac disease is uncertain; the presence of
antibodies to gluten derived proteins in patients
with coeliac disease may be merely an epiphe-
nomenon in the context of a T cell mediated
enteropathy with expansion of the relevant
populations of T helper as well as effector cells.22
It is certainly possible that mucosal IgM anti¬
body is immunopathogenic, for example by
fixing complement in the immediate vicinity of
enterocytes.
This study shows the dissociation of systemic
and intestinal humoral immune responses in
patients with coeliac disease, and is evidence that
for the study of immunopathology of intestinal
disease, direct investigation of the gut is
mandatory.
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